
==== Front
Transl Neurodegener
Transl Neurodegener
Translational Neurodegeneration
2047-9158
BioMed Central London

432
10.1186/s40035-024-00432-x
Review
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu Enjie 1
Zhang Yao 2
http://orcid.org/0000-0002-0181-4415
Wang Jian-Zhi wangjz@mail.hust.edu.cn

134
1 https://ror.org/056swr059 grid.412633.1 Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China
2 grid.33199.31 0000 0004 0368 7223 Department of Endocrine, Liyuan Hospital, Key Laboratory of Ministry of Education for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077 China
3 https://ror.org/00p991c53 grid.33199.31 0000 0004 0368 7223 Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030 China
4 https://ror.org/02afcvw97 grid.260483.b 0000 0000 9530 8833 Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, 226000 China
4 9 2024
4 9 2024
2024
13 4512 3 2024
11 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies.

Keywords

Alzheimer’s disease
Neurodegeneration
Tau
β-Amyloid
Diagnosis
Drug development
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82001134 1949205 31730035 81721005 Liu Enjie Wang Jian-Zhi the Guangdong Provincial Key S&T Program018B030336001 Wang Jian-Zhi http://dx.doi.org/10.13039/501100006407 Natural Science Foundation of Henan Province 242300421081 Liu Enjie issue-copyright-statement© Ruijin Hospital, Shanghai Jiao Tong University 2024
==== Body
pmcIntroduction

Alzheimer's disease (AD) is the most common neurodegenerative disorder mainly affecting individuals aged over 65 [1]. Pathologically, AD is characterized by extracellular deposition of β-amyloid (Aβ) and intracellular accumulation of hyperphosphorylated tau (pTau), forming senile plaques and neurofibrillary tangles (NFTs), respectively [2–4]. Clinically, AD is associated with memory deterioration, often accompanied by aphasia, agnosia, impairment of visuospatial abilities, difficulties in abstract thinking and problem-solving, as well as personality and behavioral changes [5].

Over 95% of the AD cases have sporadic onset, in which the etiology and pathogenesis are still not clearly clarified. The apolipoprotein E (APOE) gene is considered the most significant genetic risk factor of AD [6–8]. Individuals carrying one or two APOE ε4 (APOE4) alleles have ~ 3.2 and 8–12 times higher risk of AD. Additionally, factors such as low education, smoking, estrogen reduction, high blood pressure, type-2 diabetis millitus, high cholesterol, and increased homocysteine levels are also associated with an increased risk of AD [9].

Familial AD (FAD) accounts for less than 5% of the cases and has onset before the age 65. With an autosomal-dominant inheritance pattern, FAD is primarily caused by mutations in genes for the amyloid precursor protein (APP) located on chromosome 21, PSEN1 on chromosome 14, and PSEN2 on chromosome 1. Almost all individuals carrying mutations in APP and PSEN1 are destined to develop AD, and those carrying mutations in PSEN2 have ~ 95% AD probability [10, 11].

Regarding the molecular mechanisms underlying AD pathologies and behavioral changes, the amyloid cascade hypothesis still dominates the field [12]. It is recognized that Aβ pathology may occur long before the formation of amyloid plaques; and soluble Aβ, particularly Aβ oligomers, plays a crucial role in disease progression [13]. The roles of neuroinflammation and abnormal activation of glial cells in mediating Aβ toxicity have received great attention [14]. Additionally, impaired Aβ clearance is an important mechanism leading to Aβ accumulation in the brain [15, 16].

In recent years, the critical role of tau in AD pathogenesis has been confirmed. Studies have been carried out to investigate the non-microtubule assembly and stabilizing functions of tau (such as regulating cell viability, acting as an acetyltransferase, etc.), tau release from neurons and propagation in different brain regions, the interplay of different post-translational modifications on tau proteins, and cleaved tau as "seeds" in tau aggregation, etc. [17]. In addition, APOE gene polymorphisms and chronic neuroinflammation induced by pathogen infections and glial activation in AD have also attracted attention.

The clinical diagnosis of AD has been mainly relying on doctors’ subjective evaluation based on the application of multiple psychometric scales, and biomarkers from the brain or cerebrospinal fluid (CSF) can help confirm the diagnosis [18]. In recent years, increasing studies have been aimed at searching for peripheral biomarkers from AD patients or populations with high AD risk, such as the aged populations and patients with type-2 diabetes mellitus (T2DM) [19–25]. The commonly supplied AD therapeutic drugs include cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, which can only temporally improve the symptoms but not cure the disease. Most recently, several Aβ-targeting drugs have gained official approval [26–28], and development of therapeutics targeting tau or pTau is also emerging [29–31]. Currently, animal models that can faithfully replicate the pathologies and behavioral changes observed in AD patients are still lacking, which may be one of the major obstacles to more efficient drug development.

Over all, research on AD in the recent four decades has greatly enhanced our understanding of AD pathogenesis and provided new potential tools for AD diagnosis and treatment, though many questions remain to be addressed. This review will focus on the aspects that have received widespread attention and made significant progress, including major risk factors, roles of Aβ and tau in AD pathogenesis, commonly used experimental models, and advances in the diagnosis of and disease-modifying drug development for AD. Current challenges or speculations/suggestions in the related topics are also discussed.

Major risk factors of AD

There are over 20 risk factors, including age, genetic mutation or variants, traumatic brain injury, and co-morbidities such as diabetes and infection. In light of recent progress, below we mainly review APOE and brain infections as risk factors for AD.

Role of APOE in AD

Biology of APOE isoforms and their receptors

APOE consists of 299 amino acids with a molecular weight of ~ 34 kDa. APOE has three isoforms (APOE2, APOE3, and APOE4) encoded by three alleles (ε2, ε3, and ε4). The three isoforms differ in two amino acids at positions 112 and 158 (APOE2: Cys112 and Cys158, APOE3: Cys112 and Arg158, and APOE4 Arg112 and Arg158) [32, 33]. Although studies have shown that these single amino acid polymorphisms can substantially influence the structure and function of APOE by modulating its binding to lipids and receptors, it remains unclear how this small amino acid difference leads to such profound effects on AD [34]. The secondary structure of the APOE proteins includes α-helices, β-sheets, β-turns, and irregular structures with two distinct regions: the receptor-binding region in the N-terminal and the lipid-binding region in the C-terminal [35].

APOE is known to mediate lipid transport and utilization, thereby involved in neural structure, functions, injury and repair. When the neuronal axons are injured, the distal fibers undergo typical structural and functional changes. The residual fibers with myelin sheaths undergo degeneration, which become rich in cholesterol and phospholipids (Sudanophilic bodies) [36]. During the initial phase of neuroregeneration, a significant lipid accumulation occurs at the site of injury, and macrophages migrate to the injury site, where they synthesize and secrete APOE, capturing lipid bodies and storing them in macrophages [37, 38]. The lipids carried by macrophages are utilized for axonal and myelin regeneration [39]. Although highly specialized mature neurons lack the ability to divide and proliferate, intact axons can be induced to grow collateral branches and differentiate into synapses from the damaged neuronal fibers. For example, damage to the olfactory cortex results in the loss of approximately 60% of synaptic inputs to the granule cell layer of the hippocampus, but new synapses can be formed from the sprouting of surviving axons [40]. This compensatory process is completed in several months in parallel with increased APOE expression and enhanced APOE binding to low-density lipoprotein receptor (LDL-R) [41]. Homozygous APOE knockout mice exhibit age-dependent dendritic cytoskeletal breakdown and synaptic loss, emphasizing an indispensable role of APOE in the maintenance and reconstruction of the central nerves system.

There are at least three types of APOE receptor in the brain, including very low-density lipoprotein receptor (VLDL-R) [42], LDL-R [43], and low-density lipoprotein receptor-related protein (LRP) [44]. VLDL-R and LDL-R are predominantly located on the astrocyte membrane, while LRP is mainly distributed in neurons and activated astrocytes [45]. LRP accumulates in the sites of senile plaques, with a significant difference in the length of a tetranucleotide repeat sequence (TTTC)n upstream of the LRP gene between AD patients and healthy individuals. Both APOE and APP can bind to LRP. Any structural changes in LRP can affect the uptake and metabolism of APP, leading to Aβ overproduction [46]. Currently, the relationships of LDL-R and VLDL-R gene variants with AD are still controversial.

APOE4 allele is a high-risk factor of AD

FAD is linked to the 19q13 chromosomal region, where the APOE gene is located. In the central nerves system, APOE is mainly expressed in astrocytes and contributes to a metabolic link between astrocytes and neurons. In the brains of AD patients, the level of APOE co-localized with senile plaques and NFTs in astrocytes is significantly increased compared to the control group [47]. The prevalence of AD has been strongly linked to APOE gene polymorphism. The APOE4 allele is recognized as a high-risk factor for AD and the APOE ε3 (APOE3) allele is the most common allele and does not seem to influence the risk [48]. Reducing APOE4 in carriers is a therapeutic goal for AD [49]. Although there are conflicting reports [50], APOE ε2 (APOE2) is commonly considered as an AD protective and longevity allele [51]. APOE2 gene therapy has been shown to reduce Aβ deposition and improve markers of neuroinflammation and neurodegeneration [52]. The proportion of APOE2 in long-lived elderly European and American populations is almost twice that of the general life-span population, while the frequency of APOE2 allele in AD patients is extremely low [53].

Within the central nervous system, APOE4 is produced by a variety of cell types under different conditions, posing a challenge for studying its roles in AD pathogenesis [54]. The evidence supporting APOE4 as an AD risk factor is that APOE4 increases the risk of both early- and late-onset AD [55–57]. Populations carrying one copy of APOE4 allele have a 3–4-fold increased risk of late-onset AD, while the risk increases to 8–12 folds for those carrying two copies of APOE4 [58–61]. Women with one APOE4 allele display greater risk and earlier onset of AD compared with men [62, 63]. The follicle–stimulating hormone (FSH) in females with the APOE4 but not the APOE3 allele  increases the vulnerability to AD by activating the C/EBPβ/δ-secretase signaling [64]. In APOE4/C/EBPβ double transgenic mice, key AD pathologies appear in an age-dependent manner [65]. In contrast, APOE loss-of-function variants confer resistance to AD pathology [66].

Additionally, APOE4 carriers have an earlier age of onset, who show AD symptoms at around 75 or 65 years of age, compared to the average onset age of 84 years [67, 68]. A meta-analysis revealed that increased frequency of APOE4 allele is associated with increases of age-adjusted AD incidence, whereas no such relationship exists for APOE2 and APOE3 alleles [69]. The APOE4 allele is also a susceptible factor for atherosclerosis [70], and AD patients often have vascular problems. Different from APOE2 and APOE3, APOE4 affects lipid transport and utilization, but its role in AD is not clear [71].

Microglia in APOE4 knock-in mice exhibited significantly less brain surveillance (27%) compared to APOE3 microglia at 6 months of age, and aging exacerbated this deficit [72]. APOE has the most enriched gene expression in neurodegenerative microglia. APOE4-mediated induction of ITGB8‒transforming growth factor-β (TGFβ) signaling impairs the neurodegenerative microglia response in AD via upregulation of microglial homeostatic checkpoints, including Inpp5d. Manipulating APOE4 expression in the microglial cells significantly changes the quiescent state and the functions of the microglia [73–75]. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity [76], and Aβ induces lipid droplet accumulation, tau phosphorylation and neurotoxicity in an APOE4-dependent manner [77]. APOE4 can impair neuron-astrocyte coupling of fatty acid metabolism, which could underlie the accelerated lipid dysregulation and energy deficits and increased AD risk for APOE4 carriers [78]. APOE4 leads to neurovascular dysfunction and loss of integrity of the blood–brain barrier (BBB) [79].

Role of APOE4 on Aβ pathology

(1) APOE4 promotes Aβ aggregation

In human pluripotent stem cell-derived neurons expressing APOE4, both production and release of Aβ are significantly increased. APOE4 enhances the seeding properties of Aβ, promoting its aggregation and deposition [80, 81]. In APP transgenic mice, APOE4 can form a stable complex with Aβ that is resistant to degradation [82]. Removal of APOE4 results in the disappearance of Congo red-stained Aβ plaque-like structures, while reintroducing APOE4 leads to the formation of senile plaques [83, 84]. AD patients carrying APOE4 show a high level of Aβ oligomers in synapses, which leads to the recruitment and activation of microglia [85–87]. Thus, APOE4 may damage synapses by synergistically interacting with Aβ oligomers. The C-terminal 13-kDa fragment of APOE4 can bind to Aβ and thus promote the formation of highly toxic low-molecular-weight Aβ species [88].

(2) APOE4 inhibits Aβ degradation and clearance

The clearance of Aβ from the brain relies on APOE-mediated mechanisms. APOE2 or APOE3 can form complexes with Aβ and clear Aβ from brain via binding to VLDL-R and LRP1 on the BBB, predominantly via the VLDL-R pathway. Due to the lower internalization rate of APOE4-Aβ complexes mediated by VLDL-R compared to LRP1, the efficiency of Aβ clearance is lower in the presence of APOE4 than APOE2 and APOE3 [89]. A most recent study shows that IL-33 induces expression of vascular cell adhesion molecule-1 in microglia, which promotes microglial chemotaxis toward Aβ plaque-associated APOE, leading to Aβ clearance [90].

The phagocytic and degradative capacity of astrocytes and microglia towards Aβ is also influenced by the APOE genotype. Astrocytes expressing APOE4 show reduced uptake of Aβ42 compared to those expressing APOE3 [54]. In microglia, APOE promotes Aβ degradation via neprilysin and APOE4 exhibits the lowest ability among the three isoforms [54]. APOE-mediated cholesterol efflux facilitates Aβ transport to lysosomes and enhances the intracellular Aβ degradation by microglia, and this process is impaired in cells expressing APOE4 [91].

Compared to individuals without APOE4, AD patients with APOE4 exhibit significantly reduced expression of Aβ-degrading enzymes, such as neprilysin and IDE, resulting in diminished Aβ degradation capacity [92]. In APOE4 transgenic mice, brain injection of Aβ40 induces abundant Aβ deposition in the perivascular space of lymphatic-like vessels, suggesting involvement of perivascular lymphatic system [93].

APOE on tau-associated pathologies

Compared with Aβ, much less is known regarding the effect of APOE on tau. It was reported that the postmortem brains from individuals carrying two APOE4 alleles have more tau aggregates than those carrying either one or no APOE4 allele, and this effect is Aβ-dependent. In progressive supranuclear palsy (PSP), tau pathology is associated with APOE4 [94]. The associations between synaptic density and tau pathology are regulated by the APOE4 genotype [56].

(1) Effects of APOE gene polymorphism on tau

APOE gene knockout causes tau hyperphosphorylation and aggregation, with age-dependent deterioration of neuronal dendrites and microtubules, suggesting a crucial role of APOE in maintaining normal tau metabolism and microtubule stability [95, 96]. It is generally recognized that APOE3 may confer resilience to tauopathies [97], while APOE4, especially the C-terminal truncated form (APOE4 Δ272–299), promotes tau phosphorylation/aggregation and exacerbates neurodegeneration [98–100]. Expression of APOE4 in astrocytes disrupts tau uptake, trafficking and clearance [101]. With regard to APOE2, many studies have shown protective effects against amyloid-like pathology. However, there is still controversy on the effect of APOEε2 on tau [100, 102–104]. Some studies have reported that an increased level of APOE2 protein in the brain contributes to increased tau aggregation and behavioral impairment, and that APOE2 is positively correlated with the severity of tau pathology in patients with PSP [102, 104]. It is also reported that both APOE3 and APOE2 are protective and it is the absence of APOE3 or APOE2 rather than the presence of APOE4 that promotes tau pathologies.

A recent whole-exome sequencing study revealed an additional rare homozygous mutation of APOE3 (APOE3ch, R136S) as the potential protective factor against AD [105]. In vivo follow-up by PET imaging and postmortem studies revealed that the APOE3ch delayed AD onset for almost three decades beyond the expected age of onset [106]. APOE3ch expression alleviated Aβ deposition, tau pathology, astrogliosis, and cell death, with the mechanisms involving an increased myeloid cell phagocytosis [107, 108]. This resistance may be due to the reduced pathological interactions between APOE3Ch and heparan sulfate proteoglycans (HSPGs) [109].

(2) Effects of APOE receptors on tau

LRP1 can internalize tau and then mediate tau degradation in the lysosome. LRP1 has high affinity to tau at the microtubule-binding domain of tau, while phosphorylation of tau inhibits the associations between tau and LRP1 and thus decreases the internalization of extracellular tau proteins, which may play a role in the spreading of the pathological tau in the AD brains [110]. LRP1-mediated uptake of tau is also inhibited by APOE, and APOE4 is the most potent inhibitor, likely because of its higher affinity for LRP1 [111].

Pathogenic microbial infection and AD

In recent years, the role of neuroinflammation in the occurrence and development of AD has received much attention. Various factors can induce chronic neuroinflammation through different mechanisms, promoting AD onset and progression [112].

Evidence supporting the role of microbial infection in AD

The hypothesis that AD may be caused by pathogenic infections was initially proposed by Dr. Oskar Fischer in 1907 [113]. In 1991, the DNA of herpes simplex virus type 1 (HSV-1, also known as human herpesvirus HHV-1) was detected in the brains of AD patients [114], and now HSV-1 has been experimentally confirmed to play a role in AD [115, 116]. Currently, increasing pathogens are being found to be associated with AD, such as herpesviruses HHV-1, HHV-2, HHV-3, HHV-5, HHV-6, and HHV-7, hepatitis C virus (HCV), chlamydia pneumoniae, spirochetes, periodontal bacteria, Helicobacter pylori (H. pylori), and intestinal microbiota. Antiviral drugs for herpesviruses can reduce the risk of dementia. These pathogens may enter the brain by directly crossing the BBB and/or the blood-cerebrospinal fluid barrier, or through the trigeminal system or the oral-nasal route. The pathogens may also cause inflammatory damage by secreting toxins that can enter the brain through the circulatory system [117].

Viral infection and AD

(1) Human herpesviruses

HSV-1 is a common neurotropic virus, with approximately 80% of the population carrying antibodies for HHV-1 [118, 119]. The levels of HHV-1 DNA in the brains of the elderly and AD patients are higher than that in the young people, which may be related to the age-related decline of immune function [120]. The titers of anti-HHV-1 antibodies in the CSF of the elderly and AD patients are also significantly increased [121]. APOE4 can modulate the severity of or susceptibility to microbial infections and promote HHV-1 neurotropic infection [122]. Neuronal cells infected with HHV-1 exhibit Aβ and tau aggregation [120, 123]. In 3D brain models of human induced neural stem cells that undergo differentiation and development, HSV-1 infection induces amyloid-like protein deposition, gliosis, neuroinflammation, and neural dysfunction [124].

HHV-2 infection leads to Aβ deposition, tau hyperphosphorylation, and inhibition of the non-amyloidogenic APP processing pathway [125, 126]. Epidemiological data show that exposure to Toxoplasma gondii, cytomegalovirus, or HSV-2 is associated with cognitive decline in the elder population [127]. Seropositivity for HHV-5 (cytomegalovirus, CMV) is associated with an increased risk of AD [128], and the levels of CMV antibodies are correlated with the severity of neurodegeneration. By measuring the peripheral blood leukocyte samples, the HHV-6 positive rate is 23% in AD patients and 4% in the controls; and 17% of AD patients are HHV-6-positive in brain samples. AD patients show elevated levels of HHV-6A and HHV-7 RNAs in multiple brain regions, which are correlated with plaque burden, tangle density, and the dementia severity.

(2) HCV

HCV infection is an independent risk factor for both AD and vascular dementia [129, 130]. Viruses may exert neurotoxic effects indirectly through systemic inflammation or directly by infecting the brain. HCV can cross the BBB and secrete high levels of cytokines such as IL-6 and TNF-α to induce toxic effects in the brain. In patients with hepatitis C, microglial activation positively correlates with cerebral metabolic changes [130].

Bacterial infection and AD

(1) H. pylori

H. pylori is a common resident bacterium in the stomach, infecting an estimated half of the global population [131]. In addition to its direct association with gastric ulcers and gastric cancer, H. pylori infection is closely linked to AD, atherosclerosis, hypertension, cerebral ischemia, and stroke [131]. AD patients show a significant increase in specific IgG levels against H. pylori in their blood and CSF [132]. Clinical studies have confirmed that the incidence of dementia is much higher in H. pylori-positive individuals than that in negative individuals. Experimental studies have also shown that the conditioned culture medium of H. pylori can promote tau hyperphosphorylation and Aβ overproduction.

(2) Porphyromonas gingivalis

P. gingivalis is the primary pathogen associated with chronic periodontitis. It can damage cells through its lipopolysaccharides (LPS), gingipains, and proteases produced by the bacterium. The bacteria and their molecules, such as outer membrane proteins, flagella proteins, fimbriae proteins, peptidoglycans, and proteases, can act as pathogen-associated molecular patterns. They interact with Toll-like receptors (TLRs) and induce the secretion of pro-inflammatory cytokines, leading to BBB disruption and neural damage. P. gingivalis has been detected in the brains of both AD and healthy individuals, suggesting that this bacterium may require synergistic interactions with other factors to promote AD [133].

Additionally, Chlamydia pneumoniae and spirochete bacteria have also been reported to be associated with AD. C. pneumoniae is a respiratory tract pathogen that can infect various types of brain cells and can exist within the inclusion bodies inside the cell, thereby escaping from immune recognition and lysosomal fusion. Specific DNA of C. pneumoniae has been detected in the AD brains by electron microscopy and immunohistochemistry [134]. However, due to the chronic course of AD, it is difficult to determine whether C. pneumoniae infection directly leads to AD or indirectly promotes AD progression through peripheral inflammation or respiratory dysfunction. Spirochete bacteria have also been detected in the CSF, blood, and brain tissues of some AD patients. Spirochetes are Gram-negative spiral bacteria with internal flagella that can invade the brain and establish latent and persistent infections [135]. They are the most neurotropic bacteria and can cause severe cerebrovascular pathology, cerebral hypoperfusion, brain dysfunction, and dementia.

Fungi and T. gondii in AD

Fungal DNA or proteins have been detected in the CSF and frozen brain tissues of AD patients, along with the presence of different antifungal antibodies. By using specific antibodies against fungi, researchers found that fungal infections exist in various brain areas, including cerebral cortex, cerebellum, olfactory cortex/hippocampus, and choroid plexus in AD patients. However, the role of fungal infections in AD is still uncertain [136].

Epidemiological studies have shown that olfactory dysfunction in patients with AD, multiple sclerosis, and schizophrenia is significantly associated with the elevated serum levels of anti-T. gondii IgG antibodies. Experimental research has revealed that chronic infection with T. gondii causes neuroinflammation [137].

Gut microbiota and AD

The human gut harbors bacteria, viruses, and fungi [138]. In healthy individuals, these microorganisms form a microbiota defensive barrier in the digestive tract. Recent studies reveal that alterations in gut microbiota are involved in various neurodegenerative diseases including AD [139].

Through 16S rRNA sequencing of fecal bacteria, significant differences in gut microbiota between APP/PS1 and wild-type mice have been observed [140]. The brain Aβ deposition in germ-free APP/PS1 mice is significantly lower than that in mice with normal gut microbiota. Transplantation of the AD feces significantly increased the brain Aβ level in the germ-free mice, while gut microbiota from wild-type mice did not change Aβ level. Gut microbiota plays an important role in controlling astrocyte activation, morphology, and recruitment to Aβ plaques [141]. It also regulates blood-cerebrospinal fluid barrier function and Aβ pathology [142]. Additionally, intravenous injection of outer membrane vesicles derived from AD patients into healthy mice for eight weeks increases the BBB permeability with elevated levels of brain inflammatory markers, glial cell activation, tau hyperphosphorylation, and cognitive impairment in the recipient mice [143]. These findings suggest that gut microbiota can influence brain function and lead to AD-like pathologies and cognitive deficits through the microbiota-gut-brain axis.

Role of glial cells in AD

Role of microglia in AD

Activated microglia are found surrounding senile plaques in the brains of AD patients [144]. Studies have revealed that microglia rapidly accumulate around newly formed Aβ plaques, and express various receptors involved in Aβ binding and phagocytosis, such as scavenger receptor A1, CD36 [145], CD14, TLR2, TLR4, TLR6, and TLR9 [146]. This suggests that microglia play a role in the clearance of Aβ. However, microglia isolated from the brains of AD mice exhibit decreased ability to phagocytose Aβ, possibly due to long exposure to an Aβ-rich environment that has impaired their phagocytic function [147]. Additionally, among the numerous AD risk genes reported, myeloid cell trigger receptor 2 (TREM2) and CD33 primarily act through microglia, and genetic variations in both genes can lead to reduced uptake and clearance of Aβ by microglia [147]. TREM2, CD33, and CD22 can influence the intracellular adaptor molecule CARD9; the latter can attenuate Aβ pathology and modify microglial responses in AD mice [148, 149]. Obesity also affects the function of central microglia through peripheral inflammatory responses [150]. During aging, the function of BBB is diminished, allowing peripheral inflammatory factors to enter the brain and activate microglia.

Microglia can exhibit two different phenotypes, M1 and M2, in response to different stages of inflammation or various stimulating factors [151]. M1 microglia release pro-inflammatory cytokines and exhibit reduced phagocytic capacity, while M2 microglia release anti-inflammatory cytokines and have enhanced phagocytic ability. However, the activated microglia can have beneficial or detrimental effects depending on the brain region observed, disease stage, disease model, and other factors [152]. In normal individuals, microglial activation occurs in response to neuronal damage, abnormal protein folding or aggregation, leading to the production of immune-inflammatory reactions. Optogenetic stimulation of microglia can efficiently promote both Aβ clearance and synaptic elimination in the brain parenchyma, while inhibiting C1q selectively prevents synaptic loss induced by microglial depolarization without affecting Aβ clearance [153].

Once damaged neurons or abnormal proteins are phagocytosed and cleared, inflammation subsides, and local homeostasis is restored. In the process of AD, continuous accumulation of pathologies, such as Aβ, leads to persistent microglial activation [152]. The chronic activation of microglia results in a prolonged and unresolved inflammatory state, contributing to the progression and pathogenesis of AD. Activated microglia release a large number of cytokines such as TNF-α, IL-6, IL-1α, NO, and C1q, which can directly damage the neurons. Activated microglia can engulf synapses, leading to impaired learning and memory. Dysfunctional microglia can also induce transformation of astrocytes to a toxic A1 phenotype and thereby decrease nutritional support to neurons [152]. Microglia are the major cell type expressing complement C3a receptor (C3aR) in the brain. Depletion of C3aR can reverse the HIF-1α-induced metabolic impairment and enhance microglial response to Aβ pathology [154].

Role of astrocytes in AD

Astrocytes are the most abundant cell population in the human brain and play essential roles in supporting, nourishing, and protecting neurons through various functions such as regulating neurotransmitter release and reuptake, energy metabolism, signaling pathways, ion buffering, and blood flow regulation [155]. Activation of astrocytes is involved in both neural repair and toxicity [156]. The gene expression profiling data from stimulated astrocytes reveal two forms of astrocyte activation: A1 phenotype, induced by LPS or neuronal injury, and A2 phenotype, induced by ischemia. A1 astrocytes predominantly express genes associated with the classical complement pathway, with reduced phagocytic capacity and diminished ability to promote synapse growth. They also produce neurotoxic substances that contribute to neuronal death. A2 astrocytes mainly express neurotrophic factors and possess reparative properties [157]. It is still not fully understood which factors control this phenotype transformation of astrocytes, and whether and how it is applicable for AD.

Astrocyte activation is an early event in AD and can occur prior to Aβ deposition. Astrocyte reactivity, as an important upstream event linking Aβ with initial tau pathology, may have implications for the biological definition of preclinical AD and cognitively unimpaired individuals for clinical trials [158]. Primary astrocytes treated with Aβ oligomers or astrocytes in the brains of APP/PS1 mice show morphological changes with increased level of GFAP, a marker for astrocyte activation. In susceptible brain regions of AD patients, such as the frontal lobe and hippocampus, there is a significant increase in astrocytes expressing A1-type markers such as complement C3, compared to normal controls, suggesting A1-type astrocyte activation. Activated astrocytes can also release cytokines, interleukins, and NO, exacerbating inflammatory reactions and causing damage to neurons. At the same time, astrocytes can internalize and degrade Aβ, a process that requires APOE. Astrocytes exposed to Aβ deposits show upregulated expression of extracellular Aβ-degrading enzymes such as neprilysin and IDE. Exercise-induced irisin significantly reduces Aβ pathology by increasing astrocytic release of the Aβ-degrading enzyme neprilysin [159].

In addition, astrocytic endfeet form an important component of the BBB, and the perivascular space between endothelial cells and astrocytic endfeet serves as a pathway for brain glymphatic circulation. Knockout of aquaporin-4, a water channel protein expressed in astrocytes, leads to impairment of brain glymphatic clearance and increased Aβ deposition [160]. Therefore, astrocyte dysfunction can also impair the clearance of brain metabolites and facilitate abnormal protein aggregation through damaging the glymphatic clearance system. Additionally, NOX2, Toll-like receptors, and the nuclear factor kappa-B (NF-κB) pathway activation also play important roles in AD.

Role of Aβ in AD neurodegeneration

Mechanisms underlying Aβ generation and degradation

Amyloid pathology is one of the major AD pathologies. It is generally believed that the amyloid pathology occurs preceding tau pathology. In FAD, amyloid accumulation is a hallmark of early AD development and/or a triggering event, whereas tau pathology generally comes later with more solid link to cognition/behavior issues.

Aβ generation pathways

Aβ is produced from APP. Located on chromosome 21 and spanning approximately 190 kb pairs, the APP gene consists of at least 18 exons. By alternative splicing, at least 10 different mRNA isoforms are produced, directing the translation of protein isoforms ranging from 365 to 770 amino acid residues [161]. The human brain predominantly expresses APP695 and APP770 [162]. As a type I transmembrane protein, APP comprises a long extracellular N-terminal segment and a short intracellular C-terminal segment. By interacting with the extracellular matrix, APP participates in the regulation of neuronal plasticity and repair of damaged tissues [163].

(1) Amyloidogenic pathway

β-Secretase, referred to as β-site APP-cleaving enzyme-1 (BACE1), cleaves APP695 at Asp1 between Met596 and Asp597, resulting in the release of 99-aa residue membrane-associated C-terminal fragment (CTF or C99) [164–166]. The C99 is then cleaved by γ-secretase to produce full-length Aβ composed of 39–43 amino acids including the N-terminal 28 amino acids of APP transmembrane region and an adjacent 11–15 amino acids in the transmembrane region [167]. Due to the hydrophobic nature of the last few amino acid residues at the C-terminus, the Aβ peptides with longer C-terminal are more prone to aggregation and deposition. Among different forms of Aβ, Aβ1-40 and Aβ1-42 are the most extensively investigated Aβ forms in AD research.

Recent studies show that asparagine endopeptidase (AEP) can cut APP at N373 or N585 on the extracellular space to facilitate Aβ production. The molecular mechanisms may involve removal of the N-terminal domain on APP, which facilitates more efficient BACE1 cleavage of the resultant APP C596–695 fragment. This AEP-mediated APP cleavage is also termed as the δ-secretase pathway [168–170]. AEP can also directly cut BACE1 at N294, which enhances BACE1 activity and shifts the optimal pH of BACE1 from acidic to neutral, so that BACE1 could process APP even under neutral pH or at extracellular compartment [169].

β-Secretase cleavage of APP mainly takes place in endosomes and lysosomes. Both APP and BACE1 are type I transmembrane proteins that are initially inserted into the cell membrane and then undergo internalization into endosomes and further fuse with early lysosomes. The acidic environment within endosomes and lysosomes facilitates the cleavage of APP by BACE1. BACE1 is enriched in lipid raft, which is the potential subcellular localization for Aβ generation. Active γ-secretase has been detected in cell membrane, endosomes, and lysosomes [171] (Fig. 1).Fig. 1 Amyloidogenic and non-amyloidogenic APP processing pathways. a The amyloidogenic processing pathway of APP produces full-length Aβ through BACE1 and γ-secretase cleavage. AEP cleavage at N373 and N585 makes APP more susceptible to BACE1 and thus promotes Aβ production. b The non-amyloidogenic processing pathway of APP by α-secretase within the Aβ domain or by BACE1 at Glu11 or by BACE2 at Phe20 does not produce full-length Aβ

(2) Non-amyloidogenic pathway

In physiological conditions, a majority of APP is processed by α-secretase which involves the cleavage of the peptide bond between Lys16 and Leu17 of Aβ, resulting in the production of a larger, N-terminal, soluble sAPPα fragment (sAPPα) and a C-terminal fragment of 83 amino acids (CTFα or C83) [172]. The sAPPα is secreted into the extracellular space, while C83 remains membrane-bound, which is further cleaved by γ-secretase generating a P3α fragment and CTFγ. It is generally believed that α-secretase cleavage of APP occurs at the cell membrane, which does not generate complete Aβ molecules. In addition, APP can be cleaved by BACE2 (namely θ-secretase) at Phe20 within the Aβ domain, leading to the formation of CTFθ (or C80). C80 is further cleaved by γ-secretase, generating a P3θ fragment and CTFγ that also does not produce Aβ [173–175]. BACE1 can also cleave APP at Glu11 within Aβ region, which produces C89 and a truncated Aβ11-40/42 (tAβ) [164, 166]. Figure 1 summarizes the amyloidogenic and non-amyloidogenic pathways for APP processing and Aβ production.

Aβ degradation and clearance

Normally, Aβ generation is counterbalanced by the proteolytic degradation. The involved enzymes for Aβ degradation and clearance include zinc metalloproteinase neprilysin [176], the most efficient Aβ peptidase located in the intraluminal/extracellular space and the early Golgi and ER compartments; the membrane-bound endothelin converting enzymes 1 and 2; the intracellular insulin-degrading enzyme (IDE) [177]; and plasmin, a serine protease that can degrade both monomer and fibril Aβ [178]. In addition, the matrix metalloproteases (MMPs) MMP2 and MMP9 can degrade Aβ in vitro. Cathepsin D, an aspartyl protease localized within lysosomes and endosomes, is a major Aβ-degrading enzyme in brain homogenates.

Aβ is also cleared through cell-mediated mechanisms, such as phagocytosis by microglial cells [179], transport from brain tissue to the periphery via binding with lipoproteins and mediated by related transporters such as LRP and VLDL-R [180, 181]. Capillary dysfunction impedes Aβ clearance [182]. Age-dependent loss of myelin integrity can be a driver or a risk factor of Aβ deposition [183]. β2-microglobulin (β2M), a component of major histocompatibility complex class I (MHC class I), is upregulated in AD brains and constitutes the core of Aβ plaque. A recent study indicates coaggregation of β2M with Aβ, which contributes to cognitive deficits in AD model mice [184]. Studies also show that the lymphatic system in the brain can accelerate Aβ clearance during deep sleep [185]. Thus, sleep disorders can lead to reduced Aβ clearance in the brain and promote neurodegeneration [186]. APOE4 synergizes with sleep disruption to accelerate Aβ deposition and Aβ-associated tau seeding and spreading [187].

Together, impaired degradation and/or clearance of Aβ may be caused by dysfunction of specific proteolysis or clearance systems, with a subsequent consequence of Aβ aggregation and deposition during the long course of AD.

Mechanisms underlying Aβ overproduction

Several factors, such as gene mutations in APP and presenilin (PS) catalytic subunit (γ-secretase), post-translational modifications, APOE4, aging and various environmental stimuli, can contribute to Aβ overproduction and aggregation in FAD or sporadic AD patients. However, the detailed mechanisms remain largely unclear.

APP gene mutations and post-translational modifications

Several APP mutations have been identified in FAD patients, and these mutations directly affect Aβ generation. The Swedish and E674Q mutations alter APP structure, making it more susceptible to the BACE1 cleavage [188, 189]. The Arctic and Dutch mutations occur within the Aβ peptide, making it more prone to aggregation [190]. Austrian, Iranian, French, German, and other mutations located at the C-terminal of APP promote the production of longer Aβ fragments [191]. The Flemish mutation, located in the substrate inhibitory domain of APP, results in increased APP cleavage by γ-secretase [192]. K16E or K16F mutation in Aβ1-28 and Aβ25-35 fragments leads to greater susceptibility to aggregation, and Zn2+-binding makes Aβ more stable [193].

During the constitutive secretory pathway, APP undergoes extensive post-translational modifications, including glycosylation, phosphorylation, sulfation, palmitoylation, ubiquitination and SUMOylation. Among them, increased Thr668 phosphorylation of APP has been extensively detected in AD brains with mechanisms involving increased DYRK1A (dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A) [194]. It is generally recognized that Thr668 phosphorylation facilitates β- and γ-cleavages and increases Aβ generation, although opposite results were also reported. In addition, phosphorylated Tyr682 and Tyr687 have been exclusively detected in AD brains but not in healthy controls, and these two sites seem to negatively regulate Aβ generation [195].

Activation of β-secretase

β-secretase (BACE1) is widely expressed in neurons, oligodendrocytes and astrocytes. It is predominantly localized in the acidic intracellular compartments (such as late Golgi/TGN and endosomes) with an optimal enzymatic activity at pH 4.5. The mRNA expression and activity of BACE1 are increased in the brain, CSF, peripheral blood mononuclear cells and plasma of the elderly as well as probable AD and AD patients, suggesting that plasma BACE1 activity may serve as a biomarker for predicting AD [196, 197].

Epigenetic modulations, including DNA methylation, non-coding RNA alterations, and histone modifications, are of great significance in regulating Aβ metabolism. For instance, chromatin remodeling assists BACE1 upregulation and Aβ production [196, 198]. A global decrease of DNA methylation has been detected in the hippocampus of AD patients [199], and histone hyperacetylation and DNA hypomethylation can increase APP and BACE1 transcription, possibly by activating NF-κB [200]. APP and BACE1 are upregulated as a result of demethylation at their promoters, and S-adenosylhomocysteine treatment induces hypomethylation of PSEN1 and APP accompanied by their overexpression and Aβ overproduction [201]. In addition, various types of post-translational modifications of BACE1 at multiple sites have been reported to play a crucial role in BACE1 trafficking and maturation and thus contribute to Aβ overproduction and aggregation. These modifications include acetylation at Lys-126, Lys-275, Lys-279, Lys-285, Lys-299, Lys-300, or Lys-307; N-glycosylation at Asp153, Asp172, Asp223 or Asp354; palmitoylation at Cys474, Cys478, Cys482, or Cys485; phosphorylation at Ser498 or Thr252; ubiquitination at Lys203, Lys382, or Lys501; and SUMOylation at Lys275 or Lys501 [202, 203].

Abnormalities of γ-secretase

γ-Secretase is a complex composed of PS1 (467 aa), PS2 (488 aa), Nicastrin (~ 130 kDa), APH-1 (30 kDa), and PEN-2 (12 kDa) [204], in which PS1 and PS2 can directly cleave APP at at least five adjacent sites and thus produce Aβ with 39 to 43 amino acid residuals, most commonly Aβ42. PS1 and PS2 are highly homologous 8-transmembrane proteins with 10 hydrophobic regions inserted in the membrane [205, 206], with hydrophilic N- and C-terminal located in the cytoplasm. Nicastrin is a glycoprotein and its maturation depends on the PS-mediated transport from ER to the cell membrane. Nicastrin, APH-1 and PEN-2 in the complex can stabilize or regulate PS and thus participate in γ-secretase cleavage [207–209]. A recent study shows that ganglioside GM1, the most common brain ganglioside, can specifically accelerate γ-secretase cleavage of APP without affecting other substrates including Notch1, potentially through its interaction with the N-terminal fragment of PS1 [210].

PS may be an aspartic acid-dependent protein hydrolase. Inhibiting γ-secretase can reduce the intracellular Aβ level [211]. To date, more than 400 mutations in PSEN and APP genes have been identified in early-onset FAD, with PSEN1 and PSEN2 mutations accounting for ~ 75% and ~ 12%, respectively [212]. FAD patients with PSEN mutations exhibit elevated Aβ levels in plasma and the brain. Both in vitro and in vivo experiments have confirmed that almost all PSEN mutations ultimately result in increased production of longer Aβ fragments and an elevated Aβ42/Aβ40 ratio. PSEN gene mutations may promote Aβ toxicity by simultaneously affecting APP cleavage, endocytosis, transport, and functional abnormalities, such as ER calcium homeostasis, autophagy pathways, and neuronal endocytosis.

Upregulation of δ-secretase

Recent studies reveal that AEP as a δ-secretase can cut APP to facilitate Aβ production. AEP is a cysteine protease that specifically hydrolyzes peptide bonds after asparagine residues in mammals. It has been observed that AEP is activated in normal mice in an age-dependent manner, and it is strongly activated in 5 × FAD transgenic mice and in human AD brains. Activation of AEP drives the onset of AD through cleaving tau and APP. The AEP-mediated cleavage of these peptides enhances amyloidosis and tau hyperphosphorylation, and thus induces neurodegeneration and cognitive impairment [168, 213].

As mentioned above, α-secretase cleavage of APP predominantly occurs at the plasma membrane that does not produce Aβ. Three members of the α-disintegrin and metalloproteinase (ADAM) family, ADAM9, ADAM10 and ADAM17, have been identified to possess α-secretase-like activity, which is regulated by multiple factors such as protein kinase C in the trans-Golgi-network [214]. However, it is currently not clear whether and how α-secretase plays participates in AD [215].

Mechanisms underlying Aβ aggregation

Aβ monomers can form higher-order assemblies ranging from low-molecular-weight oligomers (including dimers, trimers, tetramers, and pentamers) to midrange-molecular-weight oligomers, high-molecular-weight oligomers, protofibrils, fibrils and senile plaques. Soluble Aβ can interact with potential receptors and activate downstream pathways to generate reactive oxygen species, tau hyperphosphorylation and inflammatory responses [216]. The extracellular accumulation of insoluble Aβ can also activate neurotoxic cascades that ultimately lead to cytoskeletal changes, neuronal dysfunction and neural death [217, 218].

Compared with Aβ production, much less has been clarified for Aβ aggregation. Following production, Aβ interacts with receptors for advanced glycation end products (RAGE), which facilitates the transportation of Aβ across the BBB [219], leading to Aβ accumulation within the brain. RAGE also stimulates BACE1 expression through generating an intracellular Ca2+ response that activates NFAT1 (nuclear factor of activated T-cells 1), an activator of BACE1. BACE1 then cleaves APP to produce Aβ, forming a feedback loop to aggravate Aβ accumulation [220].

Impaired Aβ clearance could also promote Aβ accumulation. Several proteinase inhibitors, such as α1-antichymotrypsin and nexin-1, have been detected in the senile plaques of AD patients, which prevents the timely clearance of Aβ by proteases and lead to Aβ deposition [221, 222]. Inhibition of Aβ-degrading enzymes, such as neprilysin and IDE, can also result in Aβ accumulation.

Increased neuronal activity also promotes Aβ production and release [223]. Patients with temporal epilepsy often exhibit Aβ deposition in the brain at as early as 30 years of age. The frontal, parietal, and posterior cingulate cortices are the most vulnerable brain regions for Aβ deposition in AD patients, and these brain areas also show highest neuronal metabolic activity [223–225]. Several physicochemical factors, such as aluminum, iron, zinc, and acidic pH (pH 4–7), also promote Aβ aggregation.

Mechanisms or pathways involved in Aβ toxicity

Aβ is the main component of amyloid-like plaques in the brains of AD patients. Synthetic Aβ peptides can exert toxic effects both in vitro and in vivo. Down syndrome patients with trisomy 21 (owning triplicate APP gene) exhibit typical AD-like neuropathological changes and clinical manifestations, while those with duplicate chromosome 21 do not exhibit AD-like changes even at an old age [226, 227]. The FAD patients carrying mutations in APP or PSEN have increased Aβ or elevated Aβ42/Aβ40 ratio [228], and show earlier development of dementia and more rapid disease progression [229]. Several lines of transgenic mice carrying human mutant APP gene exhibit age-dependent increases of extracellular Aβ level and develop neuropathological and behavioral changes resembling AD [230]. Homozygosity for APOE4 increases Aβ burden in human brains [68].

Despite these supporting evidence, the role of Aβ in the pathogenesis of AD remains controversial. For instance, the relationship between Aβ level or brain amyloid plaque burden and the severity of cognitive impairment remains unclear; drugs targeting Aβ or its metabolism have not yet achieved the expected therapeutic effects in clinical trials, though inspiring progress has been made most recently. Therefore, Aβ may be a necessary factor but not sufficient for the development of AD. The toxicity of Aβ may require the involvement or synergistic action of other pathogenic molecules, such as tau.

Aβ induces oxidative damage

AD patients show elevated activities of superoxide dismutase and glucose-6-phosphate dehydrogenase, decreased activity of glutamine synthetase, and increased lipid peroxidation, indicating a close relationship between free radicals/oxidative damage and AD. Possible pathways through which Aβ induces oxidative damage in neuronal cells are as follows.

Aβ can induce the production of free radicals, causing extensive and severe damage to the cell membrane. Aβ primarily targets the phospholipid bilayer structure of the plasma membrane, specifically polyunsaturated fatty acids with > C = C < double bonds, leading to the formation of cytotoxic lipid radicals and lipid peroxides through their reaction with free radicals [231]. The lipid peroxides can be further decomposed to generate more free radicals, which act on other double bonds, resulting in a chain reaction of free radicals. Metal ions such as iron [232] and copper [233] and their complexes can destruct cell membranes, and increase membrane fluidity and permeability, tissue edema, and necrosis. Recent studies show that atomic structures assembled by Aβ can disrupt neuronal cell membrane, allowing water and ions to pass through, ultimately leading to cell swelling and death.

Increased Aβ causes damage to mitochondria through disruption of intracellular calcium homeostasis. Aβ can form channels in the lipid bilayer of cell membrane, which allows Ca2+ influx, leading to intracellular calcium overload and oxidative stress [234–236]. The increased calcium mediates phospholipase activation, which leads to an elevation in arachidonic acid levels, ultimately resulting in increased generation of oxygen free radicals. Mitochondrial calcium overload suppresses mitochondrial membrane potential and thus increases the level of superoxide anions. Calcium channel blockers can alleviate the cytotoxicity of Aβ [237, 238]. Amyloid-binding alcohol dehydrogenase (ABAD), also known as endoplasmic reticulum (ER) amyloid β-peptide binding protein, is composed of 262 amino acids and mainly present in the liver and the heart. In normal conditions, it is expressed at a low level in neurons. In AD brains, especially in the vicinity of Aβ deposits, ABAD is significantly increased. ABAD itself lacks a signal peptide and a transmembrane domain. Binding to Aβ42 initiates its translocation from ER to the plasma membrane; and ABAD directly links Aβ to mitochondrial toxicity in AD [239, 240]. The formation of the ABAD-Aβ complexes during this process has a toxic effect on neurons. The binding of Aβ42 to ABAD also affects the transport of APP, leading to the retention of APP, tau, α-synuclein, and other proteins in the ER, thereby impairing neuronal function [241]. Targeting the Aβ-ABAD interaction is emerging as a novel therapeutic strategy for AD [242, 243].

Reactive astrocytes surrounding senile plaques are one of the pathological hallmarks of AD, and astrocytes play important roles in the uptake of extracellular glutamate [244]. In cultured astrocytes, free radicals induced by Aβ can inhibit glutamate uptake, resulting in an increased extracellular glutamate level and excitotoxicity to neurons. As the astrocytic uptake of glutamate is ATP-dependent, impairment in glucose metabolism can suppress glutamate uptake. In addition, protein oxidation increases carbonyl content at histidine, proline, arginine, and lysine. These changes can lead to inactivation of some key enzymes, such as glutamine synthetase and creatine kinase [245].

Aβ induces inflammatory response

Various complement components (including C1q, C4d, C3b, C3C, C3d, and C5b-9), acute-phase proteins, inflammatory markers, and activated glial cells are found within or around the senile plaques of AD patients. Aβ stimulates astrocytes to produce excessive complement C3 [246]. Aβ can bind with C1q and activate the non-antibody-dependent classical complement pathway [247]. NLRP3 is a key molecule involved in inflammasome activation, and knocking out NLRP3 can reverse cognitive impairments in APP/PS1 mice [248]. The level of cleaved caspase-1, a marker of inflammasome activation, is significantly increased in AD brains. Application of non-steroidal anti-inflammatory drugs can delay or prevent AD. These lines of evidence suggest that the toxic effects of Aβ involve inflammatory processes.

Microglia play an indispensable role in mediating Aβ toxicity. Treatment of cultured neurons with 100 μM Aβ (approximately 1000 times the physiological level) does not cause significant neuronal damage. However, when neurons were cultured with microglia, only 100 nM Aβ treatment exhibits significant toxic effects.

Aβ induces synaptic dysfunction

Synaptic damage is an early event in AD neurodegeneration. Studies suggest that soluble Aβ may have stronger and earlier detrimental effects on synapses than deposited Aβ [249]. Soluble Aβ refers to the Aβ that remains in the aqueous solution after brain tissue extraction and high-speed centrifugation, and monomeric form (4 kDa) and oligomeric forms (approximately 8 kDa and 12 kDa) have been detected using ELISA and Western blotting [250]. Artificially synthesized Aβ-derived diffusible ligands (ADDLs) are small spherical structures with a diameter of approximately 5 nm, generated by incubating synthetic Aβ1-42 in cold Ham's F12 medium. In SDS-PAGE, these ADDLs exhibit apparent molecular weights of approximately 4, 8, 16, and 18 kDa. Low-molecular-weight ADDLs tend to be located at the postsynaptic sites and may induce microglial phagocytosis of synapses by recruiting activated complement factors such as C3 and C1q, resulting in dendritic spine loss and synaptic damage [86, 251]. A recent study investigated the effects of Aβ phosphorylation on neuronal autophagy and the endo-lysosomal pathway. They found that Ser8-phosphorylated Aβ accumulates in autophagosomes, while the Ser26-phosphorylated Aβ is located to lysosomes. The selective sorting of phosphorylated Aβ species results in differential impairment of vesicular transport and lysosomal function, contributing to neurotoxicity [252].

Aβ exerts toxic effects through direct or indirect interactions with various receptors, including glutamate receptors (AMPA receptor, NMDA receptors [NMDARs], metabotropic glutamate receptor 5 [mGluR5]), cholinergic receptor α7-nAChR, insulin receptor, neurotrophin receptor P75NTR, RAGE, Ephrins receptors EphB2 and EphA4, and prion protein PrP [253]. Aβ can activate the metabotropic glutamate receptor mGluR5, leading to activation of protein kinases such as p38-MAPK, JNK, and cyclin-dependent kinase (Cdk) 5, resulting in tau hyperphosphorylation and impairment of long-term potentiation (LTP) [254]. Aβ can also activate NMDAR and PP2B via calcium-mediated signaling, leading to nuclear translocation of NFATc4 (nuclear factor of activated T-cells) and loss of dendritic spines. Aβ oligomer can upregulate α7-nAChR, by which it inhibits extracellular signal-related protein kinase 2 (ERK2), and subsequently suppress cAMP-response element binding protein (CREB) phosphorylation and downregulate BDNF, and finally results in impairment of LTP [255]. Interaction of Aβ with RAGE and scavenger receptor leads to neurodegeneration and death. A recent study identified synaptic binding of transmembrane protein 97 with Aβ in the human AD brain, which might be involved in the synapse-associated toxicity of Aβ [256].

Aβ induces impairment of neuronal axoplasmic transport

After synthesis in the ER of neurons, APP is initially transported through axons to synaptic terminals, and then undergoes intracellular transcytosis to return to the neuronal cell body and dendrites. This transport relies on the interaction between APP and PS, and plays a crucial role in maintaining normal APP metabolism and affects the generation of Aβ [257, 258]. In FAD, mutations in either APP or PSEN gene can disrupt interactions between APP and PS, leading to impaired APP transport and Aβ overproduction [259]. In sporadic AD, the overall level of Aβ may be not significantly elevated, but the following factors may lead to localized Aβ aggregation affecting APP transport: (1) free radicals covalently bind to Aβ, forming localized nuclei or seed crystals which aggregate within cells and inhibit APP transport; (2) positively charged proteins such as heparan sulfate proteoglycans can accelerate Aβ aggregation; and (3) specific intracellular locations of serum amyloid component P, composed of two identical pentamers with each molecule having 10 Aβ-binding sites, can lead to local Aβ aggregation [260]. Together, Aβ and tau accumulation are the recognized pathologies in AD. Their interplay can drive AD progression through complex mechanisms. Figure 2 summarizes the mechanisms underlying Aβ accumulation and the toxicities.Fig. 2 Mechanisms underlying Aβ accumulation and toxicities. a Common factors that promote Aβ production (left) or contribute to Aβ accumulation (right). b Experimentally proven processes of amyloid plaque formation. c Neural toxicities of Aβ

Role of tau in AD neurodegeneration

Accumulation of hyperphosphorylated tau forming NFTs is a hallmark of AD. Tau pathology is positively correlated with cognitive decline. In this part, we will review how tau proteins become hyperphosphorylated and accumulated, and how the chronically accumulated tau induces neurodegeneration.

Biology of tau proteins

As a cytoskeleton component, tau accounts for over 80% of microtubule-binding proteins in neuronal cells. The classical function of tau is to promote microtubule assembly and maintain the stability of microtubules [261]. In SDS-PAGE, tau isolated from normal adult human brains shows at least six isoforms with an apparent molecular weight of approximately 48 kDa to 60 kDa [262]. These isoforms are various splicing products (352–441 amino acid residues) derived from a single gene (MAPT) located on chromosome 17 [263]. According to the numbers of N-terminal inserts and C-terminal microtubule-binding repeats, the tau proteins are classified into 0N-3R-tau (or 0N-4R-tau), 1N-3R-tau (or 1N-4R-tau), and 2N-3R-tau (or 2N-4R-tau), containing 0, 1, or 2 N-terminal inserts (0 or 29 or 58 aa), and 3 or 4 C-terminal microtubule-binding repeats (31–32 aa each) [264]. In fetal brains, only 0N-3R-tau at ~ 48 kDa has been detected by SDS-PAGE (Fig. 3) [265].Fig. 3 Schematics showing basic structures of human tau. a MAPT gene, b pre-mRNA after transcription, and c the six major protein isoforms produced by alternative splicing

The full-length tau share 89% amino acid homology between humans (441aa or Tau441) and mice (430 aa), with the main differences located in the N-terminal projection segment [266]. The full-length human tau contains 85 potential phosphorylation sites (80 serine/threonine sites and 5 tyrosine sites), and over 60 sites have been detected in AD or non-AD brains. Some of the phosphorylation sites are within the four-repeat (4R) domains (spanning from T245 to V363): S258, S262 and T263 are located inside R1; S289 and S293 in R2; S305, Y310 and S316 in R3, and S352, S356 and T361 in R4 [267–270]. Regarding the difference of phosphorylation sites between human and rodent tau, T17, T39, T50, T52, T101, S56, S113, S131, S137, S184, S238, and Y29 are the potential human phosphorylation sites not found in mouse tau, while T10, T154, T165, S148, S155, S167, and S228 are the potential mouse sites not found in human tau [266]. In addition to phosphorylation, other post-translational modifications have also been reported in tau (Fig. 4).Fig. 4 Protein sequences and post-translational modifications of human and mouse tau proteins. a Sequence alignment of human tau (NP_005901.2) and mouse tau (NP_001033698.1). Red stars, potential phosphorylation sites only in mouse tau; black stars, potential phosphorylation sites only in human tau. The inconsistent amino acids between murine Tau430 and human Tau441 are labeled in red. b Tau phosphorylation site: red represents phosphorylation sites found exclusively in the brains of AD patients; green indicates phosphorylation sites found exclusively in non-AD human brains; blue represents the phosphorylation sites found in both non-AD and AD patients; and black represents no-phosphorylation detected. c Other identified post-translational modifications of tau proteins

Biochemical analyses show that in normal brains tau has a phosphate content ranging from 2 to 3 moles per mole of tau, while the phosphate content increases to 5–9 moles per mole of tau in the brains of AD patients [271]. By SDS-PAGE, three major bands with apparent molecular weights of approximately 62–72 kDa are shown in the brain extracts of AD patients [272]. Tau proteins in AD brains can be divided into three fractions: cytoplasmic normal tau (C-tau), abnormally modified soluble tau (AD P-tau), and tau proteins abnormally modified and aggregated into paired helical filaments (PHF-tau) [273]. Under electron microscope, PHFs are shown as a right-handed helical coil with a diameter of approximately 22–24 nm, and a narrow region of ~ 10 nm at intervals of every 80 nm [274]. Abnormalities in tau protein have been observed in a class of neurodegenerative diseases known as tauopathies, including AD. Except frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), which is caused by MAPT mutations, the remaining tauopathies are associated with abnormal post-translational modifications of tau [275] (Fig. 4).

Tau protein was first discovered as a microtubule-associated protein in 1970s [276]. Since then, studies on tau had been mainly focused on its function as a cytoskeleton protein. Recently, the non-cytoskeletal roles of tau have received increasing attention. Many new binding partners for tau have been identified, including DNA, RNA, RNA-binding proteins, transcription factors, and some membrane receptors [277–281]. The novel functions of tau, such as the roles in chromosomal stability, gene expression, aprotein synthesis and cell viability, have been proposed based on the diversity of tau-binding partners coupled with the discovery of tau in the nuclei and synapses. The tau–tau interaction and propagation have led to the hypothesis that a prion-like function of pTau may be central to tauopathies [282].

Distinct cellular effects of tau phosphorylation and aggregation

Tau protein in AD brains undergoes abnormal phosphorylation, aberrant glycosylation, glycation, ubiquitination, nitration, acetylation, SUMOylation, and abnormal truncation, etc. [268]. Among these post-translational modifications, the role of tau hyperphosphorylation in AD neurodegeneration has been most extensively studied.

Responsive or reactive tau phosphorylation endows cell resistance to apoptosis

As pTau is the main component of NFTs in degenerating neurons of AD patients, many scientists assume that phosphorylation of tau may promote neuronal apoptosis. However, recent studies show that responsive tau phosphorylation not only fails to promote cell apoptosis but also enables resistance to apoptosis. The molecular mechanisms underlying the anti-apoptotic effects of tau hyperphosphorylation are not fully understood but they certainly involve the preservation of β-catenin [283, 284].

β-Catenin is a pro-survival transcription factor. Phosphorylated β-catenin is degraded in the cytoplasm by proteasome-associated proteolysis, while the non-phosphorylated β-catenin is translocated into the nucleus to promote the expression of survival factors. Tau proteins contain 85 potential phosphorylation sites that may compete with β-catenin for the phosphorylation by protein kinases, such as glycogen synthase kinase-3β (GSK-3β). Therefore, the phosphorylation of β-catenin is inhibited with an increased intracellular tau accumulation, leading to the nuclear translocation of β-catenin and cell resistance to apotosis [283].

Lee’s group found that tau protein possesses acetyltransferase activity that can catalyze self-acetylation [285]. We also observed that tau can directly acetylate β-catenin at lysine-49 and inhibit its ubiquitination and phosphorylation, thereby suppressing the cytosolic degradation of β-catenin. The nuclear translocation of β-catenin increases expression of survival factors Bcl2 and survivin, which ultimately enables cell resistance to apoptosis [284]. These findings partially explain why the neurons in AD brains do not undergo massive acute apoptosis even when they are constantly exposed to an increasingly pro-apoptotic microenvironment during AD progression.

Tau hyperphosphorylation enables cells to escape acute apoptosis. Then the cells may restore normal function if the pTau is promptly cleared. However, continuous tau hyperphosphorylation will lead to its intracellular accumulation, which will trigger a series of dysfunctions and eventually lead to chronic neurodegeneration as seen in AD brains. Therefore, the intracellular aggregation of pTau may be a critical step in the transition of tau from anti-apoptotic to pro-neurodegenerative.

Aggregation of pTau induces neurodegeneration

The intracellular accumulation of pTau induces neurodegeneration. The mechanisms involve disruption of microtubule assembly and axonal transport, damage to neuronal synapses and neural circuits, induction of subcellular organelle dysfunction, inhibition of proteolysis, and so on.

(1) Aggregation of pTau disrupts microtubules and axons

The recognized function of tau is to promote microtubule assembly and maintain the stability of microtubules, by which it establishes the track for axonal transport [286]. Studies have shown that the level of soluble tau is decreased while the insoluble aggregated tau is significantly increased in the brains of AD patients [287]. The hyperphosphorylated tau not only loses its biological activity in promoting microtubule assembly and maintaining the stability of the microtubules, but also serves as a “seed” to recruit normal soluble tau to form aggregates or take tau protein away from already formed microtubules [288–291]. The pTau can also bind the high-molecular-weight microtubule-associated protein-1 (MAP-1) and MAP-2, and take MAPs away from already formed microtubules, causing microtubule disassembly and eventually collapse [273, 288, 292, 293]. The microtubule collapse induced by pTau aggregation will disrupt axonal track formation and thus damage axonal transport [288, 294–298]. In addition, tau can bind microfilament (such as actin), tyrosine kinase (such as Fyn and Src) [299] in the synapses, histone deacetylase-6 [300], APOE, and other molecules [301–305], by which it affects downstream signaling pathways and cell functions.

(2) Aggregation of pTau impairs synapses and neural circuits

The normal tau is mainly distributed in neuronal axons, while pTau accumulates in the cell body and dendrites, leading to impairment of synapses. For instance, tau aggregation mediates the distribution of tyrosine kinase Fyn in the postsynaptic region, leading to phosphorylation and inactivation of NMDARs [304]. Tau accumulation upregulates Janus kinase 2/signal transducer and activator of transcription 1 (JAK2/STAT1) signaling, and STAT1 can directly bind to the specific GAS element of GluN1, GluN2A, and GluN2B promoters or interact with STAT3 to suppress expression of NMDARs [306, 307]. Tau accumulation disrupts intracellular calcium signaling, leading to activation of calcineurin and dephosphorylation of nuclear CREB, consequently inhibiting glutamatergic transmission and LTP [308], a fundamental feature of learning and memory.

With the development of various neural circuit tracing and manipulating techniques, the circuit mechanisms underlying AD are being revealed [309]. It has been revealed that pTau accumulation in different brain regions and different types of neuron affects neural circuit by different mechanisms. For instance, accumulation of tau within GABAergic interneurons in hippocampal dentate gyrus has a detrimental effect on adult hippocampal neurogenesis. This impairment is caused by the suppression of GABAergic transmission and the subsequent disinhibition of neural circuits within the neurogenic niche [310]. Furthermore, the pathological accumulation of tau in mossy cells induces spatial memory deficits similar to those observed in AD, and this effect is attributed to the inhibition of local neural network activity [311]. Moreover, tau accumulation within the medial septum (MS) cholinergic neurons induces a pronounced impairment in the MS-to-hippocampal CA1 circuit. Notably, those cholinergic neurons exhibiting an asymmetric discharge characteristic, particularly within the MS-hippocampal CA1 circuit, display an increased vulnerability to tau accumulation [312]. The significance of this phonomenon and the underlying mechanism deserve further inverstigation.

In the clinic, AD patients often show emotional or psychiatric symptoms in the early stage with a simultaneous spatial memory deficit. By anterograde and retrograde tracing, we have identified a novel neural circuit, the infralimbic medial prefrontal cortex-posterior basolateral amygdale-ventral hippocampal CA1 (iMPC-pBLA-vCA1) circuit that links emotions to spatial memory and is impaired in AD mice [313–315].

(3) Aggregation of pTau damages suborganelle functions

Mitochondria are the powerhouse of the cell, and mitochondrial dysfunction plays an important role in aging and AD [316, 317]. Accompanying increased tau in the cytoplasm, accumulation of elongated mitochondria has been detected around the cell nucleus [318]. Simultaneously, the mitochondrial membrane potential is increased with impaired energy production and inhibition of mitophagy [319–321]. Unlike the role of Aβ, tau aggregation disrupts mitochondrial fission–fusion by promoting fusion [318, 322], which may also explain why tau hyperphosphorylation has an anti-apoptotic effect. Intracellular aggregation of tau also induces ER stress, Golgi fragmentation, DNA double strain breaking, etc. [323–330].

(4) Aggregation of pTau inhibits autophagy

Autophagy deficits, commonly seen during aging and in AD [331, 332], can induce intracellular tau accumulation. Interestingly, studies show that intracellular tau accumulation can in turn induce autophagy deficits [333, 334].

The increased tau could inhibit autophagosome formation (early steps of the autophagy pathway) by increasing the activity of mammalian target of rapamycin kinase complex 1 (mTORC1), evidenced by the increased levels of p-4EBP1 (phosphorylated eukaryotic translation initiation factor 4E-binding protein 1), p-p70S6K1 (phosphorylated 70 kDa ribosomal protein S6 kinase 1), and p-ULK1 (phosphorylated unc-51-like autophagy-activating kinase 1). The mechanisms involve binding of tau to the prion-related domain of T cell intracellular antigen 1, which increases intercellular amino acids, leading to activation of mTORC1 and inhibition of autophagosome formation [333].

Tau accumulation can also suppress autophagosome-lysosome fusion, the downstream step of the autophagy pathway. The intracellular tau aggregation inhibits the expression of IST1, a positive modulator for the formation of the Endosomal Sorting Complex Required for Transport (ESCRT) complex that is required for autophagosome-lysosome fusion. IST1 facilitates association of CHMP2B (charged multivesicular body protein 2B) with CHMP4B/SNF7-2 to form the ESCRT-III complex, while lack of IST1 impedes formation of the complex. Tau accumulation suppresses IST1 transcription through ANP32A-regulated mask of histone acetylation [334]. These findings together suggest that tau accumulation inhibits autophagy by different molecular mechanisms, which reveal a vicious cycle of tau accumulation and autophagy deficit in the chronic course of AD neurodegeneration.

Mechanisms underlying tau hyperphosphorylation

Tau protein was first reported as a factor for microtubule assembly in 1975, and it was identified as a neuron-specific cytoskeleton protein in 1985. In 1986, Grundke-Iqbal et al. revealed that the abnormal pTau is the major protein component of the PHF/NFTs isolated from the brains of AD patients [3, 335]. Since then, over 60 phosphorylation sites have been identified in AD brain extracts [269, 270]. Phosphorylation of tau is regulated by protein kinases and phosphatases [336]. Thus, the imbalance between kinases and phosphatases is the direct cause of the hyperphosphorylation of tau proteins.

Role of protein kinases in AD-like tau hyperphosphorylation

The full-length human tau protein (441 aa) has 85 potential phosphorylating sites, in which 80 are serine/threonine (Ser/Thr) sites, and 5 are tyrosine (Tyr) sites (Fig. 4).

(1) Ser/Thr kinases

Protein kinases exhibit high diversity and possess complex regulatory mechanisms. Based on the substrate sequence characteristics, Ser/Thr kinases can be classified into two major types, i.e., proline-directed protein kinases (PDPK) and non-proline-directed protein kinases (non-PDPK) [337]. PDPK targets the motif with proline [–X–(S/T)–P], while non-PDPK targets the motif without proline [–X–(S/T)–X–] (where X represents any amino acid, S represents serine, T represents threonine, and P represents proline). Among the known AD-associated phosphorylation sites, approximately half are PDPK sites, while the other half are non-PDPK sites (Fig. 4). The identified PDPKs that can phosphorylate tau protein include ERKs, cell division cycle protein kinase-2, Cdk2, Cdk5, and GSK-3β [338]. The non-PDPKs that can phosphorylate tau protein include cyclic-AMP-dependent protein kinase (PKA), protein kinase C (PKC), calcium/calmodulin-dependent protein kinase II, rat cerebellar calcium/calmodulin-dependent protein kinase (Grkinase), PKN [339], tau tubulin kinases (TTBK) 1 and 2 [340, 341], DYRK [342], MARK [343], Chk1 and 2 [344], casein kinase-1 (CK-1), and CK-2 [345–347]. It is worth noting that the individual phosphorylation efficacy of these kinases on tau proteins may be relatively low. However, pre-incubation of tau with non-PDPKs, such as PKA, CK-1 and PKC, significantly enhances the subsequent phosphorylation rate catalyzed by PDPKs (such as GSK-3β), leading to a significant increase in tau phosphorylation level [348]. This suggests that the phosphorylation of tau catalyzed by PDPKs may be subject to positive regulation by non-PDPKs, and vice versa, which adds complexity to the phosphorylation process in vivo.

(2) Tyrosine kinases

The full-length tau protein has 5 tyrosine residues, i.e., Tyr18, Tyr29, Tyr197, Tyr310, and Tyr394. Among them, only Tyr394 phosphorylation is detectable under physiological conditions, while an increased phosphorylation at Tyr18, Tyr197, and Tyr394 has been identified in the brains of AD patients [349, 350]. Early studies demonstrated that tyrosine kinase c-Abl can phosphorylate tau at Tyr394; TTBK1 can phosphorylate tau at Tyr197; non-receptor tyrosine protein kinases such as SFK (Src family kinase) and Syk (spleen tyrosine kinase) can phosphorylate tau at Tyr18; and kinase Fyn can phosphorylate tau at Tyr18. By binding to Fyn, tau can detain Fyn at postsynaptic sites of excitatory neurons, where Fyn can phosphorylate NMDARs and PSD95, and thus enhance the excitotoxicity of NMDARs [304]. Aβ can activate Fyn to cause synaptic toxicities, and these toxic effects disappear when tau is knocked out [303], which supports an indispensable role of tau in mediating Aβ toxicity on synapses. In addition to Fyn, c-Abl is also present in NFTs and co-localizes with tau [351]. In the early stages of tangle formation, c-Abl levels are increased in neurons. Aβ treatment of primary neurons results in increased c-Abl activity, while intraperitoneal injection of c-Abl inhibitor imatinib mesylate rescues cognitive impairments in AD animal models [352]. These data suggest that tyrosine phosphorylation of tau is involved in AD. However, whether and how tyrosine phosphorylation of tau plays a role in AD neurodegeneration needs further validation.

Role of protein phosphatases in tau phosphorylation

According to their structure, composition, substrate specificity, and different activators and inhibitors, mammalian protein phosphatases can be roughly classified into five categories: PP1, PP2A, PP2B, PP2C, and PP5, all of which are expressed in the human brain [353]. When using abnormally phosphorylated tau isolated from the AD brain as a substrate, PP1, PP2A, PP2B, and PP5, but not PP2C, can dephosphorylate tau at multiple sites and restore the microtubule assembly activity of tau proteins to varying degrees [354]. Treatment of cultured cells with protein phosphatase inhibitors increases tau phosphorylation with simultaneous alterations in intermediate filament structure, loss of microtubules, and impairments of neuronal synapses and dendrites. The dephosphorylation activity of PP2A and PP2B towards the AD tau can be activated by Mn2+ and Mg2+, with Mn2+ having a stronger effect than Mg2+ [355]. The PP2B activity on tau dephosphorylation is also enhanced by Ca2+/calmodulin [356]. The dephosphorylation effects of the phosphatases on the insoluble PHF/NFT are weaker than the effects on soluble tau proteins. The details for tau dephosphorylation catalyzed by various phosphatases are as follows.

(1) PP2A

PP2A is a heterotrimer consisting of structural subunit A, regulatory subunit B and catalytic subunit C. The B subunit has four subfamilies and is encoded by 15 genes, including at least 23 isoforms. PP2A-ABαC, concentrated in the cytoplasm with small amounts in mitochondria and microsomes, is the major brain form of PP2A involved in tau dephosphorylation. PP2A binds to different sites in tau and microtubules, and changes in either component will affect tau dephosphorylation by PP2A and thus change the structure and function of microtubules.

The evidence for the involvement of PP2A in the AD-like tau phosphorylation is as follows. Reduced PP2A activity is observed in the brains of AD patients. Compared to PP1, PP2B, and PP5, PP2A is the major tau phosphatase accounting for over 70% of AD-like tau dephosphorylation in the brain tissue [357]. Furthermore, PP2A exhibits the highest specific activity in dephosphorylating tau, and thus disassembles tangles and releases free tau protein to restore biological activity of tau [358]. Inhibition of PP2A leads to AD-like hyperphosphorylation of tau protein and disruption of the cellular cytoskeleton, accompanied by impairments in spatial learning and memory in rats. In the brains of AD patients, endogenous PP2A inhibitors, I1PP2A, I2PP2A and CIP2A [359], are colocalized in the cytoplasm with PP2A within neurons, and increasing these inhibitors suppresses PP2A activity and induces tau hyperphosphorylation.

(2) PP2B

PP2B, also known as calcineurin, is the most abundant calcium-dependent phosphatase accounting for ~ 10% of the total protein in the brain. Although PP2B is highly enriched in the brain. In vitro studies demonstrated that the specific activity of PP2B on tau proteins is much lower than that of PP2A [358]. PP2B is primarily localized in the perinuclear region and dendrites of neurons, existing as a heterodimer consisting of a 61 kDa catalytic subunit (CA) that can bind to calmodulin (CaM) and a 17 kDa regulatory subunit (RB) that can bind to Ca2+. There are two isoforms of PP2B, Aa and Ab, with Aa being the predominant form in the brain. PP2B requires binding of CA and RB to exert functions and Ca2+-CaM, Mn2+ and Ni2+ activate the phosphatase. Purified PP2B from human brains can dephosphorylate pTau at multiple AD-associated sites [360], and PP2B knockout induces tau hyperphosphorylation with abnormalities of the cytoskeleton [361]. Reports on PP2B activity in the AD brain are contradictory, with some showing an increased PP2B activity rather than a decreased activity.

(3) PP1

PP1 is a complex composed of a catalytic subunit C and various regulatory subunits. It is widely expressed in the plasma membrane, cytoplasm, and subcellular organelles of pyramidal neurons. PP1 may be involved in learning and memory processes by regulating synaptic transmission and plasticity [362–364]. Tau, as an anchor protein, can interact with both PP1 and microtubule, and thereby modulate the phosphorylation state of tau [365]. In AD patients, PP1 activity is decreased [357, 366]. Although in vitro studies indicate the involvement of PP1 in tau dephosphorylation, little is known regarding the in vivo role of PP1 in dephosphorylating tau proteins. It is worth noting that kinase upregulation by PP1 (also applicable to other PPs) may counterbalance its dephosphorylating effect on tau proteins. The main physiological inhibitors of PP1 include inhibitor-1 (I-1), I-2, and I-3 [367]. Okadaic acid (OA, Ki 100 nM) and calyculin A (CA, Ki 50 nM) can also inhibit PP1 [368].

(4) PP5

PP5, highly expressed in neurons of the brain, is capable of dephosphorylating tau at multiple sites in vitro, and the activity of PP5 is decreased in the brains of AD patients [369, 370]. Currently, the role of PP5 in tau dephosphorylation in vivo or its involvement in AD is unclear.

Other factors that indirectly influence tau phosphorylation

In addition to protein kinases and phosphatases which directly phosphorylate or dephosphorylate tau proteins, other factors, such as PS1, APOE, etc., have been reported to influence tau phosphorylation indirectly. For instance, PS1 can directly bind to GSK-3β, one of the most prominent kinase in phosphorylating tau at multiple AD-associated sites, and thereby decrease the kinase activity [371]. PS1 can form a complex with β-catenin, by which it enhances the stability of β-catenin and affects tau phosphorylation through Notch and Wnt signaling. In those AD patients with PSEN1 mutations, both the stability and the level of β-catenin are significantly reduced [372]. Since both β-catenin and tau are substrates of GSK-3β, decreased β-catenin may contribute to an increased tau phosphorylation by substrate competition [283]. PSEN1 mutations can also change the intracellular transport of β-catenin, thereby affecting tau phosphorylation [373]. In addition, many studies demonstrate that the APOE4 genotype is associated with tau hyperphosphorylation compared with APOE2 and APOE3, although conflict results have been reported.

Mechanisms underlying tau aggregation

The molecular mechanisms underlying the abnormal aggregation of tau remain unclear. Studies have demonstrated that characteristic motifs, such as hexapeptides, or site-specific phosphorylation in tau proteins could promote tau aggregation. In addition, pTau proteins undergo multiple additional modifications such as glycosylation, glycation, acetylation, nitration, SUMOylation, truncation, methylation, and ubiquitination, and these post-translational modifications can also promote tau aggregation.

The aggregation propensity motif in the primary sequence of tau

Although tau itself has no specific spatial structure, the N- and C-terminal in the primary sequence of tau can fold over in the proximity to the center of the microtubule-binding domains to form a “paperclip-like” conformation. In full-length 4R tau, the two hexapeptides, 275VQIINK280 [374] and 306VQIVYK311 [375] (also known as PHF6) located at the initial sequence of 2R and 3R domains, respectively, can drive β-sheet formation. Tau phosphorylation proximal to these regions is relevant to tau aggregation. By using this motif-characteristics, K18 that is composed of the 4R domain of tau or the K18 mutant containing K280 deletion or P301L mutation (a point mutation of tau found in FTDP patients) has been used as a “seed” to efficiently promote tau aggregation [376–378].

Studies also show that the site-specific phosphorylation can directly affect the conformation of tau, thus contributing to the propensity of tau to aggregate [379–381]. For instance, phosphorylation at S202/T205/S208 within the proline-rich region (PRR) induces tau self-aggregation [382]. It is also reported that phosphorylation of tau at S198, S199, S416, S396, and S422 correlates with increased oligomerization or increased aggregation of tau proteins [383]. These data together suggest that the site-specific phosphorylation of tau may play a role in its self-aggregation, and the mechanisms involve changes in charges and conformations of tau proteins. However, it is still not clear which phosphorylation site(s) is indispensable for tau aggregation. As K18 or the mutant could efficiently mimic the AD-like tau aggregation and the cytotoxicity, the K18 models may be used for in-depth mechanistic studies and tau-targeted drug screening.

Interplay of different post-translational modifications

(1) Mutual promotion of phosphorylation and SUMOylation aggravates tau aggregation

Small ubiquitin-like modifier (SUMO) is a small ubiquitin-like protein that can reversibly modify substrate proteins in a manner similar to ubiquitination, a process known as SUMOylation [384]. This modification regulates the biological activity, subcellular localization, and stability of proteins. SUMO-1 has been found to co-localize with aggregated phosphorylated tau in the brains of AD patients and mouse models, and the level of SUMO-1 is also increased in the plasma of AD patients [385–387].In vitro studies demonstrate that tau protein at Lys340 can undergo SUMOylation, and SUMOylation of tau at Lys340 reciprocally promotes its phosphorylation at multiple AD-associated sites. As SUMOylation and ubiquitination generally occur at the same alkaline amino acid, SUMOylation of tau inhibits its ubiquitination, thus blocking its degradation by the proteasome system and leading to tau aggregation. Treatment of primary neurons with Aβ results in increased SUMOylation and phosphorylation of tau proteins [388].

(2) Aberrant acetylation and ubiquitination induce tau aggregation

In purified soluble phosphorylated tau from the AD brain, at least 19 acetylation sites have been detected, some of which overlap with the ubiquitination sites [270]. Meanwhile, more and more acetylation sites in tau are being reveled by in vitro experiments [389, 390] (Fig. 4). Ubiquitination occurs more frequently in the microtubule-binding repeats R1–R3 regions, while many acetylation sites are located in the R4 region [270, 389]. Furthermore, mass spectrometry analysis of AD brain samples revealed that both ubiquitination and acetylation occur in the late stages of tau pathology (Braak stages V–VI) and are directly associated with the seeding and aggregation properties of tau proteins [390, 391]. However, studies have also shown that acetylation of certain sites, such as Lys174, occurs in the early-to-mid stages of AD pathology [392]. In cellular experiments, histone acetyltransferase p300 can induce tau acetylation, while SIRT1 (a deacetylase) can deacetylate tau proteins [390, 393].

Interestingly, tau itself possesses acetyltransferase activity that can catalyze its self-acetylation [285]. Tau can also acetylate other substrates, such as β-catenin and GSK-3β [284, 394]. Due to the occurrence of acetylation and ubiquitination at lysine residues, increased acetylation of tau protein can lead to decreased ubiquitination level, resulting in reduced degradation. Simultaneously, acetylation interferes with the binding of tau to microtubules and promotes tau aggregation [390]. Tau acetylation and ubiquitination are both increased in the brains of AD patients, suggesting that abnormal acetylation may precede abnormal ubiquitination. Acetylation competes for the lysine residues, preventing effective ubiquitination and degradation of tau, leading to tau aggregation [395].

Ubiquitin, a peptide consisting of 76 amino acids, is covalently attached to target proteins via an isopeptide bond between its C-terminal glycine and a lysine residue of the substrate [396]. Under normal conditions, ubiquitinated proteins are degraded through the ubiquitin–proteasome pathway, where they are recognized and proteolised by proteasome. However, deregulation of the ubiquitin degradation pathway or structural changes of the targeted protein will make them less susceptible to ubiquitination, leading to impeded degradation and increased protein aggregation [397]. Interestingly, ubiquitin is significantly increased in AD brains and is primarily detected in the insoluble PHF/tangle aggregates [398]. To date, at least 28 potential ubiquitination sites on tau have been identified [399], in which 17 are exclusively present in the insoluble tau aggregates, and 16 are located in the microtubule-binding region [270, 400] (Fig. 4). The elevated ubiquitination of tau protein in the AD brains may be a consequence of its aggregation, or represent a compensatory response to degrade the abnormally aggregated tau proteins. Although the relationship of ubiquitination with acetylation, SUMOylation, and phosphorylation is still not clearly elucidated, a competition between ubiquitination and acetylation/SUMOylation has been recognized [388, 401].

During the process of tau aggregation, the microtubule-binding domain (MBD) forms the core of the aggregates through β-folding. The MBD contains 19 lysine residues which, under physiological conditions, carry a positive charge that prevents β-folding due to electrostatic repulsion. Phosphorylation of serine, threonine, and tyrosine residues in the MBD, as well as acetylation of lysine residues, may promote β-folding through a charge neutralization effect by introducing negative charges. Additionally, phosphorylation is also frequently observed in the PRR, which is believed to facilitate aggregation by spatially approaching the MBD and neutralizing its positive charges [270].

In addition, methylation of tau at arginine residues, primarily occurring in the MBD, has been revealed from both healthy and AD brains [267, 402–405] (Fig. 4). Some lysine residues (K163, K174, and K180) can be both acetylated and methylated in vivo. The exact impact of lysine methylation on endogenous tau activity remains unclear [404]. The in vitro methylated tau appears to have reduced aggregation tendencies and can promote tubulin assembly, hinting at a protective role against protein aggregation [405]. In the context of AD, methylated residues on tau aggregates raise the intriguing possibility of interfering with ubiquitination and impeding proteasome-mediated degradation [402], which may deserve further examination.

Glycosylation and glycation may differently affect tau aggregation

Glycosylation refers to the process in which specific glycosyltransferases covalently attach sugar moieties to protein molecules, forming glycoproteins through N-glycosidic or O-glycosidic bonds. In normal tissues, protein glycosylation occurs in the rough ER and Golgi apparatus during protein synthesis, either during translation (N-glycosidic bonds) or post-translationally (N- and O-glycosidic bonds) [406, 407]. The glycosyltransferases involved in this process are often membrane-bound. Tau is a cytosolic protein. Glycosylation of tau often indicates abnormalities in the membrane structure, which allows for interaction between tau and glycosyltransferases. The presence of abnormalities of membrane lipids and membrane fluidity in AD patients supports this hypothesis. Furthermore, the AD-related PS1, PS2, and APP are all membrane-associated proteins, and PS1 and PS2 are highly expressed in rough ER and Golgi apparatus. Therefore, exploring the relationship between abnormal glycosylation of tau and abnormalities of membrane proteins (PS and APP) is of significance for elucidating the mechanisms underlying AD pathogenesis.

In AD, the brain-derived PHF/tangles and the pTau are subjected to abnormal glycosylation [408, 409]. These modifications predominantly involve the addition of terminal mannose, sialic acid α-(2–3)-linked to galactose, β-galactose (1–3)-N-acetylglucosamine, and β-galactose (1–4)-N-acetylglucosamine, with N-glycosylation being the primary form. When PHF/NFT is subjected to negative staining electron microscopy in the presence of glycosidases at 37 °C, the observed PHF structures disappear, and instead, more compact and elongated fiber-like structures are formed [408]. However, deglycosylation alone does not restore the biological activity of tau, nor does it significantly increase the release of tau protein from PHF/NFT. Nevertheless, subsequent treatment with PP2A to dephosphorylate the deglycosylated tau significantly increases tau release from tangles compared to dephosphorylation alone. This suggests that the abnormal aggregation of tau in the AD brain can be reversed. Hyperphosphorylation of tau primarily contributes to the formation and stability of PHF/NFT, while tau glycosylation may contribute to the maintenance of the helical filament structure [410].

There are conflicting reports regarding the relationship between O-glycosylation and phosphorylation of tau protein [411, 412]. The pTau is O-glycosylated in the AD brain samples, but in vitro studies show coexistence of low levels of O-glycosylation and phosphorylation in tau [413, 414]. Other studies showed that fasting induces a time-dependent reduction of protein O-glycosylation with a simultaneous increase in protein phosphorylation, suggesting that the impaired glucose metabolism in the AD brains may induce tau hyperphosphorylation by decreasing O-glycosylation [413, 415]. On the other hand, self-aggregation of pTau may create a “seeding site” within affected neurons, and the increased intracellular concentration of phosphate group caused by hyperphosphorylation may make tau more susceptible to glycosylation. Therefore, it can be inferred that hyperphosphorylation may promote tau glycosylation.

In addition, tau protein in the AD brains undergoes abnormal glycation [416, 417]. Glycation refers to the process in which the ε-NH2 group of protein molecules reacts with the aldehyde groups of intracellular sugars, forming Schiff bases through oxidation without requirement of enzymes. Subsequent intramolecular rearrangement leads to the formation of insoluble, protease-resistant, and irreversible cross-linked structures known as advanced glycation end products (AGEs) [418]. Tau proteins, enriched in lysine and ε-NH2, are highly susceptible to AGE formation [419, 420]. The formation of AGEs may contribute to the transition of PHFs to NFTs, leading to irreversible damage to neurons [417, 420].

Site-specific tyrosine nitration differently affects tau aggregation

Nitration of tau protein has been observed in NFTs and tau inclusions in AD patients (Fig. 4), suggesting the involvement of tau nitration in its aggregation [421]. Treatment of tau with peroxynitrite (ONOO-) in vitro leads to 3-nitrotyrosine (3-NT) immunoreactivity and the formation of SDS- and heat-stable oligomers through dityrosine cross-linking. This 3-NT-modified tau is elevated in the brains and CSF of AD patients [422, 423]. Tau contains five tyrosine residues, Tyr18, Tyr29, Tyr197, Tyr310, and Tyr394 [424]. Nitration of tau at Tyr197 has been detected in both normal individuals and AD patients. Nitration at Tyr29 has been detected in both soluble and insoluble tau proteins from AD patients but not in normal brain tissue. Nitration at Tyr394 has been detected only in the insoluble PHF-tau derived from AD patients [425, 426]. In addition, the nitration of tau at Tyr18 is predominantly observed in the activated astrocytes in AD brains [427]. Treatment of tau with peroxynitrite in vitro results in nitration primarily at Tyr18 and Tyr29, and nitration at these sites inhibits tau aggregation [428]. With these conflicting data, the specific role and mechanism of nitration at different sites during AD progression, as well as the relationship between tyrosine phosphorylation and nitration at the Tyr sites, are currently unclear.

Truncation at various sites differently affects tau aggregation

Tau truncation refers to the enzymatic cleavage of tau proteins at its N-terminus or C-terminus, resulting in production of shorter molecular forms of tau. At least two classes of enzymes have been reported to cleave tau: the caspase family members and AEP [429].

(1) Tau truncation by caspases

Caspases are key enzymes in the apoptosis pathway. The activities of caspases-2 and -3 are increased in AD brains [430], but their roles in the induction of neuronal apoptosis in AD are still unclear [17]. Both in vitro and in vivo experiments have shown that caspases-2, -3, and -6 can cleave tau protein at Asp421, Asp418, Asp314, and Asp13 [431, 432]. The truncated forms of tau protein generated by cleavage exert toxic effects on neurons through different mechanisms [433–435]. For example, tau truncated at Asp421 by caspases-3 and -6 damages microtubules and cytoskeleton [434, 436]. Tau truncated at Asp314 by caspase-2 results in mislocation of tau into the dendritic spines and impairs the function of postsynaptic membrane glutamate receptors [432, 437], although it is also reported that the Asp314 truncation exhibits anti-aggregation properties [432, 437].

(2) Tau truncation by AEP

AEP, an endopeptidase that can cut peptide bond formed by asparagine, is primarily found in lysosomes and it is activated under acidic conditions [438, 439]. The activity of AEP is increased in the brains of aged and AD patients. An in vitro study demonstrated that AEP could cleave tau protein at Asn255 and Asn368, generating truncated forms of tau (1–368 and 256–368); and both truncated forms of tau exhibit reduced microtubule assembly capacity and are toxic to neurons [213]. Truncation of tau (especially at C-terminal) induces conformational changes of tau, by which it results in proximity of the proline-rich region to the microtubule-binding domain and thus promotes tau aggregation [440].

Sequential order of different post-translational modifications of tau

The role of different post-translational modifications in tau aggregation has been constantly revealed, but their sequential order is still unclear. A recent study analyzed the occurrence and frequency of different post-translational modifications at various tau sites in brain tissues from AD patients at different Braak stages and from control subjects [270]. Results showed that partial phosphorylation of tau protein occurs in the PRR and C-terminal at Braak stages 0–2; more phosphorylation sites are detected in these two regions at Braak stages 3–4; acetylation and ubiquitination occur in the MBD in addition to the increased phosphorylation sites in Braak stages 5–6; and various post-translational modifications significantly increase in the most severe AD patients [383]. It is speculated that phosphorylation of tau in the PRR and C-terminal region may initially change its charge and conformation, which promotes β-sheet formation in the MBD and serves as the core for tau aggregation [375]. Tau aggregation may increase its lysine acetylation which could aggravate tau accumulation by neutralizing the positive charge in the MBD region. Tau accumulation can activate the ubiquitination system to degrade tau proteins, which may explain why increased ubiquitination has been often detected in the NFTs of AD brains. In addition, truncation of tau also enhances its aggregability, which may play a role in initiating aggregation and promoting the pathological spreading of tau proteins in the early stages [441].

Tau gene mutations promote its phosphorylation and aggregation

To date, no gene mutation on tau has been found in AD patients. However, over 50 distinct mutations in tau gene have been identified in individuals with FTDP-17 [442, 443]. These mutations encompass various types, such as missense mutations, deletion mutations, silent mutations, and intronic mutations downstream of exon 10 within the coding regions of exons 9, 10, 12, and 13. Functionally, these mutations exert their effects at both RNA and protein levels [444], resulting in diminished microtubule-binding affinity of tau protein, enhanced aggregation propensity [445, 446], and an altered ratio of 4R-tau to 3R-tau isoforms, ultimately culminating in elevated levels of 4R-tau species within the brain [447]. Compared to the wild-type tau, the mutated tau proteins associated with FTDP-17 exhibit increased susceptibility to hyperphosphorylation and aggregation, thereby displaying an augmented cytotoxicity [448].

Tau mutations in FTDP-17 may contribute to increased phosphorylation through the following mechanisms. First, the mutations alter the conformation of tau to a more favorable substrate for protein kinases. Consequently, tau proteins with mutations are more prone to hyperphosphorylation. Second, several mutations in tau reduce its binding affinity with PP2A, a crucial phosphatase in tau dephosphorylation [449]. Furthermore, the mutations facilitate tau self-aggregation even at lower levels of phosphorylation [446].

There are still many other factors affecting tau phosphorylation and aggregation. For instance, heat shock protein 90, one of the major tau-binding chaperones, promotes tau phosphorylation and aggregation by binding tau at the VQIVYK motif and inducing conformational changes on tau [450]. On the other hand, Hsp70 and Hsp104 show inhibitory effects on tau seeding and aggregation [451, 452].

Mechanisms underlying tau transmission

In AD patients, tau pathology as NFTs first appears in the entorhinal cortex, and then spreads from the hippocampal limbic system to the whole brain. Based on this sequential appearance, brain pathology of AD patients can be classified into six Braak stages [453]. Currently, it is not clearly understood how the abnormal tau proteins propagate into different brain regions or are transmitted from one cell to another. Studies suggest that the transcellular tau propagation may follow the prion-like transmission pattern [454–456], but the exact mechanism underlying prion transmittion is also not clear. As tau is an intracellular protein, the transmission process should at least involve the release of intracellular tau to the interstitial space and the uptake of extracellular tau by recipient cells.

Release of intracellular tau proteins into the interstitial space

As a cytoskeleton protein, tau is distributed in the intracellular compartment, mainly in neuronal axons in physiological conditions [457, 458]. In vitro studies demonstrate that tau can be actively released into the extracellular spaces through synapses or extra-synaptic compartments, which explains the detection of tau proteins in the extracellular matrix by microdialysis or in the CSF, though the level is relatively low in physiological conditions. The CSF level of tau, especially the pTau proteins, is significantly increased in a majority of AD patients, suggesting increased tau release in AD [459–461]. These results indicate that tau proteins may be secreted by presynaptic neurons, and the secretion is significantly increased in AD patients, leading to increased tau transmission.

The trans-synaptic tau spreading is achieved by direct transmission of exosomes between neurons in both physiological and pathological conditions [462]. Interestingly, the neuron-derived exosomal tau is less phosphorylated than the tau retained in the cytosol. Whether this type of secretion has any significance is unclear [463]. It is also found that neuron depolarization or synaptic activity promotes the release of tau-containing exosomes, which highlights the importance of neuronal activity in tau transmission [462].

In addition, the increased interstitial level of tau during AD progression may also be attributed to the impaired integrity of the neuronal plasma membrane, which leads to a massive leak of tau into the extracellular space. This speculation may deserve further investigations.

Uptake of extracellular tau by the recipient cells

Cells in the central nervous system can also actively internalize monomeric tau via receptor-mediated endocytosis and non-receptor-mediated pathways. For the receptor-mediated endocytosis, it has been reported that the monomeric tau is internalized by neurons via muscarinic receptors M1 and M3 [464], while the uptake of tau by microglia is mediated by CX3CR1 [465, 466]. In astrocytes, uptake of tau-containing exosomes has not been detected [462]; instead, non-HSPG-dependent endocytosis of tau proteins has been shown [467]. The non-receptor-mediated pathways include HSPG-associated macropinocytosis [468], clathrin-mediated endocytosis and bulk endocytosis [469]. LRP1, which is abundantly expressed in neurons, microglia and astrocytes, has also been identified as a major regulator of tau spreading in the brain [470].

In summary, during the course of AD, dysregulation of protein kinases and phosphatases leads to tau hyperphosphorylation; increased tau phosphorylation inhibits the phosphorylation of β-catenin with mechanisms involving direct acetylation of β-catenin by tau, or through substrate competition of tau and β-catenin for the kinases (such as GSK-3β). The increased acetylation inhibits ubiquitination of β-catenin, which together with the reduced phosphorylation, makes β-catenin escape from proteolysis and retain in the cytoplasm. The increased cytoplasmic β-catenin is translocated into the nucleus with currently unknown mechanism and promotes expression of survival factors, such as Bcl2 and survivin. Finally, the cells escape from an acute apoptosis. If pTau can be timely dephosphorylated, the tau-related neurodegeneration can be prevented [29]. Most importantly, as dephosphorylation of tau proteins can restore their biological functions in promoting microtubule assembly and stability, it may improve the architecture of cytoskeleton and thus promote outgrowth or regeneration of the dystrophic neuronal processes as seen in AD, thereby curing AD neurodegeneration. If the pTau proteins are not timely handled, they may undergo various other post-translational modifications such as acetylation, SUMOylation, glycosylation, glycation, nitration, and truncation, etc. One of the adverse consequences of these modifications is the intracellular aggregation of tau proteins. Tau aggregation can disrupt microtubule assembly and axonal transport, induce dysfunctions of mitochondria, ER, Golgi, synapses and neural circuits, and inhibit proteolysis. The vicious cycle between tau hyperphosphorylation and aggregation continuously aggravates tau accumulation, propagation, and neural damage, ultimately leading to chronic neurodegeneration (Fig. 5).Fig. 5 Mechanisms underlying tau-associated neurodegeneration in AD. a Imbalance of protein kinases and protein phosphatases leads to tau hyperphosphorylation. b Tau hyperphosphorylation inhibits acute cell apoptosis by preserving β-catenin. c Additional post-translational modifications of pTau promote its intracellular aggregation and accumulation. d Abnormally accumulated tau protein impairs multiple cellular biological functions. Tau hyperphosphorylation and accumulation forms a vicious cycle, resulting in chronic neurodegeneration as seen in AD

AD experimental models and their characteristics

Animal models that replicate human diseases are invaluable for investigating the underlying mechanisms and developing new drugs [471]. Currently, over a hundred AD animal models have been reported, including mouse, rat, and non-human primate models. Among them, the mouse models are the most widely used. The basic features of AD mouse models include varying degrees of cognitive impairments at different ages, accompanied by synaptic damage, Aβ elevation or plaque formation, tau hyperphosphorylation and aggregation, and activation or proliferation of glial cells. Although the use of animal models has made significant contributions to unraveling the disease mechanisms, their effectiveness in drug development has been somewhat disappointing. In recent years, scientists have attempted to establish AD patient-derived cell and organoid models that better simulate their brain pathology [472].

AD mouse models

Aβ-related models

Current AD mouse models mainly focus on the APP and PSEN1 gene mutations detected in AD patients [473–476]. Based on the types of mutated genes expressed in AD mice, the Aβ-related mouse models can be broadly categorized as follows.

(1) Models expressing various APP mutations

These include PDAPP (AβPPInd) [477], Tg2576 (AβPPSwe) [478], APP23 (AβPPSwe) [479], TASD-41 (AβPPSwe, Lon) [480], J20 (AβPPSwe, Ind) [481], TgCRND8 (AβPPSwe, Ind) [482], and others [483]. Heterozygous PDAPP mice develop sulfur-positive Aβ deposits and neuroinflammatory plaques between 6 and 9 months of age [477]. Among them, the Swedish mutation (Swe, K670N/M671L) located near the N-terminus of Aβ and promoting β-cleavage, is the most common. The Indiana (Ind, V717F), London (Lon, V717I), Florida (Flo, I716V), and Iberian (Ibe, I716F) mutations are located near the C-terminal γ-cleavage site of Aβ and promote γ-cleavage of APP, resulting in the production of longer, more toxic Aβ molecules. The Dutch mutation (Dutch, Aβ E22Q), Arctic mutation (Arc, Aβ E22G), and Iowa mutation (Aβ D23N) are internal mutations within the Aβ peptide, altering the amino acid sequence of Aβ [484–487].

(2) Models simultaneously expressing mutated APP and PSEN1 genes

The PS/APP (AβPPSwe/PS1M146L) [488, 489], 2KI (AβPPSwe/PS1P264L) [490] and 5 × FAD (AβPPSwe, Lnd, Flo/PS1M146L, L286V) [491, 492] are the most commonly used models [474, 493]. The APP/PS1 mice exhibit cortical amyloid plaque deposition and glial activation at 4 months of age, along with reduced synaptic numbers in the hippocampus [490]. They also experience significant spatial learning and memory impairments at 6 months of age. In these mice, the extent of amyloid pathology is higher in females than in males. 5 × FAD mice show intraneuronal Aβ aggregation at 1.5 months of age, followed by amyloid deposition and glial activation at 2 months, and subsequently synaptic, neuron loss, and cognitive impairment at 4–5 months of age [493].

(3) Models simultaneously expressing mutated APP, PSEN1, and MAPT genes

The 3 × Tg AD (AβPPSwe/tauP301L/PS1M146V) [494–496] mice exhibit brain amyloid deposition at 3–4 months, impaired synaptic transmission and LTP at 6 months, and hippocampal tau hyperphosphorylation at 12–15 months of age; it is also reported that 3 × Tg AD mice show tau hyperphosphorylation, neuroinflammation, and reduced cognitive function at 6 months of age. The APP/PS1 and 3 × Tg AD mouse models exhibit varying degrees of tau pathology at certain age stages, but they do not form NFTs [476]. In addition, AβPPSwe and Ind mice co-transfected with APOE4 [497] or co-regulated with leptin knockout (ob/ob) are also useful models for AD research [483].

We can also replicate AD-like pathologies and behavioral changes by intraventricular or bilateral hippocampal injection of Aβ oligomers or fibers [498]. Additionally, brain region- or neural cell type-specific gene manipulation to mimic AD-like pathologies can be achieved through viral vector transduction or crossing with specific Cre mice.

Tau-related models

To date, no tau gene mutations have been found in AD patients, and tau pathology in AD is primarily caused by intracellular accumulation of wild-type tau proteins with different types of post-translational modifications.

(1) Wild-type tau models

The transgenic mice expressing human full-length wild-type tau with knockout of endogenous murine tau (PAC transgenic × MAPT KO, JAX005491) [499–502] show aggregation of insoluble pTau at 9 months of age, with spatial- and temporal-dependent progressive synaptic damage, behavioral impairment, and neuronal loss. However, the pathological and behavioral characteristics in this line gradually weaken during continuous passaging, and the mice show significantly decreased reproducibility, possibly due to copy number dropping of the gene. Mice expressing the human wild-type 0N3R tau under the control of the mouse Prnp promoter (JAX 003741) also show age-dependent pathological and behavioral changes [503].

(2) Mutant tau models

Mice expressing wild-type tau need a long time to exhibit AD-like changes, while tau mutants identified in FTDP-17 (such as P301L and P301S) induce AD-like neuropathology and cognitive deficit in a shorter time. Therefore, tau-P301L and tau-P301S are more widely used tau models. As P301L-tau0N4R (Tg4510) is unable to produce overt brain atrophy, a bi-transgenic mouse model rTg4510 (“r” refers to regulatable) with CaMK2α promoter was established by crossing Tg4510 to a driver line that harbors a tetracycline transactivator transgene [504, 505]. The homozygous progeny of the rTg4510 express human P301L-0N4R-tau specifically in the forebrain neurons, and show spatial memory deficits at 3–5 months and neuronal loss at 8 months of age [505]. These mice also show serious motor impairments, which may disturb the evaluation of cognitive functions in behavioral tests [506].

In addition, mice expressing human P301S-1N4R-tau driven by the PrP promoter on a B6/C3 background (PS19, JAX008169) show hippocampal synaptic loss and impaired synaptic function at 3 months. The filamentous tau lesions appear at 6-month, and progressive tau accumulation associated with neuron loss and hippocampal and entorhinal cortical atrophy are detected by 9–12 months of age. The mice show spatial learning and memory impairments at 7 months of age, and NFT formation and gliosis can be observed at 8 months of age [507].

(3) Truncated tau model

To better mimic the AD-like tau pathologies (i.e., wild-type tau, accumulating at adult but not the embryonic stage), we recently developed a new tet-on transgenic mouse model expressing truncated human tau N1-368 (termed hTau368), a tau fragment increased in the brains of AD patients and the aged mice. Dox treatment of the hTau368 transgenic mice at a young age for 1–2 months is sufficient for inducing overt and reversible human tau accumulation in the brain, predominantly in the hippocampus, together with the AD-like high level of pTau, glial activation, neuronal loss, impairment of hippocampal neurogenesis, synaptic degeneration and cognitive deficits [508].

Non-transgenic approaches have also been used to produce brain tau pathology, such as brain stereotaxic infusion of viral vectors containing different tau genes (commonly AAV1, 2, 6, 9, or lentivirus) into the brains of animals. These vectors can express different isoforms of tau or mixtures thereof, tau with specific phosphorylation site mutations, various tau truncations, etc. By embryonic brain injection of AAV1 viral vectors, global expression of different tau genes can be achieved. Additionally, high-aggregation PHF-tau protein extracted from AD patient brains can be injected into the brains of wild-type or tau/APP transgenic animals to simulate AD pathologies. All of these modeling methods can induce AD-like pathological and/or behavioral changes at different ages or time points after expression.

Although tau knockout mice may exhibit pathological changes such as intraneuronal iron accumulation in the later stages of aging, it seems not significantly impact mouse development and survival, suggesting the presence of compensatory mechanisms for the function of tau proteins.

Table 1 provides a summary of commonly used AD transgenic mouse models and their characteristics. These models are being extensively used in investigating AD mechanisms and developing drugs targeting pathological Aβ and tau, as well as their associated pathological and behavioral changes (http://www.alzforum.org/research-models). Table 1 Several commonly used transgenic mouse models of AD

Model Name	Transgene (Promoter)	Isoform	Genetic background	Characteristics	References	
PDAPP	hAPPInd( PDGFβ)	hAPP695,751,770	C57BL/6 × DBA2	Cognitive impairment, deposition of ThS-positive Aβ, neuroinflammatory plaques, synaptic loss, and proliferation of astrocytes and microglia after 3 months	[477]	
Tg2576	hAPPSwe( PrP)	hAPP695	C57BL/6 × SJL	After 6 months, the mice have impaired learning and memory. Abundant Aβ plaques are observed by 11–13 months	[478]	
APP23	hAPPSwe( Thy1)	hAPP751	C57BL/6 J	After 3 months, age-related spatial memory deficits become pronounced. By the sixth month, amyloid plaques and elevated p-tau levels manifest, all in the absence of neurofibrillary tangles	[479]	
TASD-41	hAPPSwe/Lon( Thy1)	hAPP751	C57BL/6 J x DBA	Plaques appear in the frontal cortex at 3–6 months and spread with age, leading to cognitive impairment by 6 months	[480]	
J20	hAPPSwe/Ind(PDGFβ)	hAPP695,751,770	C57BL/6 × DBA/2	Diffuse Aβ plaques begin at 5–7 months, becoming widespread by 8–10 months. Mice show spatial reference memory deficits by 4 months old	[481]	
TgCRND8	hAPPSwe,Ind(PrP)	hAPP695	Hybrid C3H/He- C57BL/6	At 3 months, cognitive deficits emerge in Morris water maze learning. Amyloid deposition begins, leading to plaques by 3 months. Between 7–12 months, tau undergoes hyperphosphorylation, but neurofibrillary tangles remain absent	[482]	
PS/APP	hAPPSwe(PrP);hPS1M146L(PDGFβ)	hAPP695/hPSEN1	B6/D2/Swe/SJL	Aβ accumulates in the cortex and hippocampus starting at 6 months, increasing with age. Hyperphosphorylated tau appears at 24 weeks, with no neurofibrillary tangles. Cognitive deficits emerge at around three months and worsen with age	[488, 489]	
2xKI	hAPPSwe(PrP);mPS1P264L(PS1)	hAPP695/m PSEN1	129 × Tg2576	At one month, mice exhibit elevated Aβ42/Aβ40 ratios. Bigenic mice also display accelerated amyloid deposition (around four months) and heightened reactive gliosis compared to Tg2576 mice	[490]	
5xFAD	APPSwe/Lond/Flo(Thy1);PS1M146L,L286V(Thy1)	hAPP695/hPSEN1	C57BL/6	Intraneuronal Aβ appears at 6 weeks, while extracellular amyloid plaques are detected in the hippocampus and cortex of 1.5-month-old mice. Cognitive deficits emerge between 3 and 6 months, worsening with age	[491, 492]	
3xTg-AD	APPSwe(Thy1,2);tauP301L(Thy1,2);PS1M146V( PS1)	hAPP695/hTau4R/ hPSEN1	C7BL/6;129X1SvJ;129S1/Sv	There is an increase in intracellular Aβ42 levels, synaptic dysfunction and cognitive impairments at 3–4 months. By 6 months of age, extracellular Aβ deposition occurs. By 12 months, tau pathology becomes apparent	[494–496]	
TgCRND8xapoE4KI	hAPPSwe,Ind(PrP); hApoE4( apoE)	hAPP695/h ApoE4	TgCRND8xC57BL/6 J	Comparison to TgCRND8 mice, there is an elevation of IL-1 and GFAP reactivity, accompanied by mild circadian rhythm disturbances	[497]	
htau	hTau(Tau)	hTau3R /4R	C57BL/6 J	At 9 months, tau aggregation and paired helical filaments become evident. These filaments can be isolated as early as 2 months. Hyperphosphorylated tau accumulates from six months onwards, with cognitive deficits emerging by 12 months	[499–502]	
Tau Tg	hTau (PrP)	hTau3R0N	B6SJLF1 x B6D2F1	Mice homozygous for the transgenic insert die at about three months of age. Tau-positive inclusions appear in cortical neurons and brainstem by 6 months of age. By 12 months of age endoneurial space in ventral root axons appears to increase	[503]	
rTg4510	hTauP301L(PrP);tTA(Camk2a)	hTau4R0N	129S6 X FVB	Pretangles appear at 2.5 months, followed by tangle-like inclusions in the cortex at 4 months and the hippocampus at 5.5 months. Spatial memory retention declines between 3 and 5 months	[504, 505]	

AD rat models

Currently, AD rat models are mainly focused on mutant APP.

The rat model expressing mutated hAPP (Swe and Lon mutations; APPK670N/M671L and V717F) (McGill-RThy1-APP) exhibits spatial memory loss at 3 months, working memory impairment from 3 to 6 months, and appearance of Aβ plaques, tau pathology, gliosis, synaptic and neuronal loss at 6 months of age [509, 510].

The rat model expressing hAPP (Swe) / hPSEN1 (ΔE9) (TgF344-AD) shows the development of Aβ plaques, tau pathology, cerebral amyloid angiopathy, gliosis, and neuronal loss at 16 months. Impairments of spatial memory and working memory are observed at 15 and 24 months of age, respectively [511].

The rat model expressing mutated hAPP (Swe and Lon) and PSEN1 (APPK670N, M671L/V717F/PSEN1M146V) (PSAPP) exhibits decreased LTP, abnormal performance in water maze testing, and widespread plaques and gliosis in hippocampus, cortex, olfactory bulb, thalamus, and hypothalamus at 7 months of age. However, reductions in synaptophysin and PSD95 are not observed until 22 months of age [486, 512, 513].

Non-human primate (NHP) models and AD patient-derived cell and organoid models

The current rodent models have provided valuable tools for understanding AD pathogenesis and exploiting new drugs. However, many mechanisms discovered in rodent models have not been replicated in human cells, and some drugs that were highly effective in animal models have shown poor efficacy in clinical studies. The main reason for this discrepancy may be the great difference between humans and rodents. Currently, efforts to address this issue are mainly focused on the following two directions [471].

NHP AD models

NHPs show close genetic homology to humans [484, 485, 487]. They have extended lifespan with similar life stages including childhood, adolescence, adulthood, and aging, and they can perform complex cognitive tests. For these reasons, NHPs may serve as an excellent model of AD. Indeed, multiple AD-like pathological alterations have been detected in aged orangutans, western lowland gorilla and Cynomolgus macaques, which suggest that screening naturally occurring AD in aged monkeys could be a strategy to provide AD NHP models. In addition, transgenic and brain infusion of Aβ and/or tau or their mutant genes may also simulate AD-like pathologies and cognitive deficits. Nonetheless, it is difficult to achieve inbred mating in NHPs, which makes it challenging to ensure experimental reproducibility; and the high cost and the long course of AD also make the experiments using NHPs cost-prohibitive.

AD patient-derived cell and organoid models

The human induced pluripotent stem cells (hiPSCs) are emerging as a tool for AD mechanistic studies and preclinical drug testing. The models mainly include inducing differentiation of human embryonic stem cells into neurons or/and into the brain-like tissues in vitro, or using fibroblasts derived from the skin of AD patients and inducing them to acquire stem cell characteristics through reprogramming techniques, followed by further differentiation into human neurons or brain-like tissues to replicate AD models [514–517].

Brain organoids are three-dimensional cellular aggregates derived from iPSCs that recreate different neural cell interactions and tissue characteristics in culture. To produce AD organoid models, the AD-related genes are expressed by viral vectors in human neural progenitor cells (NPC) or NPC differentiated from hiPSC (hiPSC-NPC), and the cells are cultured in specialized 3D culture dishes [518–520]. The NPCs are then induced to differentiate into mature neurons and astrocytes. By co-culturing with microglial cells, microglia migrate and invade into the culture, resulting in 3D brain-like organoid modeling. AD organoid models can recapitulate AD-like Aβ and tau pathologies [521].

Another approach involves reprogramming fibroblasts from FAD patients into FAD-induced pluripotent stem cells (FAD iPSC), followed by differentiation into mature cortical neurons to observe neuronal survival and cellular characteristics [522]. These cells can be further treated with drugs or other methods to study the pathogenesis of AD and screen for potential drugs. This approach is currently being widely used.

AD diagnosis

The most widely used diagnostic criteria for AD were established in 1984 by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) [5]. In 2011 and 2018, the National Institute of Aging and the Alzheimer's Association (NIA-AA) revised twice the criteria and developed diagnostic guidelines for different stages of AD and mild cognitive impairment (MCI) in clinical settings [523–525]. Specifically, the NIA-AA committee established the inaugural biological definition of AD in 2018, predicated upon the presence of amyloid plaques (A) and tau tangles (T), as opposed to relying solely on symptomatic manifestations. Additionally, the criteria incorporated biomarkers of neurodegeneration (N) to facilitate disease staging. Subsequently, in 2023, a revision of the diagnostic criteria for AD was introduced, taking into consideration recent breakthroughs in understanding the temporal dynamics of biomarkers. This revised framework utilizes these biomarkers to ascertain the progression of the disease. While amyloid and tau continue to hold prominence in the diagnosis and staging of AD, the "N" neurodegeneration marker has been relegated to a secondary position. Within this nascent proposal, currently in its draft phase and intended to elicit feedback from the ADRD research community, the core biomarkers for diagnosis and staging are A and T. Furthermore, this draft scheme acknowledges an expanded array of supplementary markers capable of detecting non-specific disease responses and co-pathologies [526].

Neuropsychological testing

Cognitive impairment is a significant clinical symptom in neurology, and the assessment of cognitive function primarily relies on neuropsychological testing [527]. Evaluating cognitive function comprehensively allows for a better understanding of patients' cognitive status and characteristics, which plays an essential role in the diagnosis, subtyping, and etiological analysis of cognitive impairment and dementia [528].

The evaluation of cognitive abilities in AD includes memory, language, orientation, visuospatial skills, attention, visual/auditory/tactile perceptions, and executive function. The commonly used neuropsychological assessment tools in the clinic can be categorized as follows: broad assessment scales, such as the Mini-Mental State Examination (MMSE) [529], Montreal Cognitive Assessment (MoCA) [530], Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) [531], Hasegawa Dementia Scale (HDS) [532, 533], Mattis Dementia Rating Scale [534, 535], Cognitive Abilities Screening Instrument (CASI) [536], etc.; staging scales, such as the Clinical Dementia Rating (CDR) [537] and Global Deterioration Scale (GDS) [538]; psychiatric behavior rating scales, such as the Hamilton Depression Rating Scale (HAMD) [539] and the Neuropsychiatric Inventory (NPI); discriminatory scales, such as the Hachinski Ischemic Scale. It should be noted that when using the above scales for diagnosing AD, comprehensive judgment should be made by considering clinical manifestations and other auxiliary examination results. Currently, the MMSE, MoCA, and CDR are the most commonly used neuropsychological assessment tools.

Neuroimaging examinations

Neuroimaging has been used as an auxiliary diagnostic tool for AD since 2007. The main modalities include positron emission tomography (PET) for detecting deposits of Aβ and tau protein, and brain glucose metabolism (FDG PET) [540, 541]; and magnetic resonance imaging (MRI) for detecting brain structural changes [542, 543].

11C-Pittsburgh Compound B (11C-PIB) was the earliest PET imaging agent used to detect Aβ deposits [544, 545]. It shows Aβ deposition in the frontal, parietal, and temporal lobes of AD patients [546, 547]. These pathological changes can occur before the clinical symptoms of AD, indicating its potential for early diagnosis [548]. Tau PET imaging reveals the presence of pTau tangles in the medial temporal lobe and neocortex, which is highly correlated with the severity of cognitive impairment in AD [549–551]. FDG PET, using 18F-FDG as the imaging agent, shows decreased glucose metabolism in bilateral temporal and parietal lobes, as well as the posterior cingulate cortex, in AD patients, and this is correlated with the severity of AD [526, 552]. Structural MRI displays cortical thinning in relevant brain regions of AD patients, along with atrophy in the entorhinal cortex, hippocampus, and posterior cingulate cortex, and a decrease in cortical thickness [553]. Additionally, the application of resting-state functional MRI and diffusion tensor imaging in AD diagnosis is still under research.

Biomarker analysis

The currently used biomarkers for AD diagnosis

In 2018, the NIA-AA classified AD biomarkers into A (amyloid pathology), T (tau pathology), and N (neurodegeneration) [525, 554]. The ATN classification defines AD and describes the changes in each individual at different stages of the disease [555]. The biomarkers reflecting Aβ deposition include CSF Aβ42 levels and PET imaging using Aβ ligands; those reflecting tau pathologies include CSF pTau level and PET imaging using tau ligands; those reflecting neuronal damage/neurodegenerative changes include CSF total and pTau protein levels, CSF neurofilament light chain (NFL) protein level, structural MRI, fluorodeoxyglucose (FDG) PET, and SPECT perfusion imaging, etc. [524, 525]. It is generally believed that the status of Aβ biomarkers determines whether an individual belongs to the AD spectrum, while changes in tau determine whether an individual within the AD spectrum has AD [524, 556]. Using uinoline-derived half-curcumin-dioxaborine (Q-OB) fluorescent probe for detecting Aβ oligomers may reach a preclinical diagnosis of AD [557].

The biomarkers used in AD can be divided into diagnostic and disease progressive biomarkers. The diagnostic biomarkers include Aβ42, total and pTau proteins in CSF, PET imaging using Aβ or tau ligands, and the pathogenic mutations in APP, PSEN1, and PSEN2 [525]. These diagnostic biomarkers reflect the underlying pathological processes of AD, but they may not necessarily correlate with disease severity. These biomarkers can be applied for early diagnosis and confirmation of AD. The disease progression biomarkers mainly include brain structural MRI showing hippocampal volume reduction or medial temporal lobe atrophy, FDG PET imaging, etc. Due to their lower specificity, these biomarkers can also exhibit atrophy changes in other conditions such as normal aging and other neurodegenerative diseases. They may not be present in the early stages of AD but can effectively reflect the progression of the disease, thus these markers can be used to monitor the progression of AD [558].

Potential periphery biomarkers for AD diagnosis or prediction

The above-mentioned AD diagnostic tools have limitations. Firstly, different doctors may give quite different scores even using the same neuropsychological scale, based on their subject evaluations. Secondly, although the neuroimaging measures have great advantages for the non-invasive and progressive observations, these techniques are currently too expensive to the majority of patients or families. Thirdly, CSF has to be used for measuring the currently recognized molecular biomarkers, however, lumbar puncture is generally not conveniently acceptable by the patients or their family members. Fourthly, APP, PSEN1, and PSEN2 mutations only occur in less than 5% of AD patients. Importantly, neurons are terminally differentiated cells with limited regenerating capacity, severer damage may have occurred when the patients come to the hospitals with learning and memory complains.

To deal with these limitations, cross-sectional screening and longitudinal follow-up studies have been carried out to search periphery biomarkers for pre-clinical diagnosis of AD in high-risk populations, such as those at the old age or with T2DM. By dividing the T2DM patients into two groups (i.e., with or without MCI), we found that the T2DM-MCI patients showed GSK-3β activation with olfactory dysfunction and APOE4 genetype compared with T2DM-nMCI populations [21, 25]. Addition of an increased ratio of Aβ1-42/Aβ1-40 to the activated GSK-3β-APOE4-olfactory dysfunction improved the diagnostic efficiency [19]. Further proteomic analysis of the periphery plasma showed that alpha-1-antitrypsin (SERPINA1), major viral protein (PRNP), and valosin-containing protein (VCP) had strong correlation with AD high-risk genes APP, MAPT, APOE, PSEN1, and PSEN2. Also, the levels of PP2A cancer inhibitor (CIP2A), PRNP, and corticotropin-releasing factor-binding protein (CRHBP) were significantly increased, while the level of VCP was decreased in T2DM-MCI patients compared with the T2DM-nMCI, and these changes were correlated with the MMSE score. Furthermore, the increases of PRNP, CRHBP, VCP, and GSK-3β had the greatest power to identify MCI in T2DM patients [559].

The recent development of blood biomarkers have offered diagnostic and prognostic opportunities that are not feasible using CSF or neuroimaging biomarkers [560]. Plasma Aβ42/Aβ40 ratio and pTau biomarkers targeting the epitopes Thr181 (pTau181), Thr212 (pTau212), Thr217 (pTau217), and Thr231 (pTau231) have each shown high accuracies to identify AD pathology [561–564]. Plasma level of N-terminal containing tau fragments (NTA-tau) increases across the AD continuum, especially during mid-to-late AD stages, and it is closely associated with in vivo tau tangle deposition in AD and its downstream effects [565]. The blood-based brain-derived tau (BD-tau) has been used as a biomarker for identifying Aβ-positive individuals at risk of short-term cognitive decline and atrophy, with implications for clinical trials and implementation of anti-Aβ therapies [566].

As platelets share similarities to neuron biology, it could be an ideal peripheral matrix for biomarkers of neurological disorders. By platelet proteomics, a cluster of altered proteins was identified to be associated with cognitive decline in T2DM patients. Among these proteins, only the increase of optineurin, an autophagy-related protein, was simultaneously correlated with the reduced MMSE score, the activated GSK-3β and the increased Aβ42/40 ratio. Interestingly, the increased optineurin alone could discriminate T2DM-MCI from T2DM-nMCI; and combination of the elevated optineurin with the activated GSK-3β in platelet enhanced the MCI-discriminating efficiency in T2DM patients [22]. Another platelet proteomic analysis in the aged population demonstrated that changes of polyhydroxybutyrate (PHB), ubiquinol-cytochrome C reductase hinge protein (UQCRH), CD63, glycoprotein 1b (platelet), alpha polypeptide (GP1BA), fibronectin (FINC), ras-related protein rap-1A (RAP1A), inositol 1,4,5-trisphosphate receptor type 1/2 (ITPR1/2), and ADAM metallopeptidase domain 10 (ADAM10) could effectively distinguish the cognitively impaired individuals (MCI and AD) from cognitively normal controls; and measuring four reduced proteins (PHB, UQCRH, GP1BA, and FINC) may be enough for predicting cognitive decline in MCI and AD patients [24].

By an integrated analysis of platelet and brain omics from AD patients, we also reported that the changes of 70.3% differentially expressed proteins were consistent in the platelet and the brain. Furthermore, the changes of isocitrate dehydrogenase 3β (IDH3β) and reticulon 1 (RTN1) have a potential diagnostic value for cognitive impairment; Heme oxygenase 2 (HMOX2) and serpin family A member 3 (SERPINA3) may serve as driving molecules in neurodegeneration, and their levels are changed in AD patients [23].

Gene analysis

APP, PSEN1, and PSEN2 genes have been identified as pathogenic genes in FAD, while APOE4 is a high risk gene associated with sporadic AD [7, 11, 93, 567–570]. Therefore, genetic testing can be conducted for cases with a clear family history or early-onset sporadic cases to aid in diagnosis.

Recently, multi-omics data from big cohort along with bioinformatics analysis and machine learning have revealed multiple AD risk genes, providing important information for identifying key pathogenic factors in sporadic AD [11, 571, 572]. New techniques have also been developed to enhance the sensitivity for diagnosing AD [573, 574]. AD risk gene analysis combined with brain functional and pathological imaging, especially PET imaging targeting Aβ and tau, offers possibilities for early diagnosis and intervention in AD [575, 576].

It is worthy of noting that AD is a complex chronic systemic disease, and attention should be given to the diagnosis of different subtypes of AD, which is extremely important for the development of novel disease-modifying drugs.

AD therapies and development of disease-modifying drugs

Currently, there is still a lack of effective medications or interventions that can cure AD. However, a comprehensive approach involving pharmacological, non-pharmacological, supportive, and caregiving measures can potentially improve the life quality of patients and reduce or delay the progression of AD.

Drugs being used in the clinic

Acetylcholinesterase inhibitors (AChEIs)

AChEIs are primarily used in patients with mild to moderate AD [577]. Acetylcholine (ACh) in the brain plays a role in learning and memory, and dysfunction of the cholinergic system in AD leads to decreased ACh levels. The representative AChEIs include donepezil [578], rivastigmine [579], and galantamine [580], which can increase ACh levels in the brain, enhance synaptic transmission, and improve cognitive functions. They also have some beneficial effects on psychiatric symptoms.

NMDAR antagonists

NMDARs play a crucial role in synaptic transmission, a fundamental mechanism for learning and memory. Upregulation of NMDARs in AD results in excitotoxicity characterized by calcium overload and neuronal apoptosis, along with learning and memory deficits. Memantine [581], a NMDAR antagonist, regulates glutamate activity and has certain benefits for memory and psychiatric symptoms [582].

New disease-modifying drugs under development

The multi-target drugs targeting AD pathologies (i.e., disease-modifying) are under rapid development. Among them, inspiring results have been made on drugs targeting Aβ and tau pathology.

Drug development against Aβ

Drug development against Aβ has been the main direction in the field for over two decades. The strategies include active immunity (by injecting Aβ peptide to induce antibody), passive immunity (by directly injecting antibodies against Aβ), use of β- or γ-secretase inhibitors, and blood replacement. Some milestone drugs are stated as follows.

Aducanumab, a monoclonal antibody targeting Aβ developed by Eisai/Biogen, was first conditionally approved by the U.S. Food and Drug Administration (FDA) in June 2021 [583]. This is the first new drug for AD to receive FDA approval since 2003. Following the completion of two randomized, double-blind, placebo-controlled Phase 3 clinical trials by Biogen in 2019, aducanumab was initially declared ineffective, and approximately 40% of participants experienced side effects such as brain swelling and pain [584]. As a result, aducanumab has been the subject of ongoing controversy since its approval. However, the FDA stated that the approval of aducanumab was not based on its efficacy but on its strong and reliable ability to clear Aβ, which may potentially provide clinical benefits. Ongoing large-scale clinical trials are needed to confirm the clinical efficacy of aducanumab.

Lecanemab (also known as BAN2401, marketed under the name Leqembi) is another monoclonal antibody targeting Aβ plaques, developed by Eisai/Biogene. It received expedited approval from the FDA following the release of findings from an 18-month Phase 3 clinical trial [585]. The Phase 3 trial demonstrated a significant 27% reduction in cognitive decline, indicating promising potential for individuals in the early phases of AD [585]. Mechanistically, Lecanemab can block the effects of Aβ/fibrinogen complex on blood clots and the synaptic toxicity in organotypic culture [586].

Donanemab (also known as N3pG) is a humanized IgG1 monoclonal antibody developed by Lilly from the mouse mE8-IgG2a. Unlike other therapeutic Aβ antibodies, donanemab specifically targets Aβ(p3-42), which is a pyroglutamate form of Aβ found in aggregated amyloid plaques. Its high affinity for deposited amyloid plaques differentiates it from antibodies that have low affinity for these plaques. The rationale behind donanemab is to directly target and clear existing amyloid burdens in the brain rather than solely preventing new plaque deposition or growth of existing plaques [587]. Donanemab also slows the rate of accumulation of tau NFTs in the frontal cortex and other brain regions [588]. In June 2021, Donanemab received the Breakthrough Therapy designation from the FDA to expedite its development and review process. However, in January 2023, the FDA rejected the accelerated approval application for donanemab, citing the need for additional safety data. On May 4, 2023, Lilly announced positive top-line results from the Phase 3 study Trailblazer-ALZ2 [589]. Treatment with Donanemab significantly slowed the decline on the primary outcome measure of integrated Alzheimer's Disease Rating Scale (iADRS) by 40% and demonstrated improvement in all secondary clinical endpoints [590].

Drug development against tau

The level of abnormal tau in AD brain is positively correlated with the degree of clinical dementia. The Braak-Braak classification for AD progression is based on the spreading of pTau/tangles in the specific brain areas. Animal studies have shown that tau depletion mitigates the toxic effects of Aβ. In addition, pTau is the main component of degenerative neurons in the autopsy AD brains. Therefore, targeting tau may be promising in AD drug development.

Currently, drug development strategies against tau include immunotherapies (antibodies/vaccines), suppressing the synthesis (siRNA, miRNA, ASO), inhibiting the aggregation (such as LMTX by TauRx Therapeutics), and regulating post-translational modifications.

Semorinemab (RG 6100) is a humanized IgG4 monoclonal antibody targeting the N-terminal of tau (amino acid residues 6–23). A phase 2 clinical trial showed that after 49 weeks of treatment, patients in the semorinemab group experienced 43.6% less cognitive decline than those in the placebo group. The Kd value of semorinemab binding to human tau protein is 3.8 nM [591, 592]. As the NFTs formed by pTau are located inside the neural cells, the antibodies/vaccines targeting tau proteins need to penetrate both BBB and the neural cell membrane to exert functions. The latter is an additional barrier compared with Aβ-vaccine therapies.

BIIB080 (IONIS-MAPT), an antisense oligonucleotide (ASO) co-developed by Ionis and Biogen, has shown positive results in a clinical 1b trial. The data showed that BIIB080 reduced soluble tau protein in the CSF of early AD patients in a dose-dependent and sustained manner. BIIB080 also reduced pathological tau accumulation evaluated by PET imaging. These results were presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™2023) [593]. Inhibiting tau synthesis (such as ASO) should be promising in decreasing total tau level though it is generally recognized that tau accumulation in the AD brain is not due to an increased transcription or translation.

LMTX, a tau aggregation inhibitor, has passed Phase 3 [594]. By comparing the cognitive abilities and measuring the rate of brain atrophy, researchers found that the LMTX monotherapy led to significant improvements in cognitive performance and a significant reduction in the rate of brain atrophy at doses of 100 mg or 4 mg twice daily [595].

As abnormal post-translational modifications are the major cause of tau aggregation in AD, modulating the enzymes involved in different post-translational modifications has attracted great attention. However, as the enzymes involved in tau post-translational modifications have broad substrates, either upregulating or downregulating the enzymes will unavoidably cause side effects, especially in chronic diseases like AD.

Induced-proximity technologies are newly developed approaches that do not change the enzyme activity. These approaches include proteolytic targeting chimera [596, 597] and deubiquitinating enzyme targeting chimeras [598], both promoting degradation of total tau. To specifically target the pTau which is the major component of the NFTs, we recently developed dephosphorylation targeting chimera, which can efficiently and specifically promote tau dephosphorylation with restoration of the biological function of tau [29]. A similar approach has been reported recently by Crews’ group [30].

Others

Among many other disease-modifying drug attempts, the National Medical Products Administration (NMPA) in China has conditionally approved the market application of a new drug called sodium oligomannate (also known as GV-971) for the treatment of mild to moderate AD patients [599]. GV-971 is a low-molecular-weight acidic oligosaccharide compound derived from marine brown algae. Although there are still many uncertainties, this innovative drug has provided a new therapeutic option for AD [600].

Management of psychiatric symptoms

Many AD patients experience psychiatric symptoms during certain stages of the disease, such as hallucinations, delusions, depression, anxiety, agitation, and sleep disturbance. Antidepressant [601] and antipsychotic medications can be used to manage these symptoms [602]. Selective serotonin reuptake inhibitors such as fluoxetine, paroxetine, sertraline, and citalopram are commonly used as antidepressants [601]. Atypical antipsychotics such as risperidone, olanzapine, and quetiapine are often prescribed as antipsychotic agents [602]. The principles for the use of these medications are as follows: starting with a low dose and increasing the dose gradually, with longer intervals between dose increments; using the minimum effective dose whenever possible; individualizing treatment, and keeping in mind drug interactions.

Non-pharmacological treatments

Non-pharmacological treatments encompass dietary adjustments [603] (e.g., Mediterranean diet or time-restricted feeding) [604, 605], cognitive training [606], physical exercise [607, 608], music therapy [609], etc. These measures are more readily accepted by patients and their families, and may have a preventive effect or delay the decline in daily functioning of patients, improving their life quality.

In addition, research on specific modulation of brain regions and neural circuits (such as deep brain stimulation, transcranial magnetic stimulation and phototherapy), stem cells, gene editing, etc., has attracted great attention.

Supportive care

Severe AD patients experience a significant decline in daily activities, often leading to complications such as malnutrition, pulmonary or urinary tract infections, ulcers, etc. [610]. The course of AD is typically around 5 to 10 years, and some patients survive even longer. Therefore, it is important to strengthen supportive care and provide symptomatic treatment. In addition, a healthy lifestyle is beneficial for the prevention of AD.

Conclusion

In this review, we updated the advances in AD research from basic mechanism studies to clinic diagnosis and drug development. Continued collaborative efforts and interdisciplinary research will be important in unraveling the complexities of AD and ultimately making a significant impact on the patients affected by this devastating disease.

Abbreviations

AD Alzheimer’s disease

Aβ β-Amyloid

NFT Neurofibrillary tangle

PHF Paired helical filament

APOE Apolipoprotein E

APP Amyloid precursor protein

CSF Cerebrospinal fluid

NMDA N-methyl-D-aspartate

FTDP-17 Parkinsonism linked to chromosome 17

GSK-3β Glycogen synthase kinase-3β

MAP Microtubule-associated protein

LTP Long term potentiation

PSP Progressive supranuclear palsy

CREB CAMP-response element binding protein

mTORC1 Mammalian target of rapamycin kinase complex 1

ESCRT Endosomal Sorting Complex Required for Transport

PDPK Proline-directed protein kinases

ERK Extracellular signal-related protein kinase

Cdk Cyclin-dependent kinase

PKA Cyclic-AMP-dependent protein kinase

PKC Protein kinase C

PRR Proline-rich region

SUMO Small ubiquitin-like modifier

MBD Microtubule-binding domain)

AGE Advanced glycation end product

AEP Asparagine endopeptidase

LRP Low-density lipoprotein receptor-related protein

BACE1 β-Site APP cleaving enzyme-1

IDE Intracellular insulin-degrading enzyme

MMPs The matrix metalloproteases

VLDL-R Very low-density lipoprotein receptor

LDL-R Low-density lipoprotein receptor

NF-κB Nuclear factor kappa-B

ADAM α-Disintegrin and metalloproteinase

RAGE Receptors for advanced glycation end products

BBB Blood-brain barrier

ADDLs Aβ-derived diffusible ligands

HSV Herpes simplex virus type

HHV Human herpesvirus

HCV Hepatitis C virus

LPS Lipopolysaccharides

TLRs Toll-like receptors

TREM Myeloid cell trigger receptor

NHPs Non-human primates

hiPSCs Human induced pluripotent stem cells

NPC Neural progenitor cells

T2DM Type 2 diabetes mellitus

CRHBP Corticotropin-releasing factor-binding protein

Acknowledgements

Not applicable.

Author contributions

JW Contributed to the conception of the review and writing of the manuscript. EL and YZ contributed to literature search and created the figures. All authors reviewed and approved the submitted version.

Funding

This review was supported in part by the Natural Science Foundation of China (82001134, 1949205, 31730035, 81721005), the Guangdong Provincial Key S&T Program (018B030336001), and the Natural Science Foundation of Henan (242300421081). The funders neither played a role in the study design, conduct, data collection, analysis, interpretation, nor participated in the preparation, review, approval of the manuscript.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
==== Refs
References

1. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598-1695.
2. Glenner GG Wong CW Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein Biochem Biophys Res Commun 1984 122 3 1131 1135 10.1016/0006-291X(84)91209-9 6236805
Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984;122(3):1131–5.6236805 10.1016/0006-291X(84)91209-9
3. Grundke-Iqbal I Iqbal K Tung YC Quinlan M Wisniewski HM Binder LI Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology Proc Natl Acad Sci USA 1986 83 13 4913 4917 10.1073/pnas.83.13.4913 3088567
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83(13):4913–7.3088567 10.1073/pnas.83.13.4913
4. Kosik KS Joachim CL Selkoe DJ Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease Proc Natl Acad Sci USA 1986 83 11 4044 4048 10.1073/pnas.83.11.4044 2424016
Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA. 1986;83(11):4044–8.2424016 10.1073/pnas.83.11.4044
5. McKhann G Drachman D Folstein M Katzman R Price D Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's Disease Neurology 1984 34 7 939 944 10.1212/WNL.34.7.939 6610841
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.6610841 10.1212/WNL.34.7.939
6. Aslam MM Fan KH Lawrence E Bedison MA Snitz BE DeKosky ST Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer's disease risk Mol Psychiatry 2023 28 10 4451 4462 10.1038/s41380-023-02170-4 37666928
Aslam MM, Fan KH, Lawrence E, Bedison MA, Snitz BE, DeKosky ST, et al. Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk. Mol Psychiatry. 2023;28(10):4451–62.37666928 10.1038/s41380-023-02170-4
7. Lozupone M Panza F Impact of apolipoprotein E isoforms on sporadic Alzheimer's disease: beyond the role of amyloid beta Neural Regen Res 2024 19 1 80 83 10.4103/1673-5374.375316 37488848
Lozupone M, Panza F. Impact of apolipoprotein E isoforms on sporadic Alzheimer’s disease: beyond the role of amyloid beta. Neural Regen Res. 2024;19(1):80–3.37488848 10.4103/1673-5374.375316
8. Raulin AC Doss SV Trottier ZA Ikezu TC Bu G Liu CC ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies Mol Neurodegen 2022 17 1 72 10.1186/s13024-022-00574-4
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegen. 2022;17(1):72.10.1186/s13024-022-00574-4
9. Verovnik B Khachatryan E Šuput D Van Hulle MM Effects of risk factors on longitudinal changes in brain structure and function in the progression of AD Alzheimers Dement 2023 19 6 2666 2676 10.1002/alz.12991 36807765
Verovnik B, Khachatryan E, Šuput D, Van Hulle MM. Effects of risk factors on longitudinal changes in brain structure and function in the progression of AD. Alzheimers Dement. 2023;19(6):2666–76.36807765 10.1002/alz.12991
10. Dorszewska J Prendecki M Oczkowska A Dezor M Kozubski W Molecular basis of familial and sporadic Alzheimer's Disease Curr Alzheimer Res 2016 13 9 952 963 10.2174/1567205013666160314150501 26971934
Dorszewska J, Prendecki M, Oczkowska A, Dezor M, Kozubski W. Molecular basis of familial and sporadic Alzheimer’s Disease. Curr Alzheimer Res. 2016;13(9):952–63.26971934 10.2174/1567205013666160314150501
11. Quan M Cao S Wang Q Wang S Jia J Genetic phenotypes of Alzheimer's Disease: mechanisms and potential therapy Phenomics (Cham, Switzerland) 2023 3 4 333 349 10.1007/s43657-023-00098-x 37589021
Quan M, Cao S, Wang Q, Wang S, Jia J. Genetic phenotypes of Alzheimer’s Disease: mechanisms and potential therapy. Phenomics (Cham, Switzerland). 2023;3(4):333–49.37589021 10.1007/s43657-023-00098-x
12. Hampel H Hardy J Blennow K Chen C Perry G Kim SH The Amyloid-β pathway in Alzheimer's Disease Mol Psychiatry 2021 26 10 5481 5503 10.1038/s41380-021-01249-0 34456336
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β pathway in Alzheimer’s Disease. Mol Psychiatry. 2021;26(10):5481–503.34456336 10.1038/s41380-021-01249-0
13. Jagust WJ Teunissen CE DeCarli C The complex pathway between amyloid β and cognition: implications for therapy Lancet Neurol 2023 22 9 847 857 10.1016/S1474-4422(23)00128-X 37454670
Jagust WJ, Teunissen CE, DeCarli C. The complex pathway between amyloid β and cognition: implications for therapy. Lancet Neurol. 2023;22(9):847–57.37454670 10.1016/S1474-4422(23)00128-X
14. Simons M Levin J Dichgans M Tipping points in neurodegeneration Neuron 2023 111 19 2954 2968 10.1016/j.neuron.2023.05.031 37385247
Simons M, Levin J, Dichgans M. Tipping points in neurodegeneration. Neuron. 2023;111(19):2954–68.37385247 10.1016/j.neuron.2023.05.031
15. Cai W Wu T Chen N The amyloid-beta clearance: from molecular targets to glial and neural cells Biomolecules 2023 13 2 313 10.3390/biom13020313 36830682
Cai W, Wu T, Chen N. The amyloid-beta clearance: from molecular targets to glial and neural cells. Biomolecules. 2023;13(2):313.36830682 10.3390/biom13020313
16. Ni J Xie Z Quan Z Meng J Qing H How brain 'cleaners' fail: Mechanisms and therapeutic value of microglial phagocytosis in Alzheimer's disease Glia 2024 72 2 227 244 10.1002/glia.24465 37650384
Ni J, Xie Z, Quan Z, Meng J, Qing H. How brain “cleaners” fail: Mechanisms and therapeutic value of microglial phagocytosis in Alzheimer’s disease. Glia. 2024;72(2):227–44.37650384 10.1002/glia.24465
17. Yang Y Wang JZ Nature of tau-associated neurodegeneration and the molecular mechanisms J Alzheimers Dis 2018 62 3 1305 1317 10.3233/JAD-170788 29562535
Yang Y, Wang JZ. Nature of tau-associated neurodegeneration and the molecular mechanisms. J Alzheimers Dis. 2018;62(3):1305–17.29562535 10.3233/JAD-170788
18. Self WK Holtzman DM Emerging diagnostics and therapeutics for Alzheimer disease Nat Med 2023 29 9 2187 2199 10.1038/s41591-023-02505-2 37667136
Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med. 2023;29(9):2187–99.37667136 10.1038/s41591-023-02505-2
19. Liu Y Zhang S He B Chen L Ke D Zhao S Periphery biomarkers for objective diagnosis of cognitive decline in type 2 diabetes patients Front Cell Dev Biol 2021 9 752753 10.3389/fcell.2021.752753 34746146
Liu Y, Zhang S, He B, Chen L, Ke D, Zhao S, et al. Periphery biomarkers for objective diagnosis of cognitive decline in type 2 diabetes patients. Front Cell Dev Biol. 2021;9: 752753.34746146 10.3389/fcell.2021.752753
20. Gao Y Yu H Liu Y Xu Z He B Liu H GSK-3β activation mediates apolipoprotein E4-associated cognitive impairment in type 2 diabetes mellitus: a multicenter, cross-sectional study J Diabetes 2024 16 1 e13470 10.1111/1753-0407.13470 37700547
Gao Y, Yu H, Liu Y, Xu Z, He B, Liu H, et al. GSK-3β activation mediates apolipoprotein E4-associated cognitive impairment in type 2 diabetes mellitus: a multicenter, cross-sectional study. J Diabetes. 2024;16(1): e13470.37700547 10.1111/1753-0407.13470
21. Xu ZP Yang SL Zhao S Zheng CH Li HH Zhang Y Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: a multicentre, retrospective, nested case-control study EBioMedicine 2016 5 105 113 10.1016/j.ebiom.2016.02.014 27077117
Xu ZP, Yang SL, Zhao S, Zheng CH, Li HH, Zhang Y, et al. Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: a multicentre, retrospective, nested case-control study. EBioMedicine. 2016;5:105–13.27077117 10.1016/j.ebiom.2016.02.014
22. Yu H Liu Y He T Zhang Y He J Li M Platelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients Aging Cell 2021 20 10 e13469 10.1111/acel.13469 34528736
Yu H, Liu Y, He T, Zhang Y, He J, Li M, et al. Platelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients. Aging Cell. 2021;20(10): e13469.34528736 10.1111/acel.13469
23. Yu H Li M Pan Q Liu Y Zhang Y He T Integrated analyses of brain and platelet omics reveal their common altered and driven molecules in Alzheimer's disease MedComm 2022 3 4 e180 10.1002/mco2.180 36254251
Yu H, Li M, Pan Q, Liu Y, Zhang Y, He T, et al. Integrated analyses of brain and platelet omics reveal their common altered and driven molecules in Alzheimer’s disease. MedComm. 2022;3(4): e180.36254251 10.1002/mco2.180
24. Yu H Liu Y He B He T Chen C He J Platelet biomarkers for a descending cognitive function: a proteomic approach Aging Cell 2021 20 5 e13358 10.1111/acel.13358 33942972
Yu H, Liu Y, He B, He T, Chen C, He J, et al. Platelet biomarkers for a descending cognitive function: a proteomic approach. Aging Cell. 2021;20(5): e13358.33942972 10.1111/acel.13358
25. Gao Y Liu Y Zhang Y Wang Y Zheng J Xu Z Olfactory threshold test as a quick screening tool for cognitive impairment: analysis of two independent cohorts J Alzheimers Dis 2023 93 1 169 178 10.3233/JAD-230023 36970911
Gao Y, Liu Y, Zhang Y, Wang Y, Zheng J, Xu Z, et al. Olfactory threshold test as a quick screening tool for cognitive impairment: analysis of two independent cohorts. J Alzheimers Dis. 2023;93(1):169–78.36970911 10.3233/JAD-230023
26. Ramanan VK Armstrong MJ Choudhury P Coerver KA Hamilton RH Klein BC Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology Neurology 2023 101 19 842 852 10.1212/WNL.0000000000207757 37495380
Ramanan VK, Armstrong MJ, Choudhury P, Coerver KA, Hamilton RH, Klein BC, et al. Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology. 2023;101(19):842–52.37495380 10.1212/WNL.0000000000207757
27. van der Flier WM de Vugt ME Smets EMA Blom M Teunissen CE Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia Nat Aging 2023 3 5 494 505 10.1038/s43587-023-00404-2 37202515
van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia. Nat Aging. 2023;3(5):494–505.37202515 10.1038/s43587-023-00404-2
28. Belder CRS Schott JM Fox NC Preparing for disease-modifying therapies in Alzheimer's disease Lancet Neurol 2023 22 9 782 783 10.1016/S1474-4422(23)00274-0 37463598
Belder CRS, Schott JM, Fox NC. Preparing for disease-modifying therapies in Alzheimer’s disease. Lancet Neurol. 2023;22(9):782–3.37463598 10.1016/S1474-4422(23)00274-0
29. Zheng J Tian N Liu F Zhang Y Su J Gao Y A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies Signal Transduct Target Ther 2021 6 1 269 10.1038/s41392-021-00669-2 34262014
Zheng J, Tian N, Liu F, Zhang Y, Su J, Gao Y, et al. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies. Signal Transduct Target Ther. 2021;6(1):269.34262014 10.1038/s41392-021-00669-2
30. Hu Z Chen PH Li W Douglas T Hines J Liu Y Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality J Am Chem Soc 2023 10.1021/jacs.2c11706 38155551
Hu Z, Chen PH, Li W, Douglas T, Hines J, Liu Y, et al. Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality. J Am Chem Soc. 2023. 10.1021/jacs.2c11706.38155551 10.1021/jacs.2c11706
31. Moore KBE Hung TJ Fortin JS Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies Drug Discov Today 2023 28 3 103487 10.1016/j.drudis.2023.103487 36634842
Moore KBE, Hung TJ, Fortin JS. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer’s disease and related tauopathies. Drug Discov Today. 2023;28(3): 103487.36634842 10.1016/j.drudis.2023.103487
32. Kim J Basak JM Holtzman DM The role of apolipoprotein E in Alzheimer's disease Neuron 2009 63 3 287 303 10.1016/j.neuron.2009.06.026 19679070
Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron. 2009;63(3):287–303.19679070 10.1016/j.neuron.2009.06.026
33. Mahley RW Apolipoprotein E: cholesterol transport protein with expanding role in cell biology Science (New York, NY) 1988 240 4852 622 630 10.1126/science.3283935
Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (New York, NY). 1988;240(4852):622–30.10.1126/science.3283935
34. Martens YA Zhao N Liu CC Kanekiyo T Yang AJ Goate AM ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias Neuron 2022 110 8 1304 1317 10.1016/j.neuron.2022.03.004 35298921
Martens YA, Zhao N, Liu CC, Kanekiyo T, Yang AJ, Goate AM, et al. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer’s disease and related dementias. Neuron. 2022;110(8):1304–17.35298921 10.1016/j.neuron.2022.03.004
35. Windham IA Cohen S The cell biology of APOE in the brain Trends Cell Biol 2024 34 4 338 348 10.1016/j.tcb.2023.09.004 37805344
Windham IA, Cohen S. The cell biology of APOE in the brain. Trends Cell Biol. 2024;34(4):338–48.37805344 10.1016/j.tcb.2023.09.004
36. Scanu A Oriente P Szajewski JM Mc CL Page IH Triton hyperlipemia in dogs. II. Atheroscieross, diffuse lipidosis, and deletion of fat stores produced by prolonged administration of the non-tonic surface-active agent J Exp Med 1961 114 3 279 294 10.1084/jem.114.3.279 13747053
Scanu A, Oriente P, Szajewski JM, Mc CL, Page IH. Triton hyperlipemia in dogs. II. Atheroscieross, diffuse lipidosis, and deletion of fat stores produced by prolonged administration of the non-tonic surface-active agent. J Exp Med. 1961;114(3):279–94.13747053 10.1084/jem.114.3.279
37. Bellosta S Mahley RW Sanan DA Murata J Newland DL Taylor JM Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice J Clin Invest 1995 96 5 2170 2179 10.1172/JCI118271 7593602
Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 1995;96(5):2170–9.7593602 10.1172/JCI118271
38. Fazio S Babaev VR Murray AB Hasty AH Carter KJ Gleaves LA Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages Proc Natl Acad Sci USA 1997 94 9 4647 4652 10.1073/pnas.94.9.4647 9114045
Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA. 1997;94(9):4647–52.9114045 10.1073/pnas.94.9.4647
39. McNamara NB Munro DAD Bestard-Cuche N Uyeda A Bogie JFJ Hoffmann A Microglia regulate central nervous system myelin growth and integrity Nature 2023 613 7942 120 129 10.1038/s41586-022-05534-y 36517604
McNamara NB, Munro DAD, Bestard-Cuche N, Uyeda A, Bogie JFJ, Hoffmann A, et al. Microglia regulate central nervous system myelin growth and integrity. Nature. 2023;613(7942):120–9.36517604 10.1038/s41586-022-05534-y
40. Beffert U Cohn JS Petit-Turcotte C Tremblay M Aumont N Ramassamy C Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent Brain Res 1999 843 1–2 87 94 10.1016/S0006-8993(99)01894-6 10528114
Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer’s disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999;843(1–2):87–94.10528114 10.1016/S0006-8993(99)01894-6
41. Narita M Holtzman DM Fagan AM LaDu MJ Yu L Han X Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein J Biochem 2002 132 5 743 749 10.1093/oxfordjournals.jbchem.a003282 12417024
Narita M, Holtzman DM, Fagan AM, LaDu MJ, Yu L, Han X, et al. Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. J Biochem. 2002;132(5):743–9.12417024 10.1093/oxfordjournals.jbchem.a003282
42. Trommsdorff M Gotthardt M Hiesberger T Shelton J Stockinger W Nimpf J Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2 Cell 1999 97 6 689 701 10.1016/S0092-8674(00)80782-5 10380922
Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97(6):689–701.10380922 10.1016/S0092-8674(00)80782-5
43. Herz J Bock HH Lipoprotein receptors in the nervous system Annu Rev Biochem 2002 71 405 434 10.1146/annurev.biochem.71.110601.135342 12045102
Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem. 2002;71:405–34.12045102 10.1146/annurev.biochem.71.110601.135342
44. Herz J Hamann U Rogne S Myklebost O Gausepohl H Stanley KK Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor EMBO J 1988 7 13 4119 4127 10.1002/j.1460-2075.1988.tb03306.x 3266596
Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988;7(13):4119–27.3266596 10.1002/j.1460-2075.1988.tb03306.x
45. Lane-Donovan C Herz J ApoE, ApoE receptors, and the synapse in Alzheimer's Disease Trends Endocrinol Metab 2017 28 4 273 284 10.1016/j.tem.2016.12.001 28057414
Lane-Donovan C, Herz J. ApoE, ApoE receptors, and the synapse in Alzheimer’s Disease. Trends Endocrinol Metab. 2017;28(4):273–84.28057414 10.1016/j.tem.2016.12.001
46. Kounnas MZ Moir RD Rebeck GW Bush AI Argraves WS Tanzi RE LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation Cell 1995 82 2 331 340 10.1016/0092-8674(95)90320-8 7543026
Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82(2):331–40.7543026 10.1016/0092-8674(95)90320-8
47. Namba Y Tomonaga M Kawasaki H Otomo E Ikeda K Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease Brain Res 1991 541 1 163 166 10.1016/0006-8993(91)91092-F 2029618
Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163–6.2029618 10.1016/0006-8993(91)91092-F
48. Tiraboschi P Hansen LA Masliah E Alford M Thal LJ Corey-Bloom J Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease Neurology 2004 62 11 1977 1983 10.1212/01.WNL.0000128091.92139.0F 15184600
Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62(11):1977–83.15184600 10.1212/01.WNL.0000128091.92139.0F
49. Vance JM Farrer LA Huang Y Cruchaga C Hyman BT Pericak-Vance MA Report of the APOE4 national institute on aging/alzheimer disease sequencing project consortium working group: reducing APOE4 in carriers is a therapeutic goal for Alzheimer's disease Ann Neurol 2024 95 4 625 634 10.1002/ana.26864 38180638
Vance JM, Farrer LA, Huang Y, Cruchaga C, Hyman BT, Pericak-Vance MA, et al. Report of the APOE4 national institute on aging/alzheimer disease sequencing project consortium working group: reducing APOE4 in carriers is a therapeutic goal for Alzheimer’s disease. Ann Neurol. 2024;95(4):625–34.38180638 10.1002/ana.26864
50. Ikeda K Akiyama H Arai T Sahara N Mori H Usami M A subset of senile dementia with high incidence of the apolipoprotein E epsilon2 allele Ann Neurol 1997 41 5 693 695 10.1002/ana.410410522 9153535
Ikeda K, Akiyama H, Arai T, Sahara N, Mori H, Usami M, et al. A subset of senile dementia with high incidence of the apolipoprotein E epsilon2 allele. Ann Neurol. 1997;41(5):693–5.9153535 10.1002/ana.410410522
51. Corder EH Saunders AM Risch NJ Strittmatter WJ Schmechel DE Gaskell PC Jr Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Nat Genet 1994 7 2 180 184 10.1038/ng0694-180 7920638
Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180–4.7920638 10.1038/ng0694-180
52. Jackson RJ Keiser MS Meltzer JC Fykstra DP Dierksmeier SE Hajizadeh S APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease Mol Ther 2024 32 1373 10.1016/j.ymthe.2024.03.024 38504517
Jackson RJ, Keiser MS, Meltzer JC, Fykstra DP, Dierksmeier SE, Hajizadeh S, et al. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Mol Ther. 2024;32:1373.38504517 10.1016/j.ymthe.2024.03.024
53. Farrer LA Cupples LA Haines JL Hyman B Kukull WA Mayeux R Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium JAMA 1997 278 16 1349 1356 10.1001/jama.1997.03550160069041 9343467
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–56.9343467 10.1001/jama.1997.03550160069041
54. Blumenfeld J Yip O Kim MJ Huang Y Cell type-specific roles of APOE4 in Alzheimer disease Nat Rev Neurosci 2024 25 2 91 110 10.1038/s41583-023-00776-9 38191720
Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024;25(2):91–110.38191720 10.1038/s41583-023-00776-9
55. Sakurai R Pieruccini-Faria F Cornish B Fraser J Binns MA Beaton D Link among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study Alzheimers Dement 2024 20 4 2968 2979 10.1002/alz.13740 38470007
Sakurai R, Pieruccini-Faria F, Cornish B, Fraser J, Binns MA, Beaton D, et al. Link among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study. Alzheimers Dement. 2024;20(4):2968–79.38470007 10.1002/alz.13740
56. He K Li B Wang J Wang Y You Z Chen X APOE epsilon4 is associated with decreased synaptic density in cognitively impaired participants Alzheimers Dement 2024 20 3157 10.1002/alz.13775 38477490
He K, Li B, Wang J, Wang Y, You Z, Chen X, et al. APOE epsilon4 is associated with decreased synaptic density in cognitively impaired participants. Alzheimers Dement. 2024;20:3157.38477490 10.1002/alz.13775
57. Belloy ME Andrews SJ Le Guen Y Cuccaro M Farrer LA Napolioni V APOE genotype and Alzheimer disease risk across age, sex, and population ancestry JAMA Neurol 2023 80 12 1284 1294 10.1001/jamaneurol.2023.3599 37930705
Belloy ME, Andrews SJ, Le Guen Y, Cuccaro M, Farrer LA, Napolioni V, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 2023;80(12):1284–94.37930705 10.1001/jamaneurol.2023.3599
58. Long JM Holtzman DM Alzheimer disease: an update on pathobiology and treatment strategies Cell 2019 179 2 312 339 10.1016/j.cell.2019.09.001 31564456
Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312–39.31564456 10.1016/j.cell.2019.09.001
59. Langella S Barksdale NG Vasquez D Aguillon D Chen Y Su Y Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease Nat Commun 2023 14 1 5120 10.1038/s41467-023-40775-z 37612284
Langella S, Barksdale NG, Vasquez D, Aguillon D, Chen Y, Su Y, et al. Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer’s disease. Nat Commun. 2023;14(1):5120.37612284 10.1038/s41467-023-40775-z
60. Operto G Molinuevo JL Cacciaglia R Falcon C Brugulat-Serrat A Suarez-Calvet M Interactive effect of age and APOE-epsilon4 allele load on white matter myelin content in cognitively normal middle-aged subjects Neuroimage Clin 2019 24 101983 10.1016/j.nicl.2019.101983 31520917
Operto G, Molinuevo JL, Cacciaglia R, Falcon C, Brugulat-Serrat A, Suarez-Calvet M, et al. Interactive effect of age and APOE-epsilon4 allele load on white matter myelin content in cognitively normal middle-aged subjects. Neuroimage Clin. 2019;24: 101983.31520917 10.1016/j.nicl.2019.101983
61. Saunders AM Strittmatter WJ Schmechel D George-Hyslop PH Pericak-Vance MA Joo SH Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease Neurology 1993 43 8 1467 1472 10.1212/WNL.43.8.1467 8350998
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–72.8350998 10.1212/WNL.43.8.1467
62. Neu SC Pa J Kukull W Beekly D Kuzma A Gangadharan P Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis JAMA Neurol 2017 74 10 1178 1189 10.1001/jamaneurol.2017.2188 28846757
Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178–89.28846757 10.1001/jamaneurol.2017.2188
63. Altmann A Tian L Henderson VW Greicius MD Alzheimer's Disease Neuroimaging Initiative I. Sex modifies the APOE-related risk of developing Alzheimer disease Ann Neurol 2014 75 4 563 573 10.1002/ana.24135 24623176
Altmann A, Tian L, Henderson VW, Greicius MD. Alzheimer’s Disease Neuroimaging Initiative I. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563–73.24623176 10.1002/ana.24135
64. Maniv I Sarji M Bdarneh A Feldman A Ankawa R Koren E Altered ubiquitin signaling induces Alzheimer's disease-like hallmarks in a three-dimensional human neural cell culture model Nat Commun 2023 14 1 5922 10.1038/s41467-023-41545-7 37739965
Maniv I, Sarji M, Bdarneh A, Feldman A, Ankawa R, Koren E, et al. Altered ubiquitin signaling induces Alzheimer’s disease-like hallmarks in a three-dimensional human neural cell culture model. Nat Commun. 2023;14(1):5922.37739965 10.1038/s41467-023-41545-7
65. Qian Z Wang Z Li B Meng X Kuang Z Li Y Thy1-ApoE4/C/EBPbeta double transgenic mice act as a sporadic model with Alzheimer's disease Mol Psychiatry 2024 10.1038/s41380-024-02565-x 38658772
Qian Z, Wang Z, Li B, Meng X, Kuang Z, Li Y, et al. Thy1-ApoE4/C/EBPbeta double transgenic mice act as a sporadic model with Alzheimer’s disease. Mol Psychiatry. 2024. 10.1038/s41380-024-02565-x.38658772 10.1038/s41380-024-02565-x
66. Chemparathy A Le Guen Y Chen S Lee EG Leong L Gorzynski JE APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's disease pathology Neuron 2024 112 7 1110 1116 e1115 10.1016/j.neuron.2024.01.008 38301647
Chemparathy A, Le Guen Y, Chen S, Lee EG, Leong L, Gorzynski JE, et al. APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology. Neuron. 2024;112(7):1110-1116 e1115.38301647 10.1016/j.neuron.2024.01.008
67. Wolf AB Caselli RJ Reiman EM Valla J APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease Neurobiol Aging 2013 34 4 1007 1017 10.1016/j.neurobiolaging.2012.10.011 23159550
Wolf AB, Caselli RJ, Reiman EM, Valla J. APOE and neuroenergetics: an emerging paradigm in Alzheimer’s disease. Neurobiol Aging. 2013;34(4):1007–17.23159550 10.1016/j.neurobiolaging.2012.10.011
68. Corder EH Saunders AM Strittmatter WJ Schmechel DE Gaskell PC Small GW Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 1993 261 5123 921 923 10.1126/science.8346443 8346443
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.8346443 10.1126/science.8346443
69. Yin YW Li JC Wang JZ Li BH Pi Y Yang QW Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis Neurosci Lett 2012 514 1 6 11 10.1016/j.neulet.2012.02.031 22381401
Yin YW, Li JC, Wang JZ, Li BH, Pi Y, Yang QW, et al. Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis. Neurosci Lett. 2012;514(1):6–11.22381401 10.1016/j.neulet.2012.02.031
70. Prince M Lovestone S Cervilla J Joels S Powell J Russ C The association between APOE and dementia does not seem to be mediated by vascular factors Neurology 2000 54 2 397 402 10.1212/WNL.54.2.397 10668701
Prince M, Lovestone S, Cervilla J, Joels S, Powell J, Russ C, et al. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology. 2000;54(2):397–402.10668701 10.1212/WNL.54.2.397
71. Yamazaki Y Zhao N Caulfield TR Liu CC Bu G Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies Nat Rev Neurol 2019 15 9 501 518 10.1038/s41582-019-0228-7 31367008
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–18.31367008 10.1038/s41582-019-0228-7
72. Sepulveda J Kim JY Binder J Vicini S Rebeck GW APOE4 genotype and aging impair injury-induced microglial behavior in brain slices, including toward Abeta, through P2RY12 Mol Neurodegener 2024 19 1 24 10.1186/s13024-024-00714-y 38468308
Sepulveda J, Kim JY, Binder J, Vicini S, Rebeck GW. APOE4 genotype and aging impair injury-induced microglial behavior in brain slices, including toward Abeta, through P2RY12. Mol Neurodegener. 2024;19(1):24.38468308 10.1186/s13024-024-00714-y
73. Yin Z Rosenzweig N Kleemann KL Zhang X Brandao W Margeta MA APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFbeta-mediated checkpoints Nat Immunol 2023 24 11 1839 1853 10.1038/s41590-023-01627-6 37749326
Yin Z, Rosenzweig N, Kleemann KL, Zhang X, Brandao W, Margeta MA, et al. APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFbeta-mediated checkpoints. Nat Immunol. 2023;24(11):1839–53.37749326 10.1038/s41590-023-01627-6
74. Liu CC Wang N Chen Y Inoue Y Shue F Ren Y Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease Nat Immunol 2023 24 11 1854 1866 10.1038/s41590-023-01640-9 37857825
Liu CC, Wang N, Chen Y, Inoue Y, Shue F, Ren Y, et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nat Immunol. 2023;24(11):1854–66.37857825 10.1038/s41590-023-01640-9
75. Eskandari-Sedighi G Blurton-Jones M Microglial APOE4: more is less and less is more Mol Neurodegener 2023 18 1 99 10.1186/s13024-023-00693-6 38115077
Eskandari-Sedighi G, Blurton-Jones M. Microglial APOE4: more is less and less is more. Mol Neurodegener. 2023;18(1):99.38115077 10.1186/s13024-023-00693-6
76. Victor MB Leary N Luna X Meharena HS Scannail AN Bozzelli PL Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity Cell Stem Cell 2022 29 8 1197 1212 e1198 10.1016/j.stem.2022.07.005 35931030
Victor MB, Leary N, Luna X, Meharena HS, Scannail AN, Bozzelli PL, et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell. 2022;29(8):1197-1212 e1198.35931030 10.1016/j.stem.2022.07.005
77. Haney MS Palovics R Munson CN Long C Johansson PK Yip O APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia Nature 2024 628 8006 154 161 10.1038/s41586-024-07185-7 38480892
Haney MS, Palovics R, Munson CN, Long C, Johansson PK, Yip O, et al. APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia. Nature. 2024;628(8006):154–61.38480892 10.1038/s41586-024-07185-7
78. Qi G Mi Y Shi X Gu H Brinton RD Yin F ApoE4 impairs neuron-astrocyte coupling of fatty acid metabolism Cell Rep 2021 34 1 108572 10.1016/j.celrep.2020.108572 33406436
Qi G, Mi Y, Shi X, Gu H, Brinton RD, Yin F. ApoE4 impairs neuron-astrocyte coupling of fatty acid metabolism. Cell Rep. 2021;34(1): 108572.33406436 10.1016/j.celrep.2020.108572
79. Montagne A Nation DA Sagare AP Barisano G Sweeney MD Chakhoyan A APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline Nature 2020 581 7806 71 76 10.1038/s41586-020-2247-3 32376954
Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71–6.32376954 10.1038/s41586-020-2247-3
80. Liu CC Zhao N Fu Y Wang N Linares C Tsai CW ApoE4 accelerates early seeding of amyloid pathology Neuron 2017 96 5 1024 1032.e1023 10.1016/j.neuron.2017.11.013 29216449
Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96(5):1024-1032.e1023.29216449 10.1016/j.neuron.2017.11.013
81. Kim H Kim S Cho B Shin J Kim J APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer's disease Transl Neurodegen 2022 11 1 45 10.1186/s40035-022-00319-9
Kim H, Kim S, Cho B, Shin J, Kim J. APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease. Transl Neurodegen. 2022;11(1):45.10.1186/s40035-022-00319-9
82. Tai LM Bilousova T Jungbauer L Roeske SK Youmans KL Yu C Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples J Biol Chem 2013 288 8 5914 5926 10.1074/jbc.M112.442103 23293020
Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288(8):5914–26.23293020 10.1074/jbc.M112.442103
83. Mahan TE Wang C Bao X Choudhury A Ulrich JD Holtzman DM Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis Mol Neurodegen 2022 17 1 13 10.1186/s13024-022-00516-0
Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol Neurodegen. 2022;17(1):13.10.1186/s13024-022-00516-0
84. Bales KR Verina T Dodel RC Du Y Altstiel L Bender M Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition Nat Genet 1997 17 3 263 264 10.1038/ng1197-263 9354781
Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17(3):263–4.9354781 10.1038/ng1197-263
85. Raulin AC Doss SV Heckman MG Craver EC Li Z Ikezu TC Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease Acta Neuropathol Commun 2024 12 1 25 10.1186/s40478-024-01731-0 38336940
Raulin AC, Doss SV, Heckman MG, Craver EC, Li Z, Ikezu TC, et al. Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer’s disease. Acta Neuropathol Commun. 2024;12(1):25.38336940 10.1186/s40478-024-01731-0
86. Hong S Beja-Glasser VF Nfonoyim BM Frouin A Li S Ramakrishnan S Complement and microglia mediate early synapse loss in Alzheimer mouse models Science 2016 352 6286 712 716 10.1126/science.aad8373 27033548
Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712–6.27033548 10.1126/science.aad8373
87. Rodriguez GA Tai LM LaDu MJ Rebeck GW Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition J Neuroinflammation 2014 11 111 10.1186/1742-2094-11-111 24948358
Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J Neuroinflammation. 2014;11:111.24948358 10.1186/1742-2094-11-111
88. Wellnitz S Friedlein A Bonanni C Anquez V Goepfert F Loetscher H A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers J Neurochem 2005 94 5 1351 1360 10.1111/j.1471-4159.2005.03295.x 16011742
Wellnitz S, Friedlein A, Bonanni C, Anquez V, Goepfert F, Loetscher H, et al. A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers. J Neurochem. 2005;94(5):1351–60.16011742 10.1111/j.1471-4159.2005.03295.x
89. Deane R Sagare A Hamm K Parisi M Lane S Finn MB apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain J Clin Invest 2008 118 12 4002 4013 10.1172/JCI36663 19033669
Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002–13.19033669 10.1172/JCI36663
90. Lau SF Wu W Wong HY Ouyang L Qiao Y Xu J The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer's disease pathology Nat Aging 2023 3 10 1219 1236 10.1038/s43587-023-00491-1 37735240
Lau SF, Wu W, Wong HY, Ouyang L, Qiao Y, Xu J, et al. The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology. Nat Aging. 2023;3(10):1219–36.37735240 10.1038/s43587-023-00491-1
91. Michikawa M Fan QW Isobe I Yanagisawa K Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture J Neurochem 2000 74 3 1008 1016 10.1046/j.1471-4159.2000.0741008.x 10693931
Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000;74(3):1008–16.10693931 10.1046/j.1471-4159.2000.0741008.x
92. Miners JS Van Helmond Z Chalmers K Wilcock G Love S Kehoe PG Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy J Neuropathol Exp Neurol 2006 65 10 1012 1021 10.1097/01.jnen.0000240463.87886.9a 17021406
Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006;65(10):1012–21.17021406 10.1097/01.jnen.0000240463.87886.9a
93. Mentis AA Dardiotis E Chrousos GP Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework Mol Psychiatry 2021 26 4 1075 1097 10.1038/s41380-020-0731-7 32355332
Mentis AA, Dardiotis E, Chrousos GP. Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework. Mol Psychiatry. 2021;26(4):1075–97.32355332 10.1038/s41380-020-0731-7
94. Tsuboi Y Josephs KA Cookson N Dickson DW APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy Neurology 2003 60 2 240 245 10.1212/01.WNL.0000044340.37138.A9 12552038
Tsuboi Y, Josephs KA, Cookson N, Dickson DW. APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy. Neurology. 2003;60(2):240–5.12552038 10.1212/01.WNL.0000044340.37138.A9
95. Ji Y Gong Y Gan W Beach T Holtzman DM Wisniewski T Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients Neuroscience 2003 122 2 305 315 10.1016/j.neuroscience.2003.08.007 14614898
Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer’s disease patients. Neuroscience. 2003;122(2):305–15.14614898 10.1016/j.neuroscience.2003.08.007
96. Genis I Gordon I Sehayek E Michaelson DM Phosphorylation of tau in apolipoprotein E-deficient mice Neurosci Lett 1995 199 1 5 8 10.1016/0304-3940(95)12007-Q 8584225
Genis I, Gordon I, Sehayek E, Michaelson DM. Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett. 1995;199(1):5–8.8584225 10.1016/0304-3940(95)12007-Q
97. Flaherty D Lu Q Soria J Wood JG Regulation of tau phosphorylation in microtubule fractions by apolipoprotein E J Neurosci Res 1999 56 3 271 274 10.1002/(SICI)1097-4547(19990501)56:3<271::AID-JNR6>3.0.CO;2-5 10336256
Flaherty D, Lu Q, Soria J, Wood JG. Regulation of tau phosphorylation in microtubule fractions by apolipoprotein E. J Neurosci Res. 1999;56(3):271–4.10336256 10.1002/(SICI)1097-4547(19990501)56:3<271::AID-JNR6>3.0.CO;2-5
98. Shi Y Yamada K Liddelow SA Smith ST Zhao L Luo W ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy Nature 2017 549 7673 523 527 10.1038/nature24016 28959956
Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523–7.28959956 10.1038/nature24016
99. Wang C Xiong M Gratuze M Bao X Shi Y Andhey PS Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia Neuron 2021 109 10 1657 1674.e1657 10.1016/j.neuron.2021.03.024 33831349
Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021;109(10):1657-1674.e1657.33831349 10.1016/j.neuron.2021.03.024
100. Young CB Johns E Kennedy G Belloy ME Insel PS Greicius MD APOE effects on regional tau in preclinical Alzheimer's disease Mol Neurodegen 2023 18 1 1 10.1186/s13024-022-00590-4
Young CB, Johns E, Kennedy G, Belloy ME, Insel PS, Greicius MD, et al. APOE effects on regional tau in preclinical Alzheimer’s disease. Mol Neurodegen. 2023;18(1):1.10.1186/s13024-022-00590-4
101. Eisenbaum M Pearson A Ortiz C Mullan M Crawford F Ojo J ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes Glia 2024 72 1 184 205 10.1002/glia.24469 37668005
Eisenbaum M, Pearson A, Ortiz C, Mullan M, Crawford F, Ojo J, et al. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia. 2024;72(1):184–205.37668005 10.1002/glia.24469
102. Zhao N Liu CC Van Ingelgom AJ Linares C Kurti A Knight JA APOE ε2 is associated with increased tau pathology in primary tauopathy Nat Commun 2018 9 1 4388 10.1038/s41467-018-06783-0 30348994
Zhao N, Liu CC, Van Ingelgom AJ, Linares C, Kurti A, Knight JA, et al. APOE ε2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9(1):4388.30348994 10.1038/s41467-018-06783-0
103. Li Z Shue F Zhao N Shinohara M Bu G APOE2: protective mechanism and therapeutic implications for Alzheimer's disease Mol Neurodegen 2020 15 1 63 10.1186/s13024-020-00413-4
Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease. Mol Neurodegen. 2020;15(1):63.10.1186/s13024-020-00413-4
104. Zhao N Liu CC Van Ingelgom AJ Linares C Kurti A Knight JA APOE epsilon2 is associated with increased tau pathology in primary tauopathy Nat Commun 2018 9 1 4388 10.1038/s41467-018-06783-0 30348994
Zhao N, Liu CC, Van Ingelgom AJ, Linares C, Kurti A, Knight JA, et al. APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9(1):4388.30348994 10.1038/s41467-018-06783-0
105. Nelson MR Liu P Agrawal A Yip O Blumenfeld J Traglia M The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation Nat Neurosci 2023 26 12 2104 2121 10.1038/s41593-023-01480-8 37957317
Nelson MR, Liu P, Agrawal A, Yip O, Blumenfeld J, Traglia M, et al. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26(12):2104–21.37957317 10.1038/s41593-023-01480-8
106. Sepulveda-Falla D Sanchez JS Almeida MC Boassa D Acosta-Uribe J Vila-Castelar C Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia Acta Neuropathol 2022 144 3 589 601 10.1007/s00401-022-02467-8 35838824
Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. Acta Neuropathol. 2022;144(3):589–601.35838824 10.1007/s00401-022-02467-8
107. Chen Y Song S Parhizkar S Lord J Zhu Y Strickland MR APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread Cell 2024 187 2 428 445 e420 10.1016/j.cell.2023.11.029 38086389
Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, et al. APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread. Cell. 2024;187(2):428-445 e420.38086389 10.1016/j.cell.2023.11.029
108. Liu H Mei F Ye R Han X Wang S Ding Y APOE3ch alleviates Abeta and tau pathology and neurodegeneration in the human APP(NL-G-F) cerebral organoid model of Alzheimer's disease Cell Res 2024 10.1038/s41422-024-00957-w 39143121
Liu H, Mei F, Ye R, Han X, Wang S, Ding Y, et al. APOE3ch alleviates Abeta and tau pathology and neurodegeneration in the human APP(NL-G-F) cerebral organoid model of Alzheimer’s disease. Cell Res. 2024. 10.1038/s41422-024-00957-w.39143121 10.1038/s41422-024-00957-w
109. Marino C Perez-Corredor P O'Hare M Heuer A Chmielewska N Gordon H APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation Alzheimers Dement 2024 20 2 819 836 10.1002/alz.13436 37791598
Marino C, Perez-Corredor P, O’Hare M, Heuer A, Chmielewska N, Gordon H, et al. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement. 2024;20(2):819–36.37791598 10.1002/alz.13436
110. Cooper JM Lathuiliere A Migliorini M Arai AL Wani MM Dujardin S Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism J Biol Chem 2021 296 100715 10.1016/j.jbc.2021.100715 33930462
Cooper JM, Lathuiliere A, Migliorini M, Arai AL, Wani MM, Dujardin S, et al. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J Biol Chem. 2021;296: 100715.33930462 10.1016/j.jbc.2021.100715
111. Shinohara M Tachibana M Kanekiyo T Bu G Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies J Lipid Res 2017 58 7 1267 1281 10.1194/jlr.R075796 28381441
Shinohara M, Tachibana M, Kanekiyo T, Bu G. Role of LRP1 in the pathogenesis of Alzheimer’s disease: evidence from clinical and preclinical studies. J Lipid Res. 2017;58(7):1267–81.28381441 10.1194/jlr.R075796
112. Ganz T Fainstein N Ben-Hur T When the infectious environment meets the AD brain Mol Neurodegen 2022 17 1 53 10.1186/s13024-022-00559-3
Ganz T, Fainstein N, Ben-Hur T. When the infectious environment meets the AD brain. Mol Neurodegen. 2022;17(1):53.10.1186/s13024-022-00559-3
113. Goedert M Oskar Fischer and the study of dementia Brain 2009 132 Pt 4 1102 1111 18952676
Goedert M. Oskar Fischer and the study of dementia. Brain. 2009;132(Pt 4):1102–11.18952676
114. Jamieson GA Maitland NJ Wilcock GK Craske J Itzhaki RF Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains J Med Virol 1991 33 4 224 227 10.1002/jmv.1890330403 1649907
Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF. Latent herpes simplex virus type 1 in normal and Alzheimer’s disease brains. J Med Virol. 1991;33(4):224–7.1649907 10.1002/jmv.1890330403
115. Linard M Letenneur L Garrigue I Doize A Dartigues JF Helmer C Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease Alzheimers Dement 2020 16 1 200 208 10.1002/alz.12008 31914220
Linard M, Letenneur L, Garrigue I, Doize A, Dartigues JF, Helmer C. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer’s disease. Alzheimers Dement. 2020;16(1):200–8.31914220 10.1002/alz.12008
116. Itzhaki RF Herpes simplex virus type 1 and Alzheimer's disease: possible mechanisms and signposts FASEB J 2017 31 8 3216 3226 10.1096/fj.201700360 28765170
Itzhaki RF. Herpes simplex virus type 1 and Alzheimer’s disease: possible mechanisms and signposts. FASEB J. 2017;31(8):3216–26.28765170 10.1096/fj.201700360
117. Catumbela CSG Giridharan VV Barichello T Morales R Clinical evidence of human pathogens implicated in Alzheimer's disease pathology and the therapeutic efficacy of antimicrobials: an overview Transl Neurodegen 2023 12 1 37 10.1186/s40035-023-00369-7
Catumbela CSG, Giridharan VV, Barichello T, Morales R. Clinical evidence of human pathogens implicated in Alzheimer’s disease pathology and the therapeutic efficacy of antimicrobials: an overview. Transl Neurodegen. 2023;12(1):37.10.1186/s40035-023-00369-7
118. Katz I De Luca F Dzudzor B Sarpong BK Osei-Appiah B Azoulay D Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana's healthy population Sci Rep 2020 10 1 2814 10.1038/s41598-020-59693-x 32071361
Katz I, De Luca F, Dzudzor B, Sarpong BK, Osei-Appiah B, Azoulay D, et al. Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana’s healthy population. Sci Rep. 2020;10(1):2814.32071361 10.1038/s41598-020-59693-x
119. Sochocka M Zwolińska K Leszek J The infectious etiology of Alzheimer's disease Curr Neuropharmacol 2017 15 7 996 1009 10.2174/1570159X15666170313122937 28294067
Sochocka M, Zwolińska K, Leszek J. The infectious etiology of Alzheimer’s disease. Curr Neuropharmacol. 2017;15(7):996–1009.28294067 10.2174/1570159X15666170313122937
120. Wozniak MA Mee AP Itzhaki RF Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques J Pathol 2009 217 1 131 138 10.1002/path.2449 18973185
Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol. 2009;217(1):131–8.18973185 10.1002/path.2449
121. Marcocci ME Napoletani G Protto V Kolesova O Piacentini R Li Puma DD Herpes simplex virus-1 in the brain: the dark side of a sneaky infection Trends Microbiol 2020 28 10 808 820 10.1016/j.tim.2020.03.003 32386801
Marcocci ME, Napoletani G, Protto V, Kolesova O, Piacentini R, Li Puma DD, et al. Herpes simplex virus-1 in the brain: the dark side of a sneaky infection. Trends Microbiol. 2020;28(10):808–20.32386801 10.1016/j.tim.2020.03.003
122. Itzhaki R Herpes simplex virus type 1, apolipoprotein E and Alzheimer' disease Herpes 2004 11 Suppl 2 77A 82A 15960905
Itzhaki R. Herpes simplex virus type 1, apolipoprotein E and Alzheimer’ disease. Herpes. 2004;11(Suppl 2):77A-82A.15960905
123. Mielcarska MB Skowrońska K Wyżewski Z Toka FN Disrupting neurons and glial cells oneness in the brain-the possible causal role of herpes simplex virus type 1 (HSV-1) in Alzheimer's Disease Int J Mol Sci 2021 23 1 242 10.3390/ijms23010242 35008671
Mielcarska MB, Skowrońska K, Wyżewski Z, Toka FN. Disrupting neurons and glial cells oneness in the brain-the possible causal role of herpes simplex virus type 1 (HSV-1) in Alzheimer’s Disease. Int J Mol Sci. 2021;23(1):242.35008671 10.3390/ijms23010242
124. Cairns DM Rouleau N Parker RN Walsh KG Gehrke L Kaplan DL A 3D human brain-like tissue model of herpes-induced Alzheimer's disease Sci Adv 2020 6 19 eaay8828 10.1126/sciadv.aay8828 32494701
Cairns DM, Rouleau N, Parker RN, Walsh KG, Gehrke L, Kaplan DL. A 3D human brain-like tissue model of herpes-induced Alzheimer’s disease. Sci Adv. 2020;6(19):eaay8828.32494701 10.1126/sciadv.aay8828
125. Sait A Angeli C Doig AJ Day PJR Viral involvement in Alzheimer's disease ACS Chem Neurosci 2021 12 7 1049 1060 10.1021/acschemneuro.0c00719 33687205
Sait A, Angeli C, Doig AJ, Day PJR. Viral involvement in Alzheimer’s disease. ACS Chem Neurosci. 2021;12(7):1049–60.33687205 10.1021/acschemneuro.0c00719
126. Lin WR Wozniak MA Cooper RJ Wilcock GK Itzhaki RF Herpesviruses in brain and Alzheimer's disease J Pathol 2002 197 3 395 402 10.1002/path.1127 12115887
Lin WR, Wozniak MA, Cooper RJ, Wilcock GK, Itzhaki RF. Herpesviruses in brain and Alzheimer’s disease. J Pathol. 2002;197(3):395–402.12115887 10.1002/path.1127
127. Nimgaonkar VL Yolken RH Wang T Chang CC McClain L McDade E Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort Alzheimer Dis Assoc Disord 2016 30 3 216 222 10.1097/WAD.0000000000000133 26710257
Nimgaonkar VL, Yolken RH, Wang T, Chang CC, McClain L, McDade E, et al. Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort. Alzheimer Dis Assoc Disord. 2016;30(3):216–22.26710257 10.1097/WAD.0000000000000133
128. Barnes LL Capuano AW Aiello AE Turner AD Yolken RH Torrey EF Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals J Infect Dis 2015 211 2 230 237 10.1093/infdis/jiu437 25108028
Barnes LL, Capuano AW, Aiello AE, Turner AD, Yolken RH, Torrey EF, et al. Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis. 2015;211(2):230–7.25108028 10.1093/infdis/jiu437
129. Chiu WC Tsan YT Tsai SL Chang CJ Wang JD Chen PC Hepatitis C viral infection and the risk of dementia Eur J Neurol 2014 21 8 1068 e1059 10.1111/ene.12317 24313931
Chiu WC, Tsan YT, Tsai SL, Chang CJ, Wang JD, Chen PC. Hepatitis C viral infection and the risk of dementia. Eur J Neurol. 2014;21(8):1068-e1059.24313931 10.1111/ene.12317
130. Grover VP Pavese N Koh SB Wylezinska M Saxby BK Gerhard A Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation J Viral Hepat 2012 19 2 e89 96 10.1111/j.1365-2893.2011.01510.x 22239531
Grover VP, Pavese N, Koh SB, Wylezinska M, Saxby BK, Gerhard A, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat. 2012;19(2):e89-96.22239531 10.1111/j.1365-2893.2011.01510.x
131. Xie J Cools L Van Imschoot G Van Wonterghem E Pauwels MJ Vlaeminck I Helicobacter pylori-derived outer membrane vesicles contribute to Alzheimer's disease pathogenesis via C3–C3aR signalling J Extracell Vesicles 2023 12 2 e12306 10.1002/jev2.12306 36792546
Xie J, Cools L, Van Imschoot G, Van Wonterghem E, Pauwels MJ, Vlaeminck I, et al. Helicobacter pylori-derived outer membrane vesicles contribute to Alzheimer’s disease pathogenesis via C3–C3aR signalling. J Extracell Vesicles. 2023;12(2): e12306.36792546 10.1002/jev2.12306
132. Doulberis M Kotronis G Thomann R Polyzos SA Boziki M Gialamprinou D Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far? Helicobacter 2018 23 1 e12454 10.1111/hel.12454
Doulberis M, Kotronis G, Thomann R, Polyzos SA, Boziki M, Gialamprinou D, et al. Review: Impact of Helicobacter pylori on Alzheimer’s disease: What do we know so far? Helicobacter. 2018;23(1): e12454.10.1111/hel.12454
133. Dominy SS Lynch C Ermini F Benedyk M Marczyk A Konradi A Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors Sci Adv 2019 5 1 eaau3333 10.1126/sciadv.aau3333 30746447
Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333.30746447 10.1126/sciadv.aau3333
134. Balin BJ Gérard HC Arking EJ Appelt DM Branigan PJ Abrams JT Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain Med Microbiol Immunol 1998 187 1 23 42 10.1007/s004300050071 9749980
Balin BJ, Gérard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer’s brain. Med Microbiol Immunol. 1998;187(1):23–42.9749980 10.1007/s004300050071
135. Miklossy J Khalili K Gern L Ericson RL Darekar P Bolle L Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease J Alzheimers Dis 2004 6 6 639 649 10.3233/JAD-2004-6608 15665404
Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis. 2004;6(6):639–49.15665404 10.3233/JAD-2004-6608
136. Alonso R Pisa D Marina AI Morato E Rábano A Carrasco L Fungal infection in patients with Alzheimer's disease J Alzheimers Dis 2014 41 1 301 311 10.3233/JAD-132681 24614898
Alonso R, Pisa D, Marina AI, Morato E, Rábano A, Carrasco L. Fungal infection in patients with Alzheimer’s disease. J Alzheimers Dis. 2014;41(1):301–11.24614898 10.3233/JAD-132681
137. Ortiz-Guerrero G Gonzalez-Reyes RE de la Torre A Medina-Rincón G Nava-Mesa MO Pathophysiological mechanisms of cognitive impairment and neurodegeneration by Toxoplasma gondii infection Brain Sci 2020 10 6 369 10.3390/brainsci10060369 32545619
Ortiz-Guerrero G, Gonzalez-Reyes RE, de la Torre A, Medina-Rincón G, Nava-Mesa MO. Pathophysiological mechanisms of cognitive impairment and neurodegeneration by Toxoplasma gondii infection. Brain Sci. 2020;10(6):369.32545619 10.3390/brainsci10060369
138. Varesi A Pierella E Romeo M Piccini GB Alfano C Bjørklund G The potential role of gut microbiota in Alzheimer's disease: from diagnosis to treatment Nutrients 2022 14 3 668 10.3390/nu14030668 35277027
Varesi A, Pierella E, Romeo M, Piccini GB, Alfano C, Bjørklund G, et al. The potential role of gut microbiota in Alzheimer’s disease: from diagnosis to treatment. Nutrients. 2022;14(3):668.35277027 10.3390/nu14030668
139. Fitzgerald E Murphy S Martinson HA Alpha-synuclein pathology and the role of the microbiota in Parkinson's disease Front Neurosci 2019 13 369 10.3389/fnins.2019.00369 31068777
Fitzgerald E, Murphy S, Martinson HA. Alpha-synuclein pathology and the role of the microbiota in Parkinson’s disease. Front Neurosci. 2019;13:369.31068777 10.3389/fnins.2019.00369
140. Liu J Yu C Li R Liu K Jin G Ge R High-altitude Tibetan fermented milk ameliorated cognitive dysfunction by modified gut microbiota in Alzheimer's disease transgenic mice Food Funct 2020 11 6 5308 5319 10.1039/C9FO03007G 32458851
Liu J, Yu C, Li R, Liu K, Jin G, Ge R, et al. High-altitude Tibetan fermented milk ameliorated cognitive dysfunction by modified gut microbiota in Alzheimer’s disease transgenic mice. Food Funct. 2020;11(6):5308–19.32458851 10.1039/C9FO03007G
141. Chandra S Di Meco A Dodiya HB Popovic J Cuddy LK Weigle IQ The gut microbiome regulates astrocyte reaction to Abeta amyloidosis through microglial dependent and independent mechanisms Mol Neurodegener 2023 18 1 45 10.1186/s13024-023-00635-2 37415149
Chandra S, Di Meco A, Dodiya HB, Popovic J, Cuddy LK, Weigle IQ, et al. The gut microbiome regulates astrocyte reaction to Abeta amyloidosis through microglial dependent and independent mechanisms. Mol Neurodegener. 2023;18(1):45.37415149 10.1186/s13024-023-00635-2
142. Xie J Bruggeman A De Nolf C Vandendriessche C Van Imschoot G Van Wonterghem E Gut microbiota regulates blood-cerebrospinal fluid barrier function and Abeta pathology EMBO J 2023 42 17 e111515 10.15252/embj.2022111515 37427561
Xie J, Bruggeman A, De Nolf C, Vandendriessche C, Van Imschoot G, Van Wonterghem E, et al. Gut microbiota regulates blood-cerebrospinal fluid barrier function and Abeta pathology. EMBO J. 2023;42(17): e111515.37427561 10.15252/embj.2022111515
143. Wei S Peng W Mai Y Li K Wei W Hu L Outer membrane vesicles enhance tau phosphorylation and contribute to cognitive impairment J Cell Physiol 2020 235 5 4843 4855 10.1002/jcp.29362 31663118
Wei S, Peng W, Mai Y, Li K, Wei W, Hu L, et al. Outer membrane vesicles enhance tau phosphorylation and contribute to cognitive impairment. J Cell Physiol. 2020;235(5):4843–55.31663118 10.1002/jcp.29362
144. Hansen DV Hanson JE Sheng M Microglia in Alzheimer's disease J Cell Biol 2018 217 2 459 472 10.1083/jcb.201709069 29196460
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217(2):459–72.29196460 10.1083/jcb.201709069
145. Ouyang P Cai Z Peng J Lin S Chen X Chen C SELENOK-dependent CD36 palmitoylation regulates microglial functions and Abeta phagocytosis Redox Biol 2024 70 103064 10.1016/j.redox.2024.103064 38320455
Ouyang P, Cai Z, Peng J, Lin S, Chen X, Chen C, et al. SELENOK-dependent CD36 palmitoylation regulates microglial functions and Abeta phagocytosis. Redox Biol. 2024;70: 103064.38320455 10.1016/j.redox.2024.103064
146. Sarlus H Heneka MT Microglia in Alzheimer's disease J Clin Invest 2017 127 9 3240 3249 10.1172/JCI90606 28862638
Sarlus H, Heneka MT. Microglia in Alzheimer’s disease. J Clin Invest. 2017;127(9):3240–9.28862638 10.1172/JCI90606
147. Wang J Qin X Sun H He M Lv Q Gao C Nogo receptor impairs the clearance of fibril amyloid-β by microglia and accelerates Alzheimer's-like disease progression Aging Cell 2021 20 12 e13515 10.1111/acel.13515 34821024
Wang J, Qin X, Sun H, He M, Lv Q, Gao C, et al. Nogo receptor impairs the clearance of fibril amyloid-β by microglia and accelerates Alzheimer’s-like disease progression. Aging Cell. 2021;20(12): e13515.34821024 10.1111/acel.13515
148. Ennerfelt H Holliday C Shapiro DA Zengeler KE Bolte AC Ulland TK CARD9 attenuates Abeta pathology and modifies microglial responses in an Alzheimer's disease mouse model Proc Natl Acad Sci USA 2023 120 24 e2303760120 10.1073/pnas.2303760120 37276426
Ennerfelt H, Holliday C, Shapiro DA, Zengeler KE, Bolte AC, Ulland TK, et al. CARD9 attenuates Abeta pathology and modifies microglial responses in an Alzheimer’s disease mouse model. Proc Natl Acad Sci USA. 2023;120(24): e2303760120.37276426 10.1073/pnas.2303760120
149. Griciuc A Patel S Federico AN Choi SH Innes BJ Oram MK TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer's disease Neuron 2019 103 5 820 835.e827 10.1016/j.neuron.2019.06.010 31301936
Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, et al. TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron. 2019;103(5):820-835.e827.31301936 10.1016/j.neuron.2019.06.010
150. Cope EC LaMarca EA Monari PK Olson LB Martinez S Zych AD Microglia play an active role in obesity-associated cognitive decline J Neurosci 2018 38 41 8889 8904 10.1523/JNEUROSCI.0789-18.2018 30201764
Cope EC, LaMarca EA, Monari PK, Olson LB, Martinez S, Zych AD, et al. Microglia play an active role in obesity-associated cognitive decline. J Neurosci. 2018;38(41):8889–904.30201764 10.1523/JNEUROSCI.0789-18.2018
151. Heneka MT Carson MJ El Khoury J Landreth GE Brosseron F Feinstein DL Neuroinflammation in Alzheimer's disease Lancet Neurol 2015 14 4 388 405 10.1016/S1474-4422(15)70016-5 25792098
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.25792098 10.1016/S1474-4422(15)70016-5
152. Guo S Wang H Yin Y Microglia polarization from M1 to M2 in neurodegenerative diseases Front Aging Neurosci 2022 14 815347 10.3389/fnagi.2022.815347 35250543
Guo S, Wang H, Yin Y. Microglia polarization from M1 to M2 in neurodegenerative diseases. Front Aging Neurosci. 2022;14: 815347.35250543 10.3389/fnagi.2022.815347
153. Lv Z Chen L Chen P Peng H Rong Y Hong W Clearance of beta-amyloid and synapses by the optogenetic depolarization of microglia is complement selective Neuron 2024 112 5 740 754 e747 10.1016/j.neuron.2023.12.003 38295790
Lv Z, Chen L, Chen P, Peng H, Rong Y, Hong W, et al. Clearance of beta-amyloid and synapses by the optogenetic depolarization of microglia is complement selective. Neuron. 2024;112(5):740-754 e747.38295790 10.1016/j.neuron.2023.12.003
154. Gedam M Comerota MM Propson NE Chen T Jin F Wang MC Complement C3aR depletion reverses HIF-1alpha-induced metabolic impairment and enhances microglial response to Abeta pathology J Clin Invest 2023 10.1172/JCI167501 37317973
Gedam M, Comerota MM, Propson NE, Chen T, Jin F, Wang MC, et al. Complement C3aR depletion reverses HIF-1alpha-induced metabolic impairment and enhances microglial response to Abeta pathology. J Clin Invest. 2023. 10.1172/JCI167501.37317973 10.1172/JCI167501
155. Uddin MS Lim LW Glial cells in Alzheimer's disease: from neuropathological changes to therapeutic implications Ageing Res Rev 2022 78 101622 10.1016/j.arr.2022.101622 35427810
Uddin MS, Lim LW. Glial cells in Alzheimer’s disease: from neuropathological changes to therapeutic implications. Ageing Res Rev. 2022;78: 101622.35427810 10.1016/j.arr.2022.101622
156. Singh D Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease J Neuroinflammation 2022 19 1 206 10.1186/s12974-022-02565-0 35978311
Singh D. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease. J Neuroinflammation. 2022;19(1):206.35978311 10.1186/s12974-022-02565-0
157. Kwon HS Koh SH Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes Transl Neurodegen 2020 9 1 42 10.1186/s40035-020-00221-2
Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegen. 2020;9(1):42.10.1186/s40035-020-00221-2
158. Bellaver B Povala G Ferreira PCL Ferrari-Souza JP Leffa DT Lussier FZ Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease Nat Med 2023 29 7 1775 1781 10.1038/s41591-023-02380-x 37248300
Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer’s disease. Nat Med. 2023;29(7):1775–81.37248300 10.1038/s41591-023-02380-x
159. Kim E Kim H Jedrychowski MP Bakiasi G Park J Kruskop J Irisin reduces amyloid-beta by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling Neuron 2023 111 22 3619 3633 e3618 10.1016/j.neuron.2023.08.012 37689059
Kim E, Kim H, Jedrychowski MP, Bakiasi G, Park J, Kruskop J, et al. Irisin reduces amyloid-beta by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling. Neuron. 2023;111(22):3619-3633 e3618.37689059 10.1016/j.neuron.2023.08.012
160. Murdock MH Yang CY Sun N Pao PC Blanco-Duque C Kahn MC Multisensory gamma stimulation promotes glymphatic clearance of amyloid Nature 2024 627 8002 149 156 10.1038/s41586-024-07132-6 38418876
Murdock MH, Yang CY, Sun N, Pao PC, Blanco-Duque C, Kahn MC, et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature. 2024;627(8002):149–56.38418876 10.1038/s41586-024-07132-6
161. Jacobsen JS Muenkel HA Blume AJ Vitek MP A novel species-specific RNA related to alternatively spliced amyloid precursor protein mRNAs Neurobiol Aging 1991 12 5 575 583 10.1016/0197-4580(91)90089-3 1722873
Jacobsen JS, Muenkel HA, Blume AJ, Vitek MP. A novel species-specific RNA related to alternatively spliced amyloid precursor protein mRNAs. Neurobiol Aging. 1991;12(5):575–83.1722873 10.1016/0197-4580(91)90089-3
162. Bayer TA Cappai R Masters CL Beyreuther K Multhaup G It all sticks together–the APP-related family of proteins and Alzheimer's disease Mol Psychiatry 1999 4 6 524 528 10.1038/sj.mp.4000552 10578233
Bayer TA, Cappai R, Masters CL, Beyreuther K, Multhaup G. It all sticks together–the APP-related family of proteins and Alzheimer’s disease. Mol Psychiatry. 1999;4(6):524–8.10578233 10.1038/sj.mp.4000552
163. Readhead B Haure-Mirande JV Zhang B Haroutunian V Gandy S Schadt EE Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Δexon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology Mol Psychiatry 2016 21 8 1099 1111 10.1038/mp.2015.167 26552589
Readhead B, Haure-Mirande JV, Zhang B, Haroutunian V, Gandy S, Schadt EE, et al. Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Δexon9) mouse models identifies shared features with human Alzheimer’s brain molecular pathology. Mol Psychiatry. 2016;21(8):1099–111.26552589 10.1038/mp.2015.167
164. Deng Y Wang Z Wang R Zhang X Zhang S Wu Y Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis Eur J Neurosci 2013 37 12 1962 1969 10.1111/ejn.12235 23773065
Deng Y, Wang Z, Wang R, Zhang X, Zhang S, Wu Y, et al. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis. Eur J Neurosci. 2013;37(12):1962–9.23773065 10.1111/ejn.12235
165. Takami M Nagashima Y Sano Y Ishihara S Morishima-Kawashima M Funamoto S gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment J Neurosci 2009 29 41 13042 13052 10.1523/JNEUROSCI.2362-09.2009 19828817
Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042–52.19828817 10.1523/JNEUROSCI.2362-09.2009
166. Zhang S Wang Z Cai F Zhang M Wu Y Zhang J BACE1 cleavage site selection critical for amyloidogenesis and Alzheimer's Pathogenesis J Neurosci 2017 37 29 6915 6925 10.1523/JNEUROSCI.0340-17.2017 28626014
Zhang S, Wang Z, Cai F, Zhang M, Wu Y, Zhang J, et al. BACE1 cleavage site selection critical for amyloidogenesis and Alzheimer’s Pathogenesis. J Neurosci. 2017;37(29):6915–25.28626014 10.1523/JNEUROSCI.0340-17.2017
167. Glenner GG Wong CW Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem Biophys Res Commun 1984 120 3 885 890 10.1016/S0006-291X(84)80190-4 6375662
Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885–90.6375662 10.1016/S0006-291X(84)80190-4
168. Zhang Z Song M Liu X Su Kang S Duong DM Seyfried NT Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease Nat Commun 2015 6 8762 10.1038/ncomms9762 26549211
Zhang Z, Song M, Liu X, Su Kang S, Duong DM, Seyfried NT, et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat Commun. 2015;6:8762.26549211 10.1038/ncomms9762
169. Xia Y Wang ZH Zhang Z Liu X Yu SP Wang JZ Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer's disease Prog Neurobiol 2021 204 102113 10.1016/j.pneurobio.2021.102113 34166772
Xia Y, Wang ZH, Zhang Z, Liu X, Yu SP, Wang JZ, et al. Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer’s disease. Prog Neurobiol. 2021;204: 102113.34166772 10.1016/j.pneurobio.2021.102113
170. Zhang Z Obianyo O Dall E Du Y Fu H Liu X Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease Nat Commun 2017 8 14740 10.1038/ncomms14740 28345579
Zhang Z, Obianyo O, Dall E, Du Y, Fu H, Liu X, et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease. Nat Commun. 2017;8:14740.28345579 10.1038/ncomms14740
171. Fukumori A Okochi M Tagami S Jiang J Itoh N Nakayama T Presenilin-dependent gamma-secretase on plasma membrane and endosomes is functionally distinct Biochemistry 2006 45 15 4907 4914 10.1021/bi052412w 16605258
Fukumori A, Okochi M, Tagami S, Jiang J, Itoh N, Nakayama T, et al. Presenilin-dependent gamma-secretase on plasma membrane and endosomes is functionally distinct. Biochemistry. 2006;45(15):4907–14.16605258 10.1021/bi052412w
172. Manzine PR Ettcheto M Cano A Busquets O Marcello E Pelucchi S ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker Biomed Pharmacother 2019 113 108661 10.1016/j.biopha.2019.108661 30836275
Manzine PR, Ettcheto M, Cano A, Busquets O, Marcello E, Pelucchi S, et al. ADAM10 in Alzheimer’s disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomed Pharmacother. 2019;113: 108661.30836275 10.1016/j.biopha.2019.108661
173. Sun X Wang Y Qing H Christensen MA Liu Y Zhou W Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes FASEB J 2005 19 7 739 749 10.1096/fj.04-3426com 15857888
Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J. 2005;19(7):739–49.15857888 10.1096/fj.04-3426com
174. Wang Z Xu Q Cai F Liu X Wu Y Song W BACE2, a conditional β-secretase, contributes to Alzheimer's disease pathogenesis JCI Insight 2019 4 1 e123431 10.1172/jci.insight.123431 30626751
Wang Z, Xu Q, Cai F, Liu X, Wu Y, Song W. BACE2, a conditional β-secretase, contributes to Alzheimer’s disease pathogenesis. JCI Insight. 2019;4(1):e123431.30626751 10.1172/jci.insight.123431
175. Sun X He G Song W BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome FASEB J 2006 20 9 1369 1376 10.1096/fj.05-5632com 16816112
Sun X, He G, Song W. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome. FASEB J. 2006;20(9):1369–76.16816112 10.1096/fj.05-5632com
176. Iwata N Tsubuki S Takaki Y Watanabe K Sekiguchi M Hosoki E Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition Nat Med 2000 6 2 143 150 10.1038/72237 10655101
Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6(2):143–50.10655101 10.1038/72237
177. Vekrellis K Ye Z Qiu WQ Walsh D Hartley D Chesneau V Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme J Neurosci 2000 20 5 1657 1665 10.1523/JNEUROSCI.20-05-01657.2000 10684867
Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20(5):1657–65.10684867 10.1523/JNEUROSCI.20-05-01657.2000
178. Tseng BP Esler WP Clish CB Stimson ER Ghilardi JR Vinters HV Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations Biochemistry 1999 38 32 10424 10431 10.1021/bi990718v 10441137
Tseng BP, Esler WP, Clish CB, Stimson ER, Ghilardi JR, Vinters HV, et al. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer’s disease amyloid plaques in human brain preparations. Biochemistry. 1999;38(32):10424–31.10441137 10.1021/bi990718v
179. Wilcock DM Munireddy SK Rosenthal A Ugen KE Gordon MN Morgan D Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration Neurobiol Dis 2004 15 1 11 20 10.1016/j.nbd.2003.09.015 14751766
Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15(1):11–20.14751766 10.1016/j.nbd.2003.09.015
180. Ito S Ohtsuki S Kamiie J Nezu Y Terasaki T Cerebral clearance of human amyloid-beta peptide (1–40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes J Neurochem 2007 103 6 2482 2490 10.1111/j.1471-4159.2007.04938.x 17908238
Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-beta peptide (1–40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem. 2007;103(6):2482–90.17908238 10.1111/j.1471-4159.2007.04938.x
181. Ito S Ueno T Ohtsuki S Terasaki T Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1–40) in mouse: involvement of an LRP-1-independent pathway J Neurochem 2010 113 5 1356 1363 10.1111/j.1471-4159.2010.06708.x 20367755
Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1–40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem. 2010;113(5):1356–63.20367755 10.1111/j.1471-4159.2010.06708.x
182. Madsen LS Kjeldsen PL Ismail R Parbo P Ostergaard L Brooks DJ Capillary dysfunction in healthy elderly APOE epsilon4 carriers with raised brain Abeta deposition Alzheimers Dement 2024 20 1 459 471 10.1002/alz.13461 37679610
Madsen LS, Kjeldsen PL, Ismail R, Parbo P, Ostergaard L, Brooks DJ, et al. Capillary dysfunction in healthy elderly APOE epsilon4 carriers with raised brain Abeta deposition. Alzheimers Dement. 2024;20(1):459–71.37679610 10.1002/alz.13461
183. Depp C Sun T Sasmita AO Spieth L Berghoff SA Nazarenko T Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer's disease Nature 2023 618 7964 349 357 10.1038/s41586-023-06120-6 37258678
Depp C, Sun T, Sasmita AO, Spieth L, Berghoff SA, Nazarenko T, et al. Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer’s disease. Nature. 2023;618(7964):349–57.37258678 10.1038/s41586-023-06120-6
184. Zhao Y Zheng Q Hong Y Gao Y Hu J Lang M beta(2)-Microglobulin coaggregates with Abeta and contributes to amyloid pathology and cognitive deficits in Alzheimer's disease model mice Nat Neurosci 2023 26 7 1170 1184 10.1038/s41593-023-01352-1 37264159
Zhao Y, Zheng Q, Hong Y, Gao Y, Hu J, Lang M, et al. beta(2)-Microglobulin coaggregates with Abeta and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice. Nat Neurosci. 2023;26(7):1170–84.37264159 10.1038/s41593-023-01352-1
185. Xie L Kang H Xu Q Chen MJ Liao Y Thiyagarajan M Sleep drives metabolite clearance from the adult brain Science (New York, NY) 2013 342 6156 373 377 10.1126/science.1241224
Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science (New York, NY). 2013;342(6156):373–7.10.1126/science.1241224
186. Spira AP Gamaldo AA An Y Wu MN Simonsick EM Bilgel M Self-reported sleep and β-amyloid deposition in community-dwelling older adults JAMA Neurol 2013 70 12 1537 1543 24145859
Spira AP, Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, et al. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70(12):1537–43.24145859
187. Wang C Nambiar A Strickland MR Lee C Parhizkar S Moore AC APOE-epsilon4 synergizes with sleep disruption to accelerate Abeta deposition and Abeta-associated tau seeding and spreading J Clin Invest 2023 133 14 e169131 10.1172/JCI169131 37279069
Wang C, Nambiar A, Strickland MR, Lee C, Parhizkar S, Moore AC, et al. APOE-epsilon4 synergizes with sleep disruption to accelerate Abeta deposition and Abeta-associated tau seeding and spreading. J Clin Invest. 2023;133(14):e169131.37279069 10.1172/JCI169131
188. Haass C Lemere CA Capell A Citron M Seubert P Schenk D The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway Nat Med 1995 1 12 1291 1296 10.1038/nm1295-1291 7489411
Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat Med. 1995;1(12):1291–6.7489411 10.1038/nm1295-1291
189. Zhang Y Xie X Chen B Pan L Li J Wang W E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease Genes Dis 2024 11 2 1022 1034 10.1016/j.gendis.2023.02.051 37692508
Zhang Y, Xie X, Chen B, Pan L, Li J, Wang W, et al. E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer’s disease. Genes Dis. 2024;11(2):1022–34.37692508 10.1016/j.gendis.2023.02.051
190. Nilsberth C Westlind-Danielsson A Eckman CB Condron MM Axelman K Forsell C The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation Nat Neurosci 2001 4 9 887 893 10.1038/nn0901-887 11528419
Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The “Arctic” APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4(9):887–93.11528419 10.1038/nn0901-887
191. Tsubuki S Takaki Y Saido TC Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation Lancet 2003 361 9373 1957 1958 10.1016/S0140-6736(03)13555-6 12801742
Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet. 2003;361(9373):1957–8.12801742 10.1016/S0140-6736(03)13555-6
192. De Jonghe C Zehr C Yager D Prada CM Younkin S Hendriks L Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion Neurobiol Dis 1998 5 4 281 286 10.1006/nbdi.1998.0202 9848098
De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis. 1998;5(4):281–6.9848098 10.1006/nbdi.1998.0202
193. Canet G Zussy C Hernandez C Maurice T Desrumaux C Givalois L The pathomimetic oAβ(25)(-)(35) model of Alzheimer's disease: potential for screening of new therapeutic agents Pharmacol Ther 2023 245 108398 10.1016/j.pharmthera.2023.108398 37001735
Canet G, Zussy C, Hernandez C, Maurice T, Desrumaux C, Givalois L. The pathomimetic oAβ(25)(-)(35) model of Alzheimer’s disease: potential for screening of new therapeutic agents. Pharmacol Ther. 2023;245: 108398.37001735 10.1016/j.pharmthera.2023.108398
194. Ryoo SR Cho HJ Lee HW Jeong HK Radnaabazar C Kim YS Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease J Neurochem 2008 104 5 1333 1344 10.1111/j.1471-4159.2007.05075.x 18005339
Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS, et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease. J Neurochem. 2008;104(5):1333–44.18005339 10.1111/j.1471-4159.2007.05075.x
195. Wang X Zhou X Li G Zhang Y Wu Y Song W Modifications and trafficking of APP in the pathogenesis of Alzheimer’s disease Front Mol Neurosci 2017 10 294 10.3389/fnmol.2017.00294 28966576
Wang X, Zhou X, Li G, Zhang Y, Wu Y, Song W. Modifications and trafficking of APP in the pathogenesis of Alzheimer’s disease. Front Mol Neurosci. 2017;10:294.28966576 10.3389/fnmol.2017.00294
196. Shen Y Wang H Sun Q Yao H Keegan AP Mullan M Increased plasma beta-secretase 1 May Predict conversion to Alzheimer's Disease dementia in individuals with mild cognitive impairment Biol Psychiatry 2018 83 5 447 455 10.1016/j.biopsych.2017.02.007 28359566
Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M, et al. Increased plasma beta-secretase 1 May Predict conversion to Alzheimer’s Disease dementia in individuals with mild cognitive impairment. Biol Psychiatry. 2018;83(5):447–55.28359566 10.1016/j.biopsych.2017.02.007
197. Fukumoto H Rosene DL Moss MB Raju S Hyman BT Irizarry MC Beta-secretase activity increases with aging in human, monkey, and mouse brain Am J Pathol 2004 164 2 719 725 10.1016/S0002-9440(10)63159-8 14742275
Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004;164(2):719–25.14742275 10.1016/S0002-9440(10)63159-8
198. Marques SC Lemos R Ferreiro E Martins M de Mendonça A Santana I Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice Neuroscience 2012 220 256 266 10.1016/j.neuroscience.2012.06.029 22728099
Marques SC, Lemos R, Ferreiro E, Martins M, de Mendonça A, Santana I, et al. Epigenetic regulation of BACE1 in Alzheimer’s disease patients and in transgenic mice. Neuroscience. 2012;220:256–66.22728099 10.1016/j.neuroscience.2012.06.029
199. Chouliaras L Mastroeni D Delvaux E Grover A Kenis G Hof PR Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients Neurobiol Aging 2013 34 9 2091 2099 10.1016/j.neurobiolaging.2013.02.021 23582657
Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, Hof PR, et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. Neurobiol Aging. 2013;34(9):2091–9.23582657 10.1016/j.neurobiolaging.2013.02.021
200. Gu X Sun J Li S Wu X Li L Oxidative stress induces DNA demethylation and histone acetylation in SH-SY5Y cells: potential epigenetic mechanisms in gene transcription in Aβ production Neurobiol Aging 2013 34 4 1069 1079 10.1016/j.neurobiolaging.2012.10.013 23141413
Gu X, Sun J, Li S, Wu X, Li L. Oxidative stress induces DNA demethylation and histone acetylation in SH-SY5Y cells: potential epigenetic mechanisms in gene transcription in Aβ production. Neurobiol Aging. 2013;34(4):1069–79.23141413 10.1016/j.neurobiolaging.2012.10.013
201. Lin HC Hsieh HM Chen YH Hu ML S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters Neurotoxicology 2009 30 4 622 627 10.1016/j.neuro.2009.03.011 19635394
Lin HC, Hsieh HM, Chen YH, Hu ML. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. Neurotoxicology. 2009;30(4):622–7.19635394 10.1016/j.neuro.2009.03.011
202. Hampel H Vassar R De Strooper B Hardy J Willem M Singh N The β-secretase BACE1 in Alzheimer’s disease Biol Psychiatry 2021 89 8 745 756 10.1016/j.biopsych.2020.02.001 32223911
Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry. 2021;89(8):745–56.32223911 10.1016/j.biopsych.2020.02.001
203. Wen W Li P Liu P Xu S Wang F Huang JH Post-translational modifications of BACE1 in Alzheimer's disease Curr Neuropharmacol 2022 20 1 211 222 10.2174/1570159X19666210121163224 33475074
Wen W, Li P, Liu P, Xu S, Wang F, Huang JH. Post-translational modifications of BACE1 in Alzheimer’s disease. Curr Neuropharmacol. 2022;20(1):211–22.33475074 10.2174/1570159X19666210121163224
204. De Strooper B Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex Neuron 2003 38 1 9 12 10.1016/S0896-6273(03)00205-8 12691659
De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38(1):9–12.12691659 10.1016/S0896-6273(03)00205-8
205. Spasic D Tolia A Dillen K Baert V De Strooper B Vrijens S Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway J Biol Chem 2006 281 36 26569 26577 10.1074/jbc.M600592200 16846981
Spasic D, Tolia A, Dillen K, Baert V, De Strooper B, Vrijens S, et al. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem. 2006;281(36):26569–77.16846981 10.1074/jbc.M600592200
206. Laudon H Hansson EM Melén K Bergman A Farmery MR Winblad B A nine-transmembrane domain topology for presenilin 1 J Biol Chem 2005 280 42 35352 35360 10.1074/jbc.M507217200 16046406
Laudon H, Hansson EM, Melén K, Bergman A, Farmery MR, Winblad B, et al. A nine-transmembrane domain topology for presenilin 1. J Biol Chem. 2005;280(42):35352–60.16046406 10.1074/jbc.M507217200
207. Crystal AS Morais VA Pierson TC Pijak DS Carlin D Lee VM Membrane topology of gamma-secretase component PEN-2 J Biol Chem 2003 278 22 20117 20123 10.1074/jbc.M213107200 12639958
Crystal AS, Morais VA, Pierson TC, Pijak DS, Carlin D, Lee VM, et al. Membrane topology of gamma-secretase component PEN-2. J Biol Chem. 2003;278(22):20117–23.12639958 10.1074/jbc.M213107200
208. Francis R McGrath G Zhang J Ruddy DA Sym M Apfeld J aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation Dev Cell 2002 3 1 85 97 10.1016/S1534-5807(02)00189-2 12110170
Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3(1):85–97.12110170 10.1016/S1534-5807(02)00189-2
209. Fortna RR Crystal AS Morais VA Pijak DS Lee VM Doms RW Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex J Biol Chem 2004 279 5 3685 3693 10.1074/jbc.M310505200 14593096
Fortna RR, Crystal AS, Morais VA, Pijak DS, Lee VM, Doms RW. Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex. J Biol Chem. 2004;279(5):3685–93.14593096 10.1074/jbc.M310505200
210. Wang X Zhou R Sun X Li J Wang J Yue W Preferential regulation of gamma-secretase-mediated cleavage of APP by ganglioside GM1 reveals a potential therapeutic target for Alzheimer's disease Adv Sci (Weinh) 2023 10 32 e2303411 10.1002/advs.202303411 37759382
Wang X, Zhou R, Sun X, Li J, Wang J, Yue W, et al. Preferential regulation of gamma-secretase-mediated cleavage of APP by ganglioside GM1 reveals a potential therapeutic target for Alzheimer’s disease. Adv Sci (Weinh). 2023;10(32): e2303411.37759382 10.1002/advs.202303411
211. Weihofen A Lemberg MK Friedmann E Rueeger H Schmitz A Paganetti P Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors J Biol Chem 2003 278 19 16528 16533 10.1074/jbc.M301372200 12621027
Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Paganetti P, et al. Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. J Biol Chem. 2003;278(19):16528–33.12621027 10.1074/jbc.M301372200
212. Andrade-Guerrero J Santiago-Balmaseda A Jeronimo-Aguilar P Vargas-Rodríguez I Cadena-Suárez AR Sánchez-Garibay C Alzheimer's disease: an updated overview of its genetics Int J Mol Sci 2023 24 4 3754 10.3390/ijms24043754 36835161
Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodríguez I, Cadena-Suárez AR, Sánchez-Garibay C, et al. Alzheimer’s disease: an updated overview of its genetics. Int J Mol Sci. 2023;24(4):3754.36835161 10.3390/ijms24043754
213. Zhang Z Song M Liu X Kang SS Kwon IS Duong DM Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease Nat Med 2014 20 11 1254 1262 10.1038/nm.3700 25326800
Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med. 2014;20(11):1254–62.25326800 10.1038/nm.3700
214. Zhong S Khalil RA A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease Biochem Pharmacol 2019 164 188 204 10.1016/j.bcp.2019.03.033 30905657
Zhong S, Khalil RA. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Biochem Pharmacol. 2019;164:188–204.30905657 10.1016/j.bcp.2019.03.033
215. Khezri MR Mohebalizadeh M Ghasemnejad-Berenji M Therapeutic potential of ADAM10 modulation in Alzheimer's disease: a review of the current evidence Cell Commun Signal 2023 21 1 60 10.1186/s12964-023-01072-w 36918870
Khezri MR, Mohebalizadeh M, Ghasemnejad-Berenji M. Therapeutic potential of ADAM10 modulation in Alzheimer’s disease: a review of the current evidence. Cell Commun Signal. 2023;21(1):60.36918870 10.1186/s12964-023-01072-w
216. Jin M Shepardson N Yang T Chen G Walsh D Selkoe DJ Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration Proc Natl Acad Sci USA 2011 108 14 5819 5824 10.1073/pnas.1017033108 21421841
Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA. 2011;108(14):5819–24.21421841 10.1073/pnas.1017033108
217. Mucke L Selkoe DJ Neurotoxicity of amyloid β-protein: synaptic and network dysfunction Cold Spring Harb Perspect Med 2012 2 7 a006338 10.1101/cshperspect.a006338 22762015
Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2(7): a006338.22762015 10.1101/cshperspect.a006338
218. Zhang Y Chen H Li R Sterling K Song W Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future Signal Transduct Target Ther 2023 8 1 248 10.1038/s41392-023-01484-7 37386015
Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248.37386015 10.1038/s41392-023-01484-7
219. Deane R Du Yan S Submamaryan RK LaRue B Jovanovic S Hogg E RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain Nat Med 2003 9 7 907 913 10.1038/nm890 12808450
Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9(7):907–13.12808450 10.1038/nm890
220. Cho HJ Son SM Jin SM Hong HS Shin DH Kim SJ RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model FASEB J 2009 23 8 2639 2649 10.1096/fj.08-126383 19332646
Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer’s disease animal model. FASEB J. 2009;23(8):2639–49.19332646 10.1096/fj.08-126383
221. Wagner SL Geddes JW Cotman CW Lau AL Gurwitz D Isackson PJ Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease Proc Natl Acad Sci USA 1989 86 21 8284 8288 10.1073/pnas.86.21.8284 2813392
Wagner SL, Geddes JW, Cotman CW, Lau AL, Gurwitz D, Isackson PJ, et al. Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. Proc Natl Acad Sci USA. 1989;86(21):8284–8.2813392 10.1073/pnas.86.21.8284
222. Abraham CR Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease Neurobiol Aging 2001 22 6 931 936 10.1016/S0197-4580(01)00302-5 11755001
Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer’s disease. Neurobiol Aging. 2001;22(6):931–6.11755001 10.1016/S0197-4580(01)00302-5
223. Bero AW Yan P Roh JH Cirrito JR Stewart FR Raichle ME Neuronal activity regulates the regional vulnerability to amyloid-β deposition Nat Neurosci 2011 14 6 750 756 10.1038/nn.2801 21532579
Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci. 2011;14(6):750–6.21532579 10.1038/nn.2801
224. Sperling RA Laviolette PS O'Keefe K O'Brien J Rentz DM Pihlajamaki M Amyloid deposition is associated with impaired default network function in older persons without dementia Neuron 2009 63 2 178 188 10.1016/j.neuron.2009.07.003 19640477
Sperling RA, Laviolette PS, O’Keefe K, O’Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178–88.19640477 10.1016/j.neuron.2009.07.003
225. Maass A Berron D Harrison TM Adams JN La Joie R Baker S Alzheimer's pathology targets distinct memory networks in the ageing brain Brain 2019 142 8 2492 2509 10.1093/brain/awz154 31199481
Maass A, Berron D, Harrison TM, Adams JN, La Joie R, Baker S, et al. Alzheimer’s pathology targets distinct memory networks in the ageing brain. Brain. 2019;142(8):2492–509.31199481 10.1093/brain/awz154
226. Snyder HM Bain LJ Brickman AM Carrillo MC Esbensen AJ Espinosa JM Further understanding the connection between Alzheimer's disease and Down syndrome Alzheimers Dement 2020 16 7 1065 1077 10.1002/alz.12112 32544310
Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, et al. Further understanding the connection between Alzheimer’s disease and Down syndrome. Alzheimers Dement. 2020;16(7):1065–77.32544310 10.1002/alz.12112
227. Wisniewski KE Wisniewski HM Wen GY Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome Ann Neurol 1985 17 3 278 282 10.1002/ana.410170310 3158266
Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol. 1985;17(3):278–82.3158266 10.1002/ana.410170310
228. Lanoiselee HM Nicolas G Wallon D Rovelet-Lecrux A Lacour M Rousseau S APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases PLoS Med 2017 14 3 e1002270 10.1371/journal.pmed.1002270 28350801
Lanoiselee HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017;14(3): e1002270.28350801 10.1371/journal.pmed.1002270
229. Rovelet-Lecrux A Hannequin D Raux G Le Meur N Laquerrière A Vital A APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy Nat Genet 2006 38 1 24 26 10.1038/ng1718 16369530
Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24–6.16369530 10.1038/ng1718
230. Sasaguri H Hashimoto S Watamura N Sato K Takamura R Nagata K Recent advances in the modeling of Alzheimer's Disease Front Neurosci 2022 16 807473 10.3389/fnins.2022.807473 35431779
Sasaguri H, Hashimoto S, Watamura N, Sato K, Takamura R, Nagata K, et al. Recent advances in the modeling of Alzheimer’s Disease. Front Neurosci. 2022;16: 807473.35431779 10.3389/fnins.2022.807473
231. Yehuda S Rabinovitz S Carasso RL Mostofsky DI The role of polyunsaturated fatty acids in restoring the aging neuronal membrane Neurobiol Aging 2002 23 5 843 853 10.1016/S0197-4580(02)00074-X 12392789
Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging. 2002;23(5):843–53.12392789 10.1016/S0197-4580(02)00074-X
232. Long H Zhu W Wei L Zhao J Iron homeostasis imbalance and ferroptosis in brain diseases MedComm 2023 4 4 e298 10.1002/mco2.298 37377861
Long H, Zhu W, Wei L, Zhao J. Iron homeostasis imbalance and ferroptosis in brain diseases. MedComm. 2023;4(4): e298.37377861 10.1002/mco2.298
233. Huang X A concise review on oxidative stress-mediated ferroptosis and cuproptosis in Alzheimer's Disease Cells 2023 12 10 1369 10.3390/cells12101369 37408203
Huang X. A concise review on oxidative stress-mediated ferroptosis and cuproptosis in Alzheimer’s Disease. Cells. 2023;12(10):1369.37408203 10.3390/cells12101369
234. Fani G Mannini B Vecchi G Cascella R Cecchi C Dobson CM Aβ oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors ACS Chem Neurosci 2021 12 4 766 781 10.1021/acschemneuro.0c00811 33538575
Fani G, Mannini B, Vecchi G, Cascella R, Cecchi C, Dobson CM, et al. Aβ oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors. ACS Chem Neurosci. 2021;12(4):766–81.33538575 10.1021/acschemneuro.0c00811
235. Kelly P Sanchez-Mico MV Hou SS Whiteman S Russ A Hudry E Neuronally derived soluble abeta evokes cell-wide astrocytic calcium dysregulation in absence of amyloid plaques in vivo J Neurosci 2023 43 26 4926 4940 10.1523/JNEUROSCI.1988-22.2023 37236808
Kelly P, Sanchez-Mico MV, Hou SS, Whiteman S, Russ A, Hudry E, et al. Neuronally derived soluble abeta evokes cell-wide astrocytic calcium dysregulation in absence of amyloid plaques in vivo. J Neurosci. 2023;43(26):4926–40.37236808 10.1523/JNEUROSCI.1988-22.2023
236. Gao Q Wu G Lai KWC Cholesterol modulates the formation of the Aβ ion channel in lipid bilayers Biochemistry 2020 59 8 992 998 10.1021/acs.biochem.9b00968 31914730
Gao Q, Wu G, Lai KWC. Cholesterol modulates the formation of the Aβ ion channel in lipid bilayers. Biochemistry. 2020;59(8):992–8.31914730 10.1021/acs.biochem.9b00968
237. Zhao Y Sivaji S Chiang MC Ali H Zukowski M Ali S Amyloid beta peptides block new synapse assembly by nogo receptor-mediated inhibition of T-type calcium channels Neuron 2017 96 2 355 372.e356 10.1016/j.neuron.2017.09.041 29024660
Zhao Y, Sivaji S, Chiang MC, Ali H, Zukowski M, Ali S, et al. Amyloid beta peptides block new synapse assembly by nogo receptor-mediated inhibition of T-type calcium channels. Neuron. 2017;96(2):355-372.e356.29024660 10.1016/j.neuron.2017.09.041
238. Calvo-Rodriguez M Kharitonova EK Snyder AC Hou SS Sanchez-Mico MV Das S Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid beta aggregates in vivo in a mouse model of Alzheimer's disease Mol Neurodegener 2024 19 1 6 10.1186/s13024-024-00702-2 38238819
Calvo-Rodriguez M, Kharitonova EK, Snyder AC, Hou SS, Sanchez-Mico MV, Das S, et al. Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid beta aggregates in vivo in a mouse model of Alzheimer’s disease. Mol Neurodegener. 2024;19(1):6.38238819 10.1186/s13024-024-00702-2
239. Yan SD Fu J Soto C Chen X Zhu H Al-Mohanna F An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease Nature 1997 389 6652 689 695 10.1038/39522 9338779
Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease. Nature. 1997;389(6652):689–95.9338779 10.1038/39522
240. Lustbader JW Cirilli M Lin C Xu HW Takuma K Wang N ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease Science 2004 304 5669 448 452 10.1126/science.1091230 15087549
Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004;304(5669):448–52.15087549 10.1126/science.1091230
241. Yan SD Shi Y Zhu A Fu J Zhu H Zhu Y Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity J Biol Chem 1999 274 4 2145 2156 10.1074/jbc.274.4.2145 9890977
Yan SD, Shi Y, Zhu A, Fu J, Zhu H, Zhu Y, et al. Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity. J Biol Chem. 1999;274(4):2145–56.9890977 10.1074/jbc.274.4.2145
242. Ye Z Liu Y Jin X Wu Y Zhao H Gao T Abeta-binding with alcohol dehydrogenase drives Alzheimer's disease pathogenesis: a review Int J Biol Macromol 2024 264 Pt 2 130580 10.1016/j.ijbiomac.2024.130580 38432266
Ye Z, Liu Y, Jin X, Wu Y, Zhao H, Gao T, et al. Abeta-binding with alcohol dehydrogenase drives Alzheimer’s disease pathogenesis: a review. Int J Biol Macromol. 2024;264(Pt 2): 130580.38432266 10.1016/j.ijbiomac.2024.130580
243. Morsy A Trippier PC Amyloid-binding alcohol dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer’s disease J Med Chem 2019 62 9 4252 4264 10.1021/acs.jmedchem.8b01530 30444369
Morsy A, Trippier PC. Amyloid-binding alcohol dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2019;62(9):4252–64.30444369 10.1021/acs.jmedchem.8b01530
244. Assefa BT Gebre AK Altaye BM Reactive astrocytes as drug target in Alzheimer's Disease Biomed Res Int 2018 2018 4160247 10.1155/2018/4160247 29888263
Assefa BT, Gebre AK, Altaye BM. Reactive astrocytes as drug target in Alzheimer’s Disease. Biomed Res Int. 2018;2018:4160247.29888263 10.1155/2018/4160247
245. Aksenova MV Aksenov MY Payne RM Trojanowski JQ Schmidt ML Carney JM Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders Dement Geriatr Cogn Disord 1999 10 2 158 165 10.1159/000017098 10026391
Aksenova MV, Aksenov MY, Payne RM, Trojanowski JQ, Schmidt ML, Carney JM, et al. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord. 1999;10(2):158–65.10026391 10.1159/000017098
246. Lian H Yang L Cole A Sun L Chiang AC Fowler SW NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease Neuron 2015 85 1 101 115 10.1016/j.neuron.2014.11.018 25533482
Lian H, Yang L, Cole A, Sun L, Chiang AC, Fowler SW, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron. 2015;85(1):101–15.25533482 10.1016/j.neuron.2014.11.018
247. Fan R Tenner AJ Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures Exp Neurol 2004 185 2 241 253 10.1016/j.expneurol.2003.09.023 14736505
Fan R, Tenner AJ. Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. Exp Neurol. 2004;185(2):241–53.14736505 10.1016/j.expneurol.2003.09.023
248. Heneka MT Kummer MP Stutz A Delekate A Schwartz S Vieira-Saecker A NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice Nature 2013 493 7434 674 678 10.1038/nature11729 23254930
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–8.23254930 10.1038/nature11729
249. Tönnies E Trushina E Oxidative stress, synaptic dysfunction, and Alzheimer's disease J Alzheimers Dis 2017 57 4 1105 1121 10.3233/JAD-161088 28059794
Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J Alzheimers Dis. 2017;57(4):1105–21.28059794 10.3233/JAD-161088
250. Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002 297 5580 353 356 10.1126/science.1072994 12130773
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.12130773 10.1126/science.1072994
251. Shi XD Sun K Hu R Liu XY Hu QM Sun XY Blocking the interaction between EphB2 and ADDLs by a small peptide rescues impaired synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease J Neurosci 2016 36 47 11959 11973 10.1523/JNEUROSCI.1327-16.2016 27881781
Shi XD, Sun K, Hu R, Liu XY, Hu QM, Sun XY, et al. Blocking the interaction between EphB2 and ADDLs by a small peptide rescues impaired synaptic plasticity and memory deficits in a mouse model of Alzheimer’s disease. J Neurosci. 2016;36(47):11959–73.27881781 10.1523/JNEUROSCI.1327-16.2016
252. Kapadia A Theil S Opitz S Villacampa N Beckert H Schoch S Phosphorylation-state dependent intraneuronal sorting of Abeta differentially impairs autophagy and the endo-lysosomal system Autophagy 2024 20 1 166 187 10.1080/15548627.2023.2252300 37642583
Kapadia A, Theil S, Opitz S, Villacampa N, Beckert H, Schoch S, et al. Phosphorylation-state dependent intraneuronal sorting of Abeta differentially impairs autophagy and the endo-lysosomal system. Autophagy. 2024;20(1):166–87.37642583 10.1080/15548627.2023.2252300
253. Qiu W Liu H Liu Y Lu X Wang L Hu Y Regulation of beta-amyloid for the treatment of Alzheimer's disease: research progress of therapeutic strategies and bioactive compounds Med Res Rev 2023 43 4 1091 1140 10.1002/med.21947 36945751
Qiu W, Liu H, Liu Y, Lu X, Wang L, Hu Y, et al. Regulation of beta-amyloid for the treatment of Alzheimer’s disease: research progress of therapeutic strategies and bioactive compounds. Med Res Rev. 2023;43(4):1091–140.36945751 10.1002/med.21947
254. Renner M Lacor PN Velasco PT Xu J Contractor A Klein WL Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5 Neuron 2010 66 5 739 754 10.1016/j.neuron.2010.04.029 20547131
Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010;66(5):739–54.20547131 10.1016/j.neuron.2010.04.029
255. Fontana IC Kumar A Nordberg A The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease Nat Rev Neurol 2023 19 5 278 288 10.1038/s41582-023-00792-4 36977843
Fontana IC, Kumar A, Nordberg A. The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease. Nat Rev Neurol. 2023;19(5):278–88.36977843 10.1038/s41582-023-00792-4
256. Colom-Cadena M Toombs J Simzer E Holt K McGeachan R Tulloch J Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease Acta Neuropathol 2024 147 1 32 10.1007/s00401-023-02679-6 38319380
Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, et al. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease. Acta Neuropathol. 2024;147(1):32.38319380 10.1007/s00401-023-02679-6
257. Gunawardena S Goldstein LS Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila Neuron 2001 32 3 389 401 10.1016/S0896-6273(01)00496-2 11709151
Gunawardena S, Goldstein LS. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001;32(3):389–401.11709151 10.1016/S0896-6273(01)00496-2
258. Yamazaki T Selkoe DJ Koo EH Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons J Cell Biol 1995 129 2 431 442 10.1083/jcb.129.2.431 7721945
Yamazaki T, Selkoe DJ, Koo EH. Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol. 1995;129(2):431–42.7721945 10.1083/jcb.129.2.431
259. Rodrigues EM Weissmiller AM Goldstein LS Enhanced beta-secretase processing alters APP axonal transport and leads to axonal defects Hum Mol Genet 2012 21 21 4587 4601 10.1093/hmg/dds297 22843498
Rodrigues EM, Weissmiller AM, Goldstein LS. Enhanced beta-secretase processing alters APP axonal transport and leads to axonal defects. Hum Mol Genet. 2012;21(21):4587–601.22843498 10.1093/hmg/dds297
260. Tennent GA Lovat LB Pepys MB Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis Proc Natl Acad Sci USA 1995 92 10 4299 4303 10.1073/pnas.92.10.4299 7753801
Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA. 1995;92(10):4299–303.7753801 10.1073/pnas.92.10.4299
261. Kosik KS The molecular and cellular biology of tau Brain Pathol 1993 3 1 39 43 10.1111/j.1750-3639.1993.tb00724.x 8269082
Kosik KS. The molecular and cellular biology of tau. Brain Pathol. 1993;3(1):39–43.8269082 10.1111/j.1750-3639.1993.tb00724.x
262. Goedert M Spillantini MG Jakes R Rutherford D Crowther RA Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease Neuron 1989 3 4 519 526 10.1016/0896-6273(89)90210-9 2484340
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3(4):519–26.2484340 10.1016/0896-6273(89)90210-9
263. Goedert M Wischik CM Crowther RA Walker JE Klug A Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau Proc Natl Acad Sci USA 1988 85 11 4051 4055 10.1073/pnas.85.11.4051 3131773
Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA. 1988;85(11):4051–5.3131773 10.1073/pnas.85.11.4051
264. Lee G Cowan N Kirschner M The primary structure and heterogeneity of tau protein from mouse brain Science 1988 239 4837 285 288 10.1126/science.3122323 3122323
Lee G, Cowan N, Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science. 1988;239(4837):285–8.3122323 10.1126/science.3122323
265. Goedert M Spillantini MG Potier MC Ulrich J Crowther RA Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain EMBO J 1989 8 2 393 399 10.1002/j.1460-2075.1989.tb03390.x 2498079
Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8(2):393–9.2498079 10.1002/j.1460-2075.1989.tb03390.x
266. Hernández F Merchán-Rubira J Vallés-Saiz L Rodríguez-Matellán A Avila J Differences between human and murine tau at the N-terminal end Front Aging Neurosci 2020 12 11 10.3389/fnagi.2020.00011 32063841
Hernández F, Merchán-Rubira J, Vallés-Saiz L, Rodríguez-Matellán A, Avila J. Differences between human and murine tau at the N-terminal end. Front Aging Neurosci. 2020;12:11.32063841 10.3389/fnagi.2020.00011
267. Morris M Knudsen GM Maeda S Trinidad JC Ioanoviciu A Burlingame AL Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice Nat Neurosci 2015 18 8 1183 1189 10.1038/nn.4067 26192747
Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci. 2015;18(8):1183–9.26192747 10.1038/nn.4067
268. Martin L Latypova X Terro F Post-translational modifications of tau protein: implications for Alzheimer's disease Neurochem Int 2011 58 4 458 471 10.1016/j.neuint.2010.12.023 21215781
Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochem Int. 2011;58(4):458–71.21215781 10.1016/j.neuint.2010.12.023
269. Xia Y Prokop S Giasson BI "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies Mol Neurodegen 2021 16 1 37 10.1186/s13024-021-00460-5
Xia Y, Prokop S, Giasson BI. “Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies. Mol Neurodegen. 2021;16(1):37.10.1186/s13024-021-00460-5
270. Wesseling H Mair W Kumar M Schlaffner CN Tang S Beerepoot P Tau PTM profiles identify patient heterogeneity and stages of Alzheimer's disease Cell 2020 183 6 1699 1713.e1613 10.1016/j.cell.2020.10.029 33188775
Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P, et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell. 2020;183(6):1699-1713.e1613.33188775 10.1016/j.cell.2020.10.029
271. Wang JZ Xia YY Grundke-Iqbal I Iqbal K Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration J Alzheimers Dis 2013 33 Suppl 1 S123 139 22710920
Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis. 2013;33(Suppl 1):S123-139.22710920
272. Greenberg SG Davies P A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis Proc Natl Acad Sci USA 1990 87 15 5827 5831 10.1073/pnas.87.15.5827 2116006
Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87(15):5827–31.2116006 10.1073/pnas.87.15.5827
273. Alonso AC Grundke-Iqbal I Iqbal K Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules Nat Med 1996 2 7 783 787 10.1038/nm0796-783 8673924
Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2(7):783–7.8673924 10.1038/nm0796-783
274. Sadqi M Hernández F Pan U Pérez M Schaeberle MD Avila J Alpha-helix structure in Alzheimer's disease aggregates of tau-protein Biochemistry 2002 41 22 7150 7155 10.1021/bi025777e 12033949
Sadqi M, Hernández F, Pan U, Pérez M, Schaeberle MD, Avila J, et al. Alpha-helix structure in Alzheimer’s disease aggregates of tau-protein. Biochemistry. 2002;41(22):7150–5.12033949 10.1021/bi025777e
275. McKhann GM Albert MS Grossman M Miller B Dickson D Trojanowski JQ Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease Arch Neurol 2001 58 11 1803 1809 10.1001/archneur.58.11.1803 11708987
McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol. 2001;58(11):1803–9.11708987 10.1001/archneur.58.11.1803
276. Weingarten MD Lockwood AH Hwo SY Kirschner MW A protein factor essential for microtubule assembly Proc Natl Acad Sci USA 1975 72 5 1858 1862 10.1073/pnas.72.5.1858 1057175
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 1975;72(5):1858–62.1057175 10.1073/pnas.72.5.1858
277. Wang C Terrigno M Li J Distler T Pandya NJ Ebeling M Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation Neuron 2023 111 17 2660 2674.e2669 10.1016/j.neuron.2023.05.033 37385246
Wang C, Terrigno M, Li J, Distler T, Pandya NJ, Ebeling M, et al. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation. Neuron. 2023;111(17):2660-2674.e2669.37385246 10.1016/j.neuron.2023.05.033
278. Vanderweyde T Apicco DJ Youmans-Kidder K Ash PEA Cook C da Lummertz RE Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity Cell Rep 2016 15 7 1455 1466 10.1016/j.celrep.2016.04.045 27160897
Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PEA, Cook C, da Lummertz RE, et al. Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity. Cell Rep. 2016;15(7):1455–66.27160897 10.1016/j.celrep.2016.04.045
279. Drummond E Pires G MacMurray C Askenazi M Nayak S Bourdon M Phosphorylated tau interactome in the human Alzheimer's disease brain Brain 2020 143 9 2803 2817 10.1093/brain/awaa223 32812023
Drummond E, Pires G, MacMurray C, Askenazi M, Nayak S, Bourdon M, et al. Phosphorylated tau interactome in the human Alzheimer’s disease brain. Brain. 2020;143(9):2803–17.32812023 10.1093/brain/awaa223
280. Maziuk BF Apicco DJ Cruz AL Jiang L Ash PEA da Rocha EL RNA binding proteins co-localize with small tau inclusions in tauopathy Acta Neuropathol Commun 2018 6 1 71 10.1186/s40478-018-0574-5 30068389
Maziuk BF, Apicco DJ, Cruz AL, Jiang L, Ash PEA, da Rocha EL, et al. RNA binding proteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol Commun. 2018;6(1):71.30068389 10.1186/s40478-018-0574-5
281. Kavanagh T Halder A Drummond E Tau interactome and RNA binding proteins in neurodegenerative diseases Mol Neurodegen 2022 17 1 66 10.1186/s13024-022-00572-6
Kavanagh T, Halder A, Drummond E. Tau interactome and RNA binding proteins in neurodegenerative diseases. Mol Neurodegen. 2022;17(1):66.10.1186/s13024-022-00572-6
282. Sinsky J Pichlerova K Hanes J Tau protein interaction partners and their roles in Alzheimer’s disease and other tauopathies Int J Mol Sci 2021 22 17 9207 10.3390/ijms22179207 34502116
Sinsky J, Pichlerova K, Hanes J. Tau protein interaction partners and their roles in Alzheimer’s disease and other tauopathies. Int J Mol Sci. 2021;22(17):9207.34502116 10.3390/ijms22179207
283. Li HL Wang HH Liu SJ Deng YQ Zhang YJ Tian Q Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration Proc Natl Acad Sci USA 2007 104 9 3591 3596 10.1073/pnas.0609303104 17360687
Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, Tian Q, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer’s neurodegeneration. Proc Natl Acad Sci USA. 2007;104(9):3591–6.17360687 10.1073/pnas.0609303104
284. Liu E Zhou Q Xie AJ Li X Li M Ye J Tau acetylates and stabilizes β-catenin thereby promoting cell survival EMBO Rep 2020 21 3 e48328 10.15252/embr.201948328 31930681
Liu E, Zhou Q, Xie AJ, Li X, Li M, Ye J, et al. Tau acetylates and stabilizes β-catenin thereby promoting cell survival. EMBO Rep. 2020;21(3): e48328.31930681 10.15252/embr.201948328
285. Cohen TJ Friedmann D Hwang AW Marmorstein R Lee VM The microtubule-associated tau protein has intrinsic acetyltransferase activity Nat Struct Mol Biol 2013 20 6 756 762 10.1038/nsmb.2555 23624859
Cohen TJ, Friedmann D, Hwang AW, Marmorstein R, Lee VM. The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat Struct Mol Biol. 2013;20(6):756–62.23624859 10.1038/nsmb.2555
286. Morris M Maeda S Vossel K Mucke L The many faces of tau Neuron 2011 70 3 410 426 10.1016/j.neuron.2011.04.009 21555069
Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70(3):410–26.21555069 10.1016/j.neuron.2011.04.009
287. Kyalu Ngoie Zola N Balty C Pyr Dit Ruys S Vanparys AAT Huyghe NDG Herinckx G Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies Nat Commun 2023 14 1 3706 10.1038/s41467-023-39328-1 37349319
Kyalu Ngoie Zola N, Balty C, Pyr Dit Ruys S, Vanparys AAT, Huyghe NDG, Herinckx G, et al. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies. Nat Commun. 2023;14(1):3706.37349319 10.1038/s41467-023-39328-1
288. Alonso AC Zaidi T Grundke-Iqbal I Iqbal K Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease Proc Natl Acad Sci USA 1994 91 12 5562 5566 10.1073/pnas.91.12.5562 8202528
Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA. 1994;91(12):5562–6.8202528 10.1073/pnas.91.12.5562
289. Lewis J Dickson DW Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies Acta Neuropathol 2016 131 1 27 48 10.1007/s00401-015-1507-z 26576562
Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131(1):27–48.26576562 10.1007/s00401-015-1507-z
290. Ayers JI Giasson BI Borchelt DR Prion-like spreading in tauopathies Biol Psychiatry 2018 83 4 337 346 10.1016/j.biopsych.2017.04.003 28506438
Ayers JI, Giasson BI, Borchelt DR. Prion-like spreading in tauopathies. Biol Psychiatry. 2018;83(4):337–46.28506438 10.1016/j.biopsych.2017.04.003
291. Köpke E Tung YC Shaikh S Alonso AC Iqbal K Grundke-Iqbal I Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease J Biol Chem 1993 268 32 24374 24384 10.1016/S0021-9258(20)80536-5 8226987
Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 1993;268(32):24374–84.8226987 10.1016/S0021-9258(20)80536-5
292. Iqbal K Grundke-Iqbal I Zaidi T Merz PA Wen GY Shaikh SS Defective brain microtubule assembly in Alzheimer's disease Lancet 1986 2 8504 421 426 10.1016/S0140-6736(86)92134-3 2874414
Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, et al. Defective brain microtubule assembly in Alzheimer’s disease. Lancet. 1986;2(8504):421–6.2874414 10.1016/S0140-6736(86)92134-3
293. Alonso AD Grundke-Iqbal I Barra HS Iqbal K Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau Proc Natl Acad Sci USA 1997 94 1 298 303 10.1073/pnas.94.1.298 8990203
Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA. 1997;94(1):298–303.8990203 10.1073/pnas.94.1.298
294. Kanaan NM Morfini GA LaPointe NE Pigino GF Patterson KR Song Y Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases J Neurosci 2011 31 27 9858 9868 10.1523/JNEUROSCI.0560-11.2011 21734277
Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y, et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci. 2011;31(27):9858–68.21734277 10.1523/JNEUROSCI.0560-11.2011
295. Cowan CM Bossing T Page A Shepherd D Mudher A Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo Acta Neuropathol 2010 120 5 593 604 10.1007/s00401-010-0716-8 20617325
Cowan CM, Bossing T, Page A, Shepherd D, Mudher A. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 2010;120(5):593–604.20617325 10.1007/s00401-010-0716-8
296. Stubbs K Batchelor B Sivanantharajah L Sealey M Ramirez-Moreno M Ruiz E Tau-mediated axonal degeneration is prevented by activation of the Wld(S) pathway Brain Commun 2023 5 2 fcad052 10.1093/braincomms/fcad052 37013175
Stubbs K, Batchelor B, Sivanantharajah L, Sealey M, Ramirez-Moreno M, Ruiz E, et al. Tau-mediated axonal degeneration is prevented by activation of the Wld(S) pathway. Brain Commun. 2023;5(2):fcad052.37013175 10.1093/braincomms/fcad052
297. Christensen KR Combs B Richards C Grabinski T Alhadidy MM Kanaan NM Phosphomimetics at Ser199/Ser202/Thr205 in tau impairs axonal transport in rat hippocampal neurons Mol Neurobiol 2023 60 6 3423 3438 10.1007/s12035-023-03281-3 36859689
Christensen KR, Combs B, Richards C, Grabinski T, Alhadidy MM, Kanaan NM. Phosphomimetics at Ser199/Ser202/Thr205 in tau impairs axonal transport in rat hippocampal neurons. Mol Neurobiol. 2023;60(6):3423–38.36859689 10.1007/s12035-023-03281-3
298. Praprotnik D Smith MA Richey PL Vinters HV Perry G Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease Acta Neuropathol 1996 91 3 226 235 10.1007/s004010050420 8834534
Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer’s disease. Acta Neuropathol. 1996;91(3):226–35.8834534 10.1007/s004010050420
299. Lee G Newman ST Gard DL Band H Panchamoorthy G Tau interacts with src-family non-receptor tyrosine kinases J Cell Sci 1998 111 Pt 21 3167 3177 10.1242/jcs.111.21.3167 9763511
Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci. 1998;111(Pt 21):3167–77.9763511 10.1242/jcs.111.21.3167
300. Trzeciakiewicz H Ajit D Tseng JH Chen Y Ajit A Tabassum Z An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline Nat Commun 2020 11 1 5522 10.1038/s41467-020-19317-4 33139698
Trzeciakiewicz H, Ajit D, Tseng JH, Chen Y, Ajit A, Tabassum Z, et al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat Commun. 2020;11(1):5522.33139698 10.1038/s41467-020-19317-4
301. Martínez-Mármol R Small C Jiang A Palliyaguru T Wallis TP Gormal RS Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates Mol Psychiatry 2023 28 2 946 962 10.1038/s41380-022-01825-y 36258016
Martínez-Mármol R, Small C, Jiang A, Palliyaguru T, Wallis TP, Gormal RS, et al. Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates. Mol Psychiatry. 2023;28(2):946–62.36258016 10.1038/s41380-022-01825-y
302. Padmanabhan P Martínez-Mármol R Xia D Götz J Meunier FA Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines Elife 2019 8 e45040 10.7554/eLife.45040 31237563
Padmanabhan P, Martínez-Mármol R, Xia D, Götz J, Meunier FA. Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines. Elife. 2019;8: e45040.31237563 10.7554/eLife.45040
303. Briner A Götz J Polanco JC Fyn kinase controls tau aggregation in vivo Cell Rep 2020 32 7 108045 10.1016/j.celrep.2020.108045 32814048
Briner A, Götz J, Polanco JC. Fyn kinase controls tau aggregation in vivo. Cell Rep. 2020;32(7): 108045.32814048 10.1016/j.celrep.2020.108045
304. Ittner LM Ke YD Delerue F Bi M Gladbach A van Eersel J Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models Cell 2010 142 3 387 397 10.1016/j.cell.2010.06.036 20655099
Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387–97.20655099 10.1016/j.cell.2010.06.036
305. Tzioras M McGeachan RI Durrant CS Spires-Jones TL Synaptic degeneration in Alzheimer disease Nat Rev Neurol 2023 19 1 19 38 10.1038/s41582-022-00749-z 36513730
Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19(1):19–38.36513730 10.1038/s41582-022-00749-z
306. Li XG Hong XY Wang YL Zhang SJ Zhang JF Li XC Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression EMBO Rep 2019 20 6 e47202 10.15252/embr.201847202 31085626
Li XG, Hong XY, Wang YL, Zhang SJ, Zhang JF, Li XC, et al. Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression. EMBO Rep. 2019;20(6): e47202.31085626 10.15252/embr.201847202
307. Wan HL Hong XY Zhao ZH Li T Zhang BG Liu Q STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer's disease animal model Theranostics 2021 11 11 5511 5524 10.7150/thno.56541 33859760
Wan HL, Hong XY, Zhao ZH, Li T, Zhang BG, Liu Q, et al. STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer’s disease animal model. Theranostics. 2021;11(11):5511–24.33859760 10.7150/thno.56541
308. Yin Y Gao D Wang Y Wang ZH Wang X Ye J Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling Proc Natl Acad Sci USA 2016 113 26 E3773 3781 10.1073/pnas.1604519113 27298345
Yin Y, Gao D, Wang Y, Wang ZH, Wang X, Ye J, et al. Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling. Proc Natl Acad Sci USA. 2016;113(26):E3773-3781.27298345 10.1073/pnas.1604519113
309. Ying Y Wang JZ Illuminating neural circuits in Alzheimer's disease Neurosci Bull 2021 37 8 1203 1217 10.1007/s12264-021-00716-6 34089505
Ying Y, Wang JZ. Illuminating neural circuits in Alzheimer’s disease. Neurosci Bull. 2021;37(8):1203–17.34089505 10.1007/s12264-021-00716-6
310. Zheng J Li HL Tian N Liu F Wang L Yin Y Interneuron Accumulation of phosphorylated tau impairs adult hippocampal neurogenesis by suppressing GABAergic transmission Cell Stem Cell 2020 26 3 331 345.e336 10.1016/j.stem.2019.12.015 31978364
Zheng J, Li HL, Tian N, Liu F, Wang L, Yin Y, et al. Interneuron Accumulation of phosphorylated tau impairs adult hippocampal neurogenesis by suppressing GABAergic transmission. Cell Stem Cell. 2020;26(3):331-345.e336.31978364 10.1016/j.stem.2019.12.015
311. Li S Zhou Q Liu E Du H Yu N Yu H Alzheimer-like tau accumulation in dentate gyrus mossy cells induces spatial cognitive deficits by disrupting multiple memory-related signaling and inhibiting local neural circuit Aging Cell 2022 21 5 e13600 10.1111/acel.13600 35355405
Li S, Zhou Q, Liu E, Du H, Yu N, Yu H, et al. Alzheimer-like tau accumulation in dentate gyrus mossy cells induces spatial cognitive deficits by disrupting multiple memory-related signaling and inhibiting local neural circuit. Aging Cell. 2022;21(5): e13600.35355405 10.1111/acel.13600
312. Wu D Gao D Yu H Pi G Xiong R Lei H Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway Clin Trans Med 2021 11 6 e428 10.1002/ctm2.428
Wu D, Gao D, Yu H, Pi G, Xiong R, Lei H, et al. Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway. Clin Trans Med. 2021;11(6): e428.10.1002/ctm2.428
313. Yang Y Wang ZH Jin S Gao D Liu N Chen SP Opposite monosynaptic scaling of BLP-vCA1 inputs governs hopefulness- and helplessness-modulated spatial learning and memory Nat Commun 2016 7 11935 10.1038/ncomms11935 27411738
Yang Y, Wang ZH, Jin S, Gao D, Liu N, Chen SP, et al. Opposite monosynaptic scaling of BLP-vCA1 inputs governs hopefulness- and helplessness-modulated spatial learning and memory. Nat Commun. 2016;7:11935.27411738 10.1038/ncomms11935
314. Pi G Gao D Wu D Wang Y Lei H Zeng W Posterior basolateral amygdala to ventral hippocampal CA1 drives approach behaviour to exert an anxiolytic effect Nat Commun 2020 11 1 183 10.1038/s41467-019-13919-3 31924799
Pi G, Gao D, Wu D, Wang Y, Lei H, Zeng W, et al. Posterior basolateral amygdala to ventral hippocampal CA1 drives approach behaviour to exert an anxiolytic effect. Nat Commun. 2020;11(1):183.31924799 10.1038/s41467-019-13919-3
315. Yu H Chen L Lei H Pi G Xiong R Jiang T Infralimbic medial prefrontal cortex signalling to calbindin 1 positive neurons in posterior basolateral amygdala suppresses anxiety- and depression-like behaviours Nat Commun 2022 13 1 5462 10.1038/s41467-022-33139-6 36115848
Yu H, Chen L, Lei H, Pi G, Xiong R, Jiang T, et al. Infralimbic medial prefrontal cortex signalling to calbindin 1 positive neurons in posterior basolateral amygdala suppresses anxiety- and depression-like behaviours. Nat Commun. 2022;13(1):5462.36115848 10.1038/s41467-022-33139-6
316. Lasagna-Reeves CA Castillo-Carranza DL Sengupta U Clos AL Jackson GR Kayed R Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice Mol Neurodegener 2011 6 39 10.1186/1750-1326-6-39 21645391
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener. 2011;6:39.21645391 10.1186/1750-1326-6-39
317. Ke J Tian Q Xu Q Fu Z Fu Q Mitochondrial dysfunction: a potential target for Alzheimer's disease intervention and treatment Drug Discov Today 2021 26 8 1991 2002 10.1016/j.drudis.2021.04.025 33962036
Ke J, Tian Q, Xu Q, Fu Z, Fu Q. Mitochondrial dysfunction: a potential target for Alzheimer’s disease intervention and treatment. Drug Discov Today. 2021;26(8):1991–2002.33962036 10.1016/j.drudis.2021.04.025
318. Li XC Hu Y Wang ZH Luo Y Zhang Y Liu XP Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins Sci Rep 2016 6 24756 10.1038/srep24756 27099072
Li XC, Hu Y, Wang ZH, Luo Y, Zhang Y, Liu XP, et al. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci Rep. 2016;6:24756.27099072 10.1038/srep24756
319. Cummins N Tweedie A Zuryn S Bertran-Gonzalez J Götz J Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria EMBO J 2019 38 3 e99360 10.15252/embj.201899360 30538104
Cummins N, Tweedie A, Zuryn S, Bertran-Gonzalez J, Götz J. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J. 2019;38(3): e99360.30538104 10.15252/embj.201899360
320. Corsetti V Florenzano F Atlante A Bobba A Ciotti MT Natale F NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease Hum Mol Genet 2015 24 11 3058 3081 10.1093/hmg/ddv059 25687137
Corsetti V, Florenzano F, Atlante A, Bobba A, Ciotti MT, Natale F, et al. NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer’s disease. Hum Mol Genet. 2015;24(11):3058–81.25687137 10.1093/hmg/ddv059
321. Mary A Eysert F Checler F Chami M Mitophagy in Alzheimer's disease: molecular defects and therapeutic approaches Mol Psychiatry 2023 28 1 202 216 10.1038/s41380-022-01631-6 35665766
Mary A, Eysert F, Checler F, Chami M. Mitophagy in Alzheimer’s disease: molecular defects and therapeutic approaches. Mol Psychiatry. 2023;28(1):202–16.35665766 10.1038/s41380-022-01631-6
322. Santos RX Correia SC Wang X Perry G Smith MA Moreira PI A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease J Alzheimers Dis 2010 20 S401 412 10.3233/JAD-2010-100666 20463393
Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, et al. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease. J Alzheimers Dis. 2010;20:S401-412.20463393 10.3233/JAD-2010-100666
323. Liu ZC Fu ZQ Song J Zhang JY Wei YP Chu J Bip enhanced the association of GSK-3β with tau during ER stress both in vivo and in vitro J Alzheimers Dis 2012 29 4 727 740 10.3233/JAD-2012-111898 22460328
Liu ZC, Fu ZQ, Song J, Zhang JY, Wei YP, Chu J, et al. Bip enhanced the association of GSK-3β with tau during ER stress both in vivo and in vitro. J Alzheimers Dis. 2012;29(4):727–40.22460328 10.3233/JAD-2012-111898
324. Lin L Yang SS Chu J Wang L Ning LN Zhang T Region-specific expression of tau, amyloid-β protein precursor, and synaptic proteins at physiological condition or under endoplasmic reticulum stress in rats J Alzheimers Dis 2014 41 4 1149 1163 10.3233/JAD-140207 24787918
Lin L, Yang SS, Chu J, Wang L, Ning LN, Zhang T, et al. Region-specific expression of tau, amyloid-β protein precursor, and synaptic proteins at physiological condition or under endoplasmic reticulum stress in rats. J Alzheimers Dis. 2014;41(4):1149–63.24787918 10.3233/JAD-140207
325. Jiang Q Wang L Guan Y Xu H Niu Y Han L Golgin-84-associated Golgi fragmentation triggers tau hyperphosphorylation by activation of cyclin-dependent kinase-5 and extracellular signal-regulated kinase Neurobiol Aging 2014 35 6 1352 1363 10.1016/j.neurobiolaging.2013.11.022 24368089
Jiang Q, Wang L, Guan Y, Xu H, Niu Y, Han L, et al. Golgin-84-associated Golgi fragmentation triggers tau hyperphosphorylation by activation of cyclin-dependent kinase-5 and extracellular signal-regulated kinase. Neurobiol Aging. 2014;35(6):1352–63.24368089 10.1016/j.neurobiolaging.2013.11.022
326. Liu ZC Chu J Lin L Song J Ning LN Luo HB SIL1 rescued bip elevation-related tau hyperphosphorylation in ER stress Mol Neurobiol 2016 53 2 983 994 10.1007/s12035-014-9039-4 25575678
Liu ZC, Chu J, Lin L, Song J, Ning LN, Luo HB, et al. SIL1 rescued bip elevation-related tau hyperphosphorylation in ER stress. Mol Neurobiol. 2016;53(2):983–94.25575678 10.1007/s12035-014-9039-4
327. Antón-Fernández A Aparicio-Torres G Tapia S DeFelipe J Muñoz A Morphometric alterations of Golgi apparatus in Alzheimer's disease are related to tau hyperphosphorylation Neurobiol Dis 2017 97 Pt A 11 23 10.1016/j.nbd.2016.10.005 27793637
Antón-Fernández A, Aparicio-Torres G, Tapia S, DeFelipe J, Muñoz A. Morphometric alterations of Golgi apparatus in Alzheimer’s disease are related to tau hyperphosphorylation. Neurobiol Dis. 2017;97(Pt A):11–23.27793637 10.1016/j.nbd.2016.10.005
328. Rodríguez-Cruz F Torres-Cruz FM Monroy-Ramírez HC Escobar-Herrera J Basurto-Islas G Avila J Fragmentation of the golgi apparatus in neuroblastoma cells is associated with Tau-induced ring-shaped microtubule bundles J Alzheimers Dis 2018 65 4 1185 1207 10.3233/JAD-180547 30124450
Rodríguez-Cruz F, Torres-Cruz FM, Monroy-Ramírez HC, Escobar-Herrera J, Basurto-Islas G, Avila J, et al. Fragmentation of the golgi apparatus in neuroblastoma cells is associated with Tau-induced ring-shaped microtubule bundles. J Alzheimers Dis. 2018;65(4):1185–207.30124450 10.3233/JAD-180547
329. Xu C Guo J Li L Wang X Zhou Q Sun D Co-EXPRESSION OF THREE WILD-TYPE 3R-Tau isoforms induces memory deficit via oxidation-related DNA damage and cell death: a promising model for tauopathies J Alzheimers Dis 2020 73 3 1105 1123 10.3233/JAD-191132 31884489
Xu C, Guo J, Li L, Wang X, Zhou Q, Sun D, et al. Co-EXPRESSION OF THREE WILD-TYPE 3R-Tau isoforms induces memory deficit via oxidation-related DNA damage and cell death: a promising model for tauopathies. J Alzheimers Dis. 2020;73(3):1105–23.31884489 10.3233/JAD-191132
330. Asada-Utsugi M Uemura K Ayaki T Tu M Minamiyama S Hikiami R Failure of DNA double-strand break repair by tau mediates Alzheimer's disease pathology in vitro Commun Biol 2022 5 1 358 10.1038/s42003-022-03312-0 35418705
Asada-Utsugi M, Uemura K, Ayaki T, Tu M, Minamiyama S, Hikiami R, et al. Failure of DNA double-strand break repair by tau mediates Alzheimer’s disease pathology in vitro. Commun Biol. 2022;5(1):358.35418705 10.1038/s42003-022-03312-0
331. Liu X Ye M Ma L The emerging role of autophagy and mitophagy in tauopathies: from pathogenesis to translational implications in Alzheimer's disease Front Aging Neurosci 2022 14 1022821 10.3389/fnagi.2022.1022821 36325189
Liu X, Ye M, Ma L. The emerging role of autophagy and mitophagy in tauopathies: from pathogenesis to translational implications in Alzheimer’s disease. Front Aging Neurosci. 2022;14:1022821.36325189 10.3389/fnagi.2022.1022821
332. Zhang W Xu C Sun J Shen HM Wang J Yang C Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: pathogenic mechanisms and therapeutic potential Acta Pharm Sin B 2022 12 3 1019 1040 10.1016/j.apsb.2022.01.008 35530153
Zhang W, Xu C, Sun J, Shen HM, Wang J, Yang C. Impairment of the autophagy-lysosomal pathway in Alzheimer’s diseases: pathogenic mechanisms and therapeutic potential. Acta Pharm Sin B. 2022;12(3):1019–40.35530153 10.1016/j.apsb.2022.01.008
333. Li MZ Liu EJ Zhou QZ Li SH Liu SJ Yu HT Intracellular accumulation of tau inhibits autophagosome formation by activating TIA1-amino acid-mTORC1 signaling Mil Med Res 2022 9 1 38 35799293
Li MZ, Liu EJ, Zhou QZ, Li SH, Liu SJ, Yu HT, et al. Intracellular accumulation of tau inhibits autophagosome formation by activating TIA1-amino acid-mTORC1 signaling. Mil Med Res. 2022;9(1):38.35799293
334. Feng Q Luo Y Zhang XN Yang XF Hong XY Sun DS MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration Autophagy 2020 16 4 641 658 10.1080/15548627.2019.1633862 31223056
Feng Q, Luo Y, Zhang XN, Yang XF, Hong XY, Sun DS, et al. MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. Autophagy. 2020;16(4):641–58.31223056 10.1080/15548627.2019.1633862
335. Grundke-Iqbal I Iqbal K Quinlan M Tung YC Zaidi MS Wisniewski HM Microtubule-associated protein tau. A component of Alzheimer paired helical filaments J Biol Chem 1986 261 13 6084 6089 10.1016/S0021-9258(17)38495-8 3084478
Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261(13):6084–9.3084478 10.1016/S0021-9258(17)38495-8
336. Hanger DP Anderton BH Noble W Tau phosphorylation: the therapeutic challenge for neurodegenerative disease Trends Mol Med 2009 15 3 112 119 10.1016/j.molmed.2009.01.003 19246243
Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15(3):112–9.19246243 10.1016/j.molmed.2009.01.003
337. Martin L Latypova X Wilson CM Magnaudeix A Perrin ML Yardin C Tau protein kinases: involvement in Alzheimer's disease Ageing Res Rev 2013 12 1 289 309 10.1016/j.arr.2012.06.003 22742992
Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, et al. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev. 2013;12(1):289–309.22742992 10.1016/j.arr.2012.06.003
338. Wang JZ Liu F Microtubule-associated protein tau in development, degeneration and protection of neurons Prog Neurobiol 2008 85 2 148 175 10.1016/j.pneurobio.2008.03.002 18448228
Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol. 2008;85(2):148–75.18448228 10.1016/j.pneurobio.2008.03.002
339. Kawamata T Taniguchi T Mukai H Kitagawa M Hashimoto T Maeda K A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein J Neurosci 1998 18 18 7402 7410 10.1523/JNEUROSCI.18-18-07402.1998 9736660
Kawamata T, Taniguchi T, Mukai H, Kitagawa M, Hashimoto T, Maeda K, et al. A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. J Neurosci. 1998;18(18):7402–10.9736660 10.1523/JNEUROSCI.18-18-07402.1998
340. Sato S Cerny RL Buescher JL Ikezu T Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation J Neurochem 2006 98 5 1573 1584 10.1111/j.1471-4159.2006.04059.x 16923168
Sato S, Cerny RL, Buescher JL, Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem. 2006;98(5):1573–84.16923168 10.1111/j.1471-4159.2006.04059.x
341. Kitano-Takahashi M Morita H Kondo S Tomizawa K Kato R Tanio M Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein Acta Crystallogr Sect F Struct Biol Cryst Commun 2007 63 Pt 7 602 604 10.1107/S1744309107028783 17620722
Kitano-Takahashi M, Morita H, Kondo S, Tomizawa K, Kato R, Tanio M, et al. Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63(Pt 7):602–4.17620722 10.1107/S1744309107028783
342. Woods YL Cohen P Becker W Jakes R Goedert M Wang X The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase Biochem J 2001 355 Pt 3 609 615 10.1042/bj3550609 11311121
Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J. 2001;355(Pt 3):609–15.11311121 10.1042/bj3550609
343. Drewes G Ebneth A Preuss U Mandelkow EM Mandelkow E MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption Cell 1997 89 2 297 308 10.1016/S0092-8674(00)80208-1 9108484
Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89(2):297–308.9108484 10.1016/S0092-8674(00)80208-1
344. Mendoza J Sekiya M Taniguchi T Iijima KM Wang R Ando K Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro J Proteome Res 2013 12 6 2654 2665 10.1021/pr400008f 23550703
Mendoza J, Sekiya M, Taniguchi T, Iijima KM, Wang R, Ando K. Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro. J Proteome Res. 2013;12(6):2654–65.23550703 10.1021/pr400008f
345. Martiny-Baron G Kazanietz MG Mischak H Blumberg PM Kochs G Hug H Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976 J Biol Chem 1993 268 13 9194 9197 10.1016/S0021-9258(18)98335-3 8486620
Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem. 1993;268(13):9194–7.8486620 10.1016/S0021-9258(18)98335-3
346. Mashhoon N DeMaggio AJ Tereshko V Bergmeier SC Egli M Hoekstra MF Crystal structure of a conformation-selective casein kinase-1 inhibitor J Biol Chem 2000 275 26 20052 20060 10.1074/jbc.M001713200 10749871
Mashhoon N, DeMaggio AJ, Tereshko V, Bergmeier SC, Egli M, Hoekstra MF, et al. Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000;275(26):20052–60.10749871 10.1074/jbc.M001713200
347. Pagano MA Poletto G Di Maira G Cozza G Ruzzene M Sarno S Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors ChemBioChem 2007 8 1 129 139 10.1002/cbic.200600293 17133643
Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. ChemBioChem. 2007;8(1):129–39.17133643 10.1002/cbic.200600293
348. Wang JZ Wu Q Smith A Grundke-Iqbal I Iqbal K Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase FEBS Lett 1998 436 1 28 34 10.1016/S0014-5793(98)01090-4 9771888
Wang JZ, Wu Q, Smith A, Grundke-Iqbal I, Iqbal K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett. 1998;436(1):28–34.9771888 10.1016/S0014-5793(98)01090-4
349. Lebouvier T Scales TM Williamson R Noble W Duyckaerts C Hanger DP The microtubule-associated protein tau is also phosphorylated on tyrosine J Alzheimers Dis 2009 18 1 1 9 10.3233/JAD-2009-1116 19542604
Lebouvier T, Scales TM, Williamson R, Noble W, Duyckaerts C, Hanger DP, et al. The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis. 2009;18(1):1–9.19542604 10.3233/JAD-2009-1116
350. Montalto G Ricciarelli R Tau, tau kinases, and tauopathies: an updated overview BioFactors 2023 49 3 502 511 10.1002/biof.1930 36688478
Montalto G, Ricciarelli R. Tau, tau kinases, and tauopathies: an updated overview. BioFactors. 2023;49(3):502–11.36688478 10.1002/biof.1930
351. Jing Z Caltagarone J Bowser R Altered subcellular distribution of c-Abl in Alzheimer's disease J Alzheimers Dis 2009 17 2 409 422 10.3233/JAD-2009-1062 19363261
Jing Z, Caltagarone J, Bowser R. Altered subcellular distribution of c-Abl in Alzheimer’s disease. J Alzheimers Dis. 2009;17(2):409–22.19363261 10.3233/JAD-2009-1062
352. Alvarez AR Klein A Castro J Cancino GI Amigo J Mosqueira M Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease FASEB J 2008 22 10 3617 3627 10.1096/fj.07-102715 18591368
Alvarez AR, Klein A, Castro J, Cancino GI, Amigo J, Mosqueira M, et al. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J. 2008;22(10):3617–27.18591368 10.1096/fj.07-102715
353. Cohen PT Novel protein serine/threonine phosphatases: variety is the spice of life Trends Biochem Sci 1997 22 7 245 251 10.1016/S0968-0004(97)01060-8 9255065
Cohen PT. Novel protein serine/threonine phosphatases: variety is the spice of life. Trends Biochem Sci. 1997;22(7):245–51.9255065 10.1016/S0968-0004(97)01060-8
354. Liu F Grundke-Iqbal I Iqbal K Gong CX Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation Eur J Neurosci 2005 22 8 1942 1950 10.1111/j.1460-9568.2005.04391.x 16262633
Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci. 2005;22(8):1942–50.16262633 10.1111/j.1460-9568.2005.04391.x
355. Rahman A Grundke-Iqbal I Iqbal K Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1 Neurochem Res 2005 30 2 277 287 10.1007/s11064-005-2483-9 15895832
Rahman A, Grundke-Iqbal I, Iqbal K. Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem Res. 2005;30(2):277–87.15895832 10.1007/s11064-005-2483-9
356. Gu Z Liu W Yan Z {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution J Biol Chem 2009 284 16 10639 10649 10.1074/jbc.M806508200 19240035
Gu Z, Liu W, Yan Z. {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem. 2009;284(16):10639–49.19240035 10.1074/jbc.M806508200
357. Gong CX Singh TJ Grundke-Iqbal I Iqbal K Phosphoprotein phosphatase activities in Alzheimer disease brain J Neurochem 1993 61 3 921 927 10.1111/j.1471-4159.1993.tb03603.x 8395566
Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem. 1993;61(3):921–7.8395566 10.1111/j.1471-4159.1993.tb03603.x
358. Wang JZ Gong CX Zaidi T Grundke-Iqbal I Iqbal K Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B J Biol Chem 1995 270 9 4854 4860 10.1074/jbc.270.9.4854 7876258
Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem. 1995;270(9):4854–60.7876258 10.1074/jbc.270.9.4854
359. Chen S Li B Grundke-Iqbal I Iqbal K I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A J Biol Chem 2008 283 16 10513 10521 10.1074/jbc.M709852200 18245083
Chen S, Li B, Grundke-Iqbal I, Iqbal K. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem. 2008;283(16):10513–21.18245083 10.1074/jbc.M709852200
360. Rahman A Grundke-Iqbal I Iqbal K PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau J Neural Transm (Vienna) 2006 113 2 219 230 10.1007/s00702-005-0313-5 15959850
Rahman A, Grundke-Iqbal I, Iqbal K. PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J Neural Transm (Vienna). 2006;113(2):219–30.15959850 10.1007/s00702-005-0313-5
361. Pei JJ Sersen E Iqbal K Grundke-Iqbal I Expression of protein phosphatases (PP-1, PP-2A, PP-2B and PTP-1B) and protein kinases (MAP kinase and P34cdc2) in the hippocampus of patients with Alzheimer disease and normal aged individuals Brain Res 1994 655 1–2 70 76 10.1016/0006-8993(94)91598-9 7812792
Pei JJ, Sersen E, Iqbal K, Grundke-Iqbal I. Expression of protein phosphatases (PP-1, PP-2A, PP-2B and PTP-1B) and protein kinases (MAP kinase and P34cdc2) in the hippocampus of patients with Alzheimer disease and normal aged individuals. Brain Res. 1994;655(1–2):70–6.7812792 10.1016/0006-8993(94)91598-9
362. Foley K McKee C Nairn AC Xia H Regulation of synaptic transmission and plasticity by protein phosphatase 1 J Neurosci 2021 41 14 3040 3050 10.1523/JNEUROSCI.2026-20.2021 33827970
Foley K, McKee C, Nairn AC, Xia H. Regulation of synaptic transmission and plasticity by protein phosphatase 1. J Neurosci. 2021;41(14):3040–50.33827970 10.1523/JNEUROSCI.2026-20.2021
363. Maltsev AV Balaban PM PP1/PP2A phosphatase inhibition-induced metaplasticity in protein synthesis blocker-treated hippocampal slices: LTP and LTD, or There and Back again Biochem Biophys Res Commun 2021 558 64 70 10.1016/j.bbrc.2021.04.061 33901925
Maltsev AV, Balaban PM. PP1/PP2A phosphatase inhibition-induced metaplasticity in protein synthesis blocker-treated hippocampal slices: LTP and LTD, or There and Back again. Biochem Biophys Res Commun. 2021;558:64–70.33901925 10.1016/j.bbrc.2021.04.061
364. Gao J Hu XD Yang H Xia H Distinct roles of protein phosphatase 1 bound on neurabin and spinophilin and its regulation in AMPA receptor trafficking and LTD induction Mol Neurobiol 2018 55 9 7179 7186 10.1007/s12035-018-0886-2 29383693
Gao J, Hu XD, Yang H, Xia H. Distinct roles of protein phosphatase 1 bound on neurabin and spinophilin and its regulation in AMPA receptor trafficking and LTD induction. Mol Neurobiol. 2018;55(9):7179–86.29383693 10.1007/s12035-018-0886-2
365. Gong CX Grundke-Iqbal I Damuni Z Iqbal K Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease FEBS Lett 1994 341 1 94 98 10.1016/0014-5793(94)80247-5 8137929
Gong CX, Grundke-Iqbal I, Damuni Z, Iqbal K. Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett. 1994;341(1):94–8.8137929 10.1016/0014-5793(94)80247-5
366. Gong CX Shaikh S Wang JZ Zaidi T Grundke-Iqbal I Iqbal K Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain J Neurochem 1995 65 2 732 738 10.1046/j.1471-4159.1995.65020732.x 7616230
Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem. 1995;65(2):732–8.7616230 10.1046/j.1471-4159.1995.65020732.x
367. Srivastava G Choy MS Bolik-Coulon N Page R Peti W Inhibitor-3 inhibits Protein Phosphatase 1 via a metal binding dynamic protein-protein interaction Nat Commun 2023 14 1 1798 10.1038/s41467-023-37372-5 37002212
Srivastava G, Choy MS, Bolik-Coulon N, Page R, Peti W. Inhibitor-3 inhibits Protein Phosphatase 1 via a metal binding dynamic protein-protein interaction. Nat Commun. 2023;14(1):1798.37002212 10.1038/s41467-023-37372-5
368. Bennecib M Gong CX Grundke-Iqbal I Iqbal K Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain FEBS Lett 2000 485 1 87 93 10.1016/S0014-5793(00)02203-1 11086171
Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000;485(1):87–93.11086171 10.1016/S0014-5793(00)02203-1
369. Liu F Iqbal K Grundke-Iqbal I Rossie S Gong CX Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease J Biol Chem 2005 280 3 1790 1796 10.1074/jbc.M410775200 15546861
Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, Gong CX. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer’s disease. J Biol Chem. 2005;280(3):1790–6.15546861 10.1074/jbc.M410775200
370. Gong CX Liu F Wu G Rossie S Wegiel J Li L Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5 J Neurochem 2004 88 2 298 310 10.1111/j.1471-4159.2004.02147.x 14690518
Gong CX, Liu F, Wu G, Rossie S, Wegiel J, Li L, et al. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. J Neurochem. 2004;88(2):298–310.14690518 10.1111/j.1471-4159.2004.02147.x
371. Baki L Shioi J Wen P Shao Z Schwarzman A Gama-Sosa M PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations EMBO J 2004 23 13 2586 2596 10.1038/sj.emboj.7600251 15192701
Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004;23(13):2586–96.15192701 10.1038/sj.emboj.7600251
372. Zhang Z Hartmann H Do VM Abramowski D Sturchler-Pierrat C Staufenbiel M Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis Nature 1998 395 6703 698 702 10.1038/27208 9790190
Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 1998;395(6703):698–702.9790190 10.1038/27208
373. Nishimura M Yu G Levesque G Zhang DM Ruel L Chen F Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex Nat Med 1999 5 2 164 169 10.1038/5526 9930863
Nishimura M, Yu G, Levesque G, Zhang DM, Ruel L, Chen F, et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med. 1999;5(2):164–9.9930863 10.1038/5526
374. Mukrasch MD Biernat J von Bergen M Griesinger C Mandelkow E Zweckstetter M Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions J Biol Chem 2005 280 26 24978 24986 10.1074/jbc.M501565200 15855160
Mukrasch MD, Biernat J, von Bergen M, Griesinger C, Mandelkow E, Zweckstetter M. Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions. J Biol Chem. 2005;280(26):24978–86.15855160 10.1074/jbc.M501565200
375. von Bergen M Friedhoff P Biernat J Heberle J Mandelkow EM Mandelkow E Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure Proc Natl Acad Sci USA 2000 97 10 5129 5134 10.1073/pnas.97.10.5129 10805776
von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA. 2000;97(10):5129–34.10805776 10.1073/pnas.97.10.5129
376. Shammas SL Garcia GA Kumar S Kjaergaard M Horrocks MH Shivji N A mechanistic model of tau amyloid aggregation based on direct observation of oligomers Nat Commun 2015 6 7025 10.1038/ncomms8025 25926130
Shammas SL, Garcia GA, Kumar S, Kjaergaard M, Horrocks MH, Shivji N, et al. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat Commun. 2015;6:7025.25926130 10.1038/ncomms8025
377. Chastagner P Loria F Vargas JY Tois J Id M Okafo G Fate and propagation of endogenously formed Tau aggregates in neuronal cells EMBO Mol Med 2020 12 12 e12025 10.15252/emmm.202012025 33179866
Chastagner P, Loria F, Vargas JY, Tois J, Id M, Okafo G, et al. Fate and propagation of endogenously formed Tau aggregates in neuronal cells. EMBO Mol Med. 2020;12(12): e12025.33179866 10.15252/emmm.202012025
378. Yanamandra K Kfoury N Jiang H Mahan TE Ma S Maloney SE Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo Neuron 2013 80 2 402 414 10.1016/j.neuron.2013.07.046 24075978
Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14.24075978 10.1016/j.neuron.2013.07.046
379. Le L Lee J Im D Park S Hwang KD Lee JH Self-aggregating tau fragments recapitulate pathologic phenotypes and neurotoxicity of Alzheimer's disease in mice Adv Sci 2023 10 29 e2302035 10.1002/advs.202302035
Le L, Lee J, Im D, Park S, Hwang KD, Lee JH, et al. Self-aggregating tau fragments recapitulate pathologic phenotypes and neurotoxicity of Alzheimer’s disease in mice. Adv Sci. 2023;10(29): e2302035.10.1002/advs.202302035
380. Haase C Stieler JT Arendt T Holzer M Pseudophosphorylation of tau protein alters its ability for self-aggregation J Neurochem 2004 88 6 1509 1520 10.1046/j.1471-4159.2003.02287.x 15009652
Haase C, Stieler JT, Arendt T, Holzer M. Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem. 2004;88(6):1509–20.15009652 10.1046/j.1471-4159.2003.02287.x
381. Annadurai N Malina L Malohlava J Hajdúch M Das V Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation Biochimie 2022 200 79 86 10.1016/j.biochi.2022.05.013 35623497
Annadurai N, Malina L, Malohlava J, Hajdúch M, Das V. Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation. Biochimie. 2022;200:79–86.35623497 10.1016/j.biochi.2022.05.013
382. Despres C Byrne C Qi H Cantrelle FX Huvent I Chambraud B Identification of the Tau phosphorylation pattern that drives its aggregation Proc Natl Acad Sci USA 2017 114 34 9080 9085 10.1073/pnas.1708448114 28784767
Despres C, Byrne C, Qi H, Cantrelle FX, Huvent I, Chambraud B, et al. Identification of the Tau phosphorylation pattern that drives its aggregation. Proc Natl Acad Sci USA. 2017;114(34):9080–5.28784767 10.1073/pnas.1708448114
383. Ercan-Herbst E Ehrig J Schöndorf DC Behrendt A Klaus B Gomez Ramos B A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain Acta Neuropathol Commun 2019 7 1 192 10.1186/s40478-019-0823-2 31796124
Ercan-Herbst E, Ehrig J, Schöndorf DC, Behrendt A, Klaus B, Gomez Ramos B, et al. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer’s disease brain. Acta Neuropathol Commun. 2019;7(1):192.31796124 10.1186/s40478-019-0823-2
384. Vertegaal ACO Signalling mechanisms and cellular functions of SUMO Nat Rev Mol Cell Biol 2022 23 11 715 731 10.1038/s41580-022-00500-y 35750927
Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022;23(11):715–31.35750927 10.1038/s41580-022-00500-y
385. Knock E Matsuzaki S Takamura H Satoh K Rooke G Han K SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model Neurobiol Dis 2018 110 154 165 10.1016/j.nbd.2017.11.015 29217476
Knock E, Matsuzaki S, Takamura H, Satoh K, Rooke G, Han K, et al. SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model. Neurobiol Dis. 2018;110:154–65.29217476 10.1016/j.nbd.2017.11.015
386. Nisticò R Ferraina C Marconi V Blandini F Negri L Egebjerg J Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease Front Pharmacol 2014 5 63 24778618
Nisticò R, Ferraina C, Marconi V, Blandini F, Negri L, Egebjerg J, et al. Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer’s disease. Front Pharmacol. 2014;5:63.24778618
387. McMillan LE Brown JT Henley JM Cimarosti H Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model Neurosci Lett 2011 502 3 201 208 10.1016/j.neulet.2011.07.045 21843595
McMillan LE, Brown JT, Henley JM, Cimarosti H. Profiles of SUMO and ubiquitin conjugation in an Alzheimer’s disease model. Neurosci Lett. 2011;502(3):201–8.21843595 10.1016/j.neulet.2011.07.045
388. Luo HB Xia YY Shu XJ Liu ZC Feng Y Liu XH SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination Proc Natl Acad Sci USA 2014 111 46 16586 16591 10.1073/pnas.1417548111 25378699
Luo HB, Xia YY, Shu XJ, Liu ZC, Feng Y, Liu XH, et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci USA. 2014;111(46):16586–91.25378699 10.1073/pnas.1417548111
389. Alquezar C Arya S Kao AW Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation Front Neurol 2020 11 595532 10.3389/fneur.2020.595532 33488497
Alquezar C, Arya S, Kao AW. Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front Neurol. 2020;11: 595532.33488497 10.3389/fneur.2020.595532
390. Min SW Cho SH Zhou Y Schroeder S Haroutunian V Seeley WW Acetylation of tau inhibits its degradation and contributes to tauopathy Neuron 2010 67 6 953 966 10.1016/j.neuron.2010.08.044 20869593
Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67(6):953–66.20869593 10.1016/j.neuron.2010.08.044
391. Tseng JH Ajit A Tabassum Z Patel N Tian X Chen Y Tau seeds are subject to aberrant modifications resulting in distinct signatures Cell Rep 2021 35 4 109037 10.1016/j.celrep.2021.109037 33910013
Tseng JH, Ajit A, Tabassum Z, Patel N, Tian X, Chen Y, et al. Tau seeds are subject to aberrant modifications resulting in distinct signatures. Cell Rep. 2021;35(4): 109037.33910013 10.1016/j.celrep.2021.109037
392. Min SW Chen X Tracy TE Li Y Zhou Y Wang C Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits Nat Med 2015 21 10 1154 1162 10.1038/nm.3951 26390242
Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21(10):1154–62.26390242 10.1038/nm.3951
393. Shi N Lin Y Yan B Jiao X Ding X Wu Y Hippocampal SIRT1 improves cognitive impairment by deacetylating tau protein in diabetic models Eur J Pharmacol 2022 914 174666 10.1016/j.ejphar.2021.174666 34861210
Shi N, Lin Y, Yan B, Jiao X, Ding X, Wu Y, et al. Hippocampal SIRT1 improves cognitive impairment by deacetylating tau protein in diabetic models. Eur J Pharmacol. 2022;914: 174666.34861210 10.1016/j.ejphar.2021.174666
394. Zhou Q Li S Li M Ke D Wang Q Yang Y Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: a vicious cycle in Alzheimer neurodegeneration EBioMedicine 2022 78 103970 10.1016/j.ebiom.2022.103970 35339896
Zhou Q, Li S, Li M, Ke D, Wang Q, Yang Y, et al. Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: a vicious cycle in Alzheimer neurodegeneration. EBioMedicine. 2022;78: 103970.35339896 10.1016/j.ebiom.2022.103970
395. Cook C Carlomagno Y Gendron TF Dunmore J Scheffel K Stetler C Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance Hum Mol Genet 2014 23 1 104 116 10.1093/hmg/ddt402 23962722
Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet. 2014;23(1):104–16.23962722 10.1093/hmg/ddt402
396. Hershko A Ciechanover A The ubiquitin system Ann Rev Biochem 1998 67 425 479 10.1146/annurev.biochem.67.1.425 9759494
Hershko A, Ciechanover A. The ubiquitin system. Ann Rev Biochem. 1998;67:425–79.9759494 10.1146/annurev.biochem.67.1.425
397. Behrends C Harper JW Constructing and decoding unconventional ubiquitin chains Nat Struct Mol Biol 2011 18 5 520 528 10.1038/nsmb.2066 21540891
Behrends C, Harper JW. Constructing and decoding unconventional ubiquitin chains. Nat Struct Mol Biol. 2011;18(5):520–8.21540891 10.1038/nsmb.2066
398. Kudo T Iqbal K Ravid R Swaab DF Grundke-Iqbal I Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels Brain Res 1994 639 1 1 7 10.1016/0006-8993(94)91757-4 8180825
Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res. 1994;639(1):1–7.8180825 10.1016/0006-8993(94)91757-4
399. Abreha MH Dammer EB Ping L Zhang T Duong DM Gearing M Quantitative analysis of the brain ubiquitylome in Alzheimer's Disease Proteomics 2018 18 20 e1800108 10.1002/pmic.201800108 30230243
Abreha MH, Dammer EB, Ping L, Zhang T, Duong DM, Gearing M, et al. Quantitative analysis of the brain ubiquitylome in Alzheimer’s Disease. Proteomics. 2018;18(20): e1800108.30230243 10.1002/pmic.201800108
400. Lee MJ Lee JH Rubinsztein DC Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system Prog Neurobiol 2013 105 49 59 10.1016/j.pneurobio.2013.03.001 23528736
Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol. 2013;105:49–59.23528736 10.1016/j.pneurobio.2013.03.001
401. Gronroos E Hellman U Heldin CH Ericsson J Control of Smad7 stability by competition between acetylation and ubiquitination Mol Cell 2002 10 3 483 493 10.1016/S1097-2765(02)00639-1 12408818
Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell. 2002;10(3):483–93.12408818 10.1016/S1097-2765(02)00639-1
402. Thomas SN Funk KE Wan Y Liao Z Davies P Kuret J Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach Acta Neuropathol 2012 123 1 105 117 10.1007/s00401-011-0893-0 22033876
Thomas SN, Funk KE, Wan Y, Liao Z, Davies P, Kuret J, et al. Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol. 2012;123(1):105–17.22033876 10.1007/s00401-011-0893-0
403. Kontaxi C Piccardo P Gill AC Lysine-directed post-translational modifications of tau protein in Alzheimer's disease and related tauopathies Front Mol Biosci 2017 4 56 10.3389/fmolb.2017.00056 28848737
Kontaxi C, Piccardo P, Gill AC. Lysine-directed post-translational modifications of tau protein in Alzheimer’s disease and related tauopathies. Front Mol Biosci. 2017;4:56.28848737 10.3389/fmolb.2017.00056
404. Huseby CJ Hoffman CN Cooper GL Cocuron JC Alonso AP Thomas SN Quantification of Tau protein lysine methylation in aging and Alzheimer's Disease J Alzheimers Dis 2019 71 3 979 991 10.3233/JAD-190604 31450505
Huseby CJ, Hoffman CN, Cooper GL, Cocuron JC, Alonso AP, Thomas SN, et al. Quantification of Tau protein lysine methylation in aging and Alzheimer’s Disease. J Alzheimers Dis. 2019;71(3):979–91.31450505 10.3233/JAD-190604
405. Funk KE Thomas SN Schafer KN Cooper GL Liao Z Clark DJ Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity Biochem J 2014 462 1 77 88 10.1042/BJ20140372 24869773
Funk KE, Thomas SN, Schafer KN, Cooper GL, Liao Z, Clark DJ, et al. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J. 2014;462(1):77–88.24869773 10.1042/BJ20140372
406. Yang X Qian K Protein O-GlcNAcylation: emerging mechanisms and functions Nat Rev Mol Cell Biol 2017 18 7 452 465 10.1038/nrm.2017.22 28488703
Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017;18(7):452–65.28488703 10.1038/nrm.2017.22
407. Reily C Stewart TJ Renfrow MB Novak J Glycosylation in health and disease Nat Rev Nephrol 2019 15 6 346 366 10.1038/s41581-019-0129-4 30858582
Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15(6):346–66.30858582 10.1038/s41581-019-0129-4
408. Wang JZ Grundke-Iqbal I Iqbal K Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease Nat Med 1996 2 8 871 875 10.1038/nm0896-871 8705855
Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer’s disease. Nat Med. 1996;2(8):871–5.8705855 10.1038/nm0896-871
409. Arnold CS Johnson GV Cole RN Dong DL Lee M Hart GW The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine J Biol Chem 1996 271 46 28741 28744 10.1074/jbc.271.46.28741 8910513
Arnold CS, Johnson GV, Cole RN, Dong DL, Lee M, Hart GW. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem. 1996;271(46):28741–4.8910513 10.1074/jbc.271.46.28741
410. Liu F Zaidi T Iqbal K Grundke-Iqbal I Gong CX Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5 Neuroscience 2002 115 3 829 837 10.1016/S0306-4522(02)00510-9 12435421
Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Gong CX. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience. 2002;115(3):829–37.12435421 10.1016/S0306-4522(02)00510-9
411. Yuzwa SA Shan X Macauley MS Clark T Skorobogatko Y Vosseller K Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation Nat Chem Biol 2012 8 4 393 399 10.1038/nchembio.797 22366723
Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012;8(4):393–9.22366723 10.1038/nchembio.797
412. Yuzwa SA Yadav AK Skorobogatko Y Clark T Vosseller K Vocadlo DJ Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody Amino Acids 2011 40 3 857 868 10.1007/s00726-010-0705-1 20706749
Yuzwa SA, Yadav AK, Skorobogatko Y, Clark T, Vosseller K, Vocadlo DJ. Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody. Amino Acids. 2011;40(3):857–68.20706749 10.1007/s00726-010-0705-1
413. Liu F Iqbal K Grundke-Iqbal I Hart GW Gong CX O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease Proc Natl Acad Sci USA 2004 101 29 10804 10809 10.1073/pnas.0400348101 15249677
Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA. 2004;101(29):10804–9.15249677 10.1073/pnas.0400348101
414. Smet-Nocca C Broncel M Wieruszeski JM Tokarski C Hanoulle X Leroy A Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation Mol Biosysts 2011 7 5 1420 1429 10.1039/c0mb00337a
Smet-Nocca C, Broncel M, Wieruszeski JM, Tokarski C, Hanoulle X, Leroy A, et al. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. Mol Biosysts. 2011;7(5):1420–9.10.1039/c0mb00337a
415. Li X Lu F Wang JZ Gong CX Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting Eur J Neurosci 2006 23 8 2078 2086 10.1111/j.1460-9568.2006.04735.x 16630055
Li X, Lu F, Wang JZ, Gong CX. Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci. 2006;23(8):2078–86.16630055 10.1111/j.1460-9568.2006.04735.x
416. Ledesma MD Bonay P Colaço C Avila J Analysis of microtubule-associated protein tau glycation in paired helical filaments J Biol Chem 1994 269 34 21614 21619 10.1016/S0021-9258(17)31849-5 8063802
Ledesma MD, Bonay P, Colaço C, Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem. 1994;269(34):21614–9.8063802 10.1016/S0021-9258(17)31849-5
417. Yan SD Chen X Schmidt AM Brett J Godman G Zou YS Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress Proc Natl Acad Sci USA 1994 91 16 7787 7791 10.1073/pnas.91.16.7787 8052661
Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA. 1994;91(16):7787–91.8052661 10.1073/pnas.91.16.7787
418. Cho SJ Roman G Yeboah F Konishi Y The road to advanced glycation end products: a mechanistic perspective Curr Med Chem 2007 14 15 1653 1671 10.2174/092986707780830989 17584071
Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem. 2007;14(15):1653–71.17584071 10.2174/092986707780830989
419. Nacharaju P Ko L Yen SH Characterization of in vitro glycation sites of tau J Neurochem 1997 69 4 1709 1719 10.1046/j.1471-4159.1997.69041709.x 9326300
Nacharaju P, Ko L, Yen SH. Characterization of in vitro glycation sites of tau. J Neurochem. 1997;69(4):1709–19.9326300 10.1046/j.1471-4159.1997.69041709.x
420. Liu K Liu Y Li L Qin P Iqbal J Deng Y Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property Biochim Biophys Acta 2016 1862 2 192 201 10.1016/j.bbadis.2015.12.002 26655600
Liu K, Liu Y, Li L, Qin P, Iqbal J, Deng Y, et al. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim Biophys Acta. 2016;1862(2):192–201.26655600 10.1016/j.bbadis.2015.12.002
421. Horiguchi T Uryu K Giasson BI Ischiropoulos H LightFoot R Bellmann C Nitration of tau protein is linked to neurodegeneration in tauopathies Am J Pathol 2003 163 3 1021 1031 10.1016/S0002-9440(10)63462-1 12937143
Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, et al. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol. 2003;163(3):1021–31.12937143 10.1016/S0002-9440(10)63462-1
422. Castegna A Thongboonkerd V Klein JB Lynn B Markesbery WR Butterfield DA Proteomic identification of nitrated proteins in Alzheimer's disease brain J Neurochem 2003 85 6 1394 1401 10.1046/j.1471-4159.2003.01786.x 12787059
Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem. 2003;85(6):1394–401.12787059 10.1046/j.1471-4159.2003.01786.x
423. Williamson KS Gabbita SP Mou S West M Pye QN Markesbery WR The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain Nitric Oxid 2002 6 2 221 227 10.1006/niox.2001.0399
Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, et al. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxid. 2002;6(2):221–7.10.1006/niox.2001.0399
424. Reynolds MR Berry RW Binder LI Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease Biochemistry 2005 44 5 1690 1700 10.1021/bi047982v 15683253
Reynolds MR, Berry RW, Binder LI. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer’s disease. Biochemistry. 2005;44(5):1690–700.15683253 10.1021/bi047982v
425. Reynolds MR Reyes JF Fu Y Bigio EH Guillozet-Bongaarts AL Berry RW Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies J Neurosci 2006 26 42 10636 10645 10.1523/JNEUROSCI.2143-06.2006 17050703
Reynolds MR, Reyes JF, Fu Y, Bigio EH, Guillozet-Bongaarts AL, Berry RW, et al. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer’s disease and other tauopathies. J Neurosci. 2006;26(42):10636–45.17050703 10.1523/JNEUROSCI.2143-06.2006
426. Reyes JF Fu Y Vana L Kanaan NM Binder LI Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease Am J Pathol 2011 178 5 2275 2285 10.1016/j.ajpath.2011.01.030 21514440
Reyes JF, Fu Y, Vana L, Kanaan NM, Binder LI. Tyrosine nitration within the proline-rich region of Tau in Alzheimer’s disease. Am J Pathol. 2011;178(5):2275–85.21514440 10.1016/j.ajpath.2011.01.030
427. Reyes JF Reynolds MR Horowitz PM Fu Y Guillozet-Bongaarts AL Berry R A possible link between astrocyte activation and tau nitration in Alzheimer's disease Neurobiol Dis 2008 31 2 198 208 10.1016/j.nbd.2008.04.005 18562203
Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL, Berry R, et al. A possible link between astrocyte activation and tau nitration in Alzheimer’s disease. Neurobiol Dis. 2008;31(2):198–208.18562203 10.1016/j.nbd.2008.04.005
428. Reynolds MR Berry RW Binder LI Site-specific nitration differentially influences tau assembly in vitro Biochemistry 2005 44 42 13997 14009 10.1021/bi051028w 16229489
Reynolds MR, Berry RW, Binder LI. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry. 2005;44(42):13997–4009.16229489 10.1021/bi051028w
429. Xiong J Zhang Z Ye K C/EBPβ/AEP signaling drives Alzheimer's Disease Pathogenesis Neurosci Bull 2023 39 7 1173 1185 10.1007/s12264-023-01025-w 36735152
Xiong J, Zhang Z, Ye K. C/EBPβ/AEP signaling drives Alzheimer’s Disease Pathogenesis. Neurosci Bull. 2023;39(7):1173–85.36735152 10.1007/s12264-023-01025-w
430. Su JH Zhao M Anderson AJ Srinivasan A Cotman CW Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology Brain Res 2001 898 2 350 357 10.1016/S0006-8993(01)02018-2 11306022
Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW. Activated caspase-3 expression in Alzheimer’s and aged control brain: correlation with Alzheimer pathology. Brain Res. 2001;898(2):350–7.11306022 10.1016/S0006-8993(01)02018-2
431. Cotman CW Poon WW Rissman RA Blurton-Jones M The role of caspase cleavage of tau in Alzheimer disease neuropathology J Neuropathol Exp Neurol 2005 64 2 104 112 10.1093/jnen/64.2.104 15751224
Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol. 2005;64(2):104–12.15751224 10.1093/jnen/64.2.104
432. Pockes S Walters MA Ashe KH Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias Transl Res 2023 254 34 40 10.1016/j.trsl.2022.10.009 36343883
Pockes S, Walters MA, Ashe KH. Targeting caspase-2 interactions with tau in Alzheimer’s disease and related dementias. Transl Res. 2023;254:34–40.36343883 10.1016/j.trsl.2022.10.009
433. Gamblin TC Chen F Zambrano A Abraha A Lagalwar S Guillozet AL Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease Proc Natl Acad Sci USA 2003 100 17 10032 10037 10.1073/pnas.1630428100 12888622
Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci USA. 2003;100(17):10032–7.12888622 10.1073/pnas.1630428100
434. Pérez MJ Vergara-Pulgar K Jara C Cabezas-Opazo F Quintanilla RA Caspase-cleaved tau impairs mitochondrial dynamics in Alzheimer's Disease Mol Neurobiol 2018 55 2 1004 1018 10.1007/s12035-017-0385-x 28084594
Pérez MJ, Vergara-Pulgar K, Jara C, Cabezas-Opazo F, Quintanilla RA. Caspase-cleaved tau impairs mitochondrial dynamics in Alzheimer’s Disease. Mol Neurobiol. 2018;55(2):1004–18.28084594 10.1007/s12035-017-0385-x
435. Jarero-Basulto JJ Luna-Muñoz J Mena R Kristofikova Z Ripova D Perry G Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease J Neuropathol Exp Neurol 2013 72 12 1145 1161 10.1097/NEN.0000000000000013 24226268
Jarero-Basulto JJ, Luna-Muñoz J, Mena R, Kristofikova Z, Ripova D, Perry G, et al. Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease. J Neuropathol Exp Neurol. 2013;72(12):1145–61.24226268 10.1097/NEN.0000000000000013
436. Opland CK Bryan MR Harris B McGillion-Moore J Tian X Chen Y Activity-dependent tau cleavage by caspase-3 promotes neuronal dysfunction and synaptotoxicity iScience 2023 26 6 106905 10.1016/j.isci.2023.106905 37305696
Opland CK, Bryan MR, Harris B, McGillion-Moore J, Tian X, Chen Y, et al. Activity-dependent tau cleavage by caspase-3 promotes neuronal dysfunction and synaptotoxicity. iScience. 2023;26(6):106905.37305696 10.1016/j.isci.2023.106905
437. Zhao X Kotilinek LA Smith B Hlynialuk C Zahs K Ramsden M Caspase-2 cleavage of tau reversibly impairs memory Nat Med 2016 22 11 1268 1276 10.1038/nm.4199 27723722
Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med. 2016;22(11):1268–76.27723722 10.1038/nm.4199
438. Dall E Fegg JC Briza P Brandstetter H Structure and mechanism of an aspartimide-dependent peptide ligase in human legumain Angew Chem Int Ed Engl 2015 54 10 2917 2921 10.1002/anie.201409135 25630877
Dall E, Fegg JC, Briza P, Brandstetter H. Structure and mechanism of an aspartimide-dependent peptide ligase in human legumain. Angew Chem Int Ed Engl. 2015;54(10):2917–21.25630877 10.1002/anie.201409135
439. Jackson MA Gilding EK Shafee T Harris KS Kaas Q Poon S Molecular basis for the production of cyclic peptides by plant asparaginyl endopeptidases Nat Commun 2018 9 1 2411 10.1038/s41467-018-04669-9 29925835
Jackson MA, Gilding EK, Shafee T, Harris KS, Kaas Q, Poon S, et al. Molecular basis for the production of cyclic peptides by plant asparaginyl endopeptidases. Nat Commun. 2018;9(1):2411.29925835 10.1038/s41467-018-04669-9
440. McKibben KM Rhoades E Independent tubulin binding and polymerization by the proline-rich region of Tau is regulated by Tau's N-terminal domain J Biol Chem 2019 294 50 19381 19394 10.1074/jbc.RA119.010172 31699899
McKibben KM, Rhoades E. Independent tubulin binding and polymerization by the proline-rich region of Tau is regulated by Tau’s N-terminal domain. J Biol Chem. 2019;294(50):19381–94.31699899 10.1074/jbc.RA119.010172
441. Zilka N Filipcik P Koson P Fialova L Skrabana R Zilkova M Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo FEBS Lett 2006 580 15 3582 3588 10.1016/j.febslet.2006.05.029 16753151
Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, et al. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 2006;580(15):3582–8.16753151 10.1016/j.febslet.2006.05.029
442. Ghetti B Oblak AL Boeve BF Johnson KA Dickerson BC Goedert M Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging Neuropathol Appl Neurobiol 2015 41 1 24 46 10.1111/nan.12213 25556536
Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol. 2015;41(1):24–46.25556536 10.1111/nan.12213
443. Spillantini MG Murrell JR Goedert M Farlow MR Klug A Ghetti B Mutation in the tau gene in familial multiple system tauopathy with presenile dementia Proc Natl Acad Sci USA 1998 95 13 7737 7741 10.1073/pnas.95.13.7737 9636220
Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA. 1998;95(13):7737–41.9636220 10.1073/pnas.95.13.7737
444. Sampognaro PJ Arya S Knudsen GM Gunderson EL Sandoval-Perez A Hodul M Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases Mol Neurodegen 2023 18 1 29 10.1186/s13024-023-00621-8
Sampognaro PJ, Arya S, Knudsen GM, Gunderson EL, Sandoval-Perez A, Hodul M, et al. Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases. Mol Neurodegen. 2023;18(1):29.10.1186/s13024-023-00621-8
445. Barghorn S Zheng-Fischhöfer Q Ackmann M Biernat J von Bergen M Mandelkow EM Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias Biochemistry 2000 39 38 11714 11721 10.1021/bi000850r 10995239
Barghorn S, Zheng-Fischhöfer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39(38):11714–21.10995239 10.1021/bi000850r
446. Hong M Zhukareva V Vogelsberg-Ragaglia V Wszolek Z Reed L Miller BI Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17 Science 1998 282 5395 1914 1917 10.1126/science.282.5395.1914 9836646
Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282(5395):1914–7.9836646 10.1126/science.282.5395.1914
447. Bowles KR, Pugh DA, Pedicone C, Oja L, Weitzman SA, Liu Y, et al. Development of MAPT S305 mutation models exhibiting elevated 4R tau expression, resulting in altered neuronal and astrocytic function. bioRxiv. 2023.
448. Alonso Adel C Mederlyova A Novak M Grundke-Iqbal I Iqbal K Promotion of hyperphosphorylation by frontotemporal dementia tau mutations J Biol Chem 2004 279 33 34873 34881 10.1074/jbc.M405131200 15190058
Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem. 2004;279(33):34873–81.15190058 10.1074/jbc.M405131200
449. Sontag JM Nunbhakdi-Craig V White CL 3rd Halpain S Sontag E The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies J Biol Chem 2012 287 18 14984 14993 10.1074/jbc.M111.338681 22403409
Sontag JM, Nunbhakdi-Craig V, White CL 3rd, Halpain S, Sontag E. The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies. J Biol Chem. 2012;287(18):14984–93.22403409 10.1074/jbc.M111.338681
450. Weickert S Wawrzyniuk M John LH Rüdiger SGD Drescher M The mechanism of Hsp90-induced oligomerizaton of Tau Sci Adv 2020 6 11 eaax6999 10.1126/sciadv.aax6999 32201713
Weickert S, Wawrzyniuk M, John LH, Rüdiger SGD, Drescher M. The mechanism of Hsp90-induced oligomerizaton of Tau. Sci Adv. 2020;6(11):eaax6999.32201713 10.1126/sciadv.aax6999
451. Petrucelli L Dickson D Kehoe K Taylor J Snyder H Grover A CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation Hum Mol Genet 2004 13 7 703 714 10.1093/hmg/ddh083 14962978
Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004;13(7):703–14.14962978 10.1093/hmg/ddh083
452. Zhang X Zhang S Zhang L Lu J Zhao C Luo F Heat shock protein 104 (HSP104) chaperones soluble Tau via a mechanism distinct from its disaggregase activity J Biol Chem 2019 294 13 4956 4965 10.1074/jbc.RA118.005980 30718279
Zhang X, Zhang S, Zhang L, Lu J, Zhao C, Luo F, et al. Heat shock protein 104 (HSP104) chaperones soluble Tau via a mechanism distinct from its disaggregase activity. J Biol Chem. 2019;294(13):4956–65.30718279 10.1074/jbc.RA118.005980
453. Braak H Braak E Neuropathological stageing of Alzheimer-related changes Acta Neuropathol 1991 82 4 239 259 10.1007/BF00308809 1759558
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.1759558 10.1007/BF00308809
454. Jackson NA Guerrero-Muñoz MJ Castillo-Carranza DL The prion-like transmission of tau oligomers via exosomes Front Aging Neurosci 2022 14 974414 10.3389/fnagi.2022.974414 36062141
Jackson NA, Guerrero-Muñoz MJ, Castillo-Carranza DL. The prion-like transmission of tau oligomers via exosomes. Front Aging Neurosci. 2022;14: 974414.36062141 10.3389/fnagi.2022.974414
455. Holmes BB Diamond MI Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target J Biol Chem 2014 289 29 19855 19861 10.1074/jbc.R114.549295 24860099
Holmes BB, Diamond MI. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J Biol Chem. 2014;289(29):19855–61.24860099 10.1074/jbc.R114.549295
456. Jain N Lewis CA Ulrich JD Holtzman DM Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading J Exp Med 2023 220 1 e20220654 10.1084/jem.20220654 36219197
Jain N, Lewis CA, Ulrich JD, Holtzman DM. Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading. J Exp Med. 2023;220(1):e20220654.36219197 10.1084/jem.20220654
457. Shi M Kovac A Korff A Cook TJ Ginghina C Bullock KM CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease Alzheimers Dement 2016 12 11 1125 1131 10.1016/j.jalz.2016.04.003 27234211
Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, et al. CNS tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. Alzheimers Dement. 2016;12(11):1125–31.27234211 10.1016/j.jalz.2016.04.003
458. Binder LI Frankfurter A Rebhun LI The distribution of tau in the mammalian central nervous system J Cell Biol 1985 101 4 1371 1378 10.1083/jcb.101.4.1371 3930508
Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101(4):1371–8.3930508 10.1083/jcb.101.4.1371
459. Janelidze S Bali D Ashton NJ Barthélemy NR Vanbrabant J Stoops E Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease Brain 2023 146 4 1592 1601 10.1093/brain/awac333 36087307
Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023;146(4):1592–601.36087307 10.1093/brain/awac333
460. Sengupta U Portelius E Hansson O Farmer K Castillo-Carranza D Woltjer R Tau oligomers in cerebrospinal fluid in Alzheimer's disease Ann Clin Transl Neurol 2017 4 4 226 235 10.1002/acn3.382 28382304
Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, et al. Tau oligomers in cerebrospinal fluid in Alzheimer’s disease. Ann Clin Transl Neurol. 2017;4(4):226–35.28382304 10.1002/acn3.382
461. Wallin AK Blennow K Zetterberg H Londos E Minthon L Hansson O CSF biomarkers predict a more malignant outcome in Alzheimer disease Neurology 2010 74 19 1531 1537 10.1212/WNL.0b013e3181dd4dd8 20458070
Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531–7.20458070 10.1212/WNL.0b013e3181dd4dd8
462. Wang Y Balaji V Kaniyappan S Krüger L Irsen S Tepper K The release and trans-synaptic transmission of Tau via exosomes Mol Neurodegen 2017 12 1 5 10.1186/s13024-016-0143-y
Wang Y, Balaji V, Kaniyappan S, Krüger L, Irsen S, Tepper K, et al. The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegen. 2017;12(1):5.10.1186/s13024-016-0143-y
463. Polanco JC Hand GR Briner A Li C Götz J Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol Acta Neuropathol 2021 141 2 235 256 10.1007/s00401-020-02254-3 33417012
Polanco JC, Hand GR, Briner A, Li C, Götz J. Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. Acta Neuropathol. 2021;141(2):235–56.33417012 10.1007/s00401-020-02254-3
464. Morozova V Cohen LS Makki AE Shur A Pilar G El Idrissi A Normal and pathological tau uptake mediated by M1/M3 muscarinic receptors promotes opposite neuronal changes Front Cell Neurosci 2019 13 403 10.3389/fncel.2019.00403 31555098
Morozova V, Cohen LS, Makki AE, Shur A, Pilar G, El Idrissi A, et al. Normal and pathological tau uptake mediated by M1/M3 muscarinic receptors promotes opposite neuronal changes. Front Cell Neurosci. 2019;13:403.31555098 10.3389/fncel.2019.00403
465. Bolós M Llorens-Martín M Perea JR Jurado-Arjona J Rábano A Hernández F Absence of CX3CR1 impairs the internalization of Tau by microglia Mol Neurodegen 2017 12 1 59 10.1186/s13024-017-0200-1
Bolós M, Llorens-Martín M, Perea JR, Jurado-Arjona J, Rábano A, Hernández F, et al. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol Neurodegen. 2017;12(1):59.10.1186/s13024-017-0200-1
466. Bolós M Llorens-Martín M Jurado-Arjona J Hernández F Rábano A Avila J Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo J Alzheimers Dis 2016 50 1 77 87 10.3233/JAD-150704 26638867
Bolós M, Llorens-Martín M, Jurado-Arjona J, Hernández F, Rábano A, Avila J. Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. J Alzheimers Dis. 2016;50(1):77–87.26638867 10.3233/JAD-150704
467. Perea JR López E Díez-Ballesteros JC Ávila J Hernández F Bolós M Extracellular monomeric Tau Is internalized by astrocytes Front Neurosci 2019 13 442 10.3389/fnins.2019.00442 31118883
Perea JR, López E, Díez-Ballesteros JC, Ávila J, Hernández F, Bolós M. Extracellular monomeric Tau Is internalized by astrocytes. Front Neurosci. 2019;13:442.31118883 10.3389/fnins.2019.00442
468. Holmes BB DeVos SL Kfoury N Li M Jacks R Yanamandra K Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds Proc Natl Acad Sci USA 2013 110 33 E3138 3147 10.1073/pnas.1301440110 23898162
Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA. 2013;110(33):E3138-3147.23898162 10.1073/pnas.1301440110
469. Evans LD Wassmer T Fraser G Smith J Perkinton M Billinton A Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways Cell Rep 2018 22 13 3612 3624 10.1016/j.celrep.2018.03.021 29590627
Evans LD, Wassmer T, Fraser G, Smith J, Perkinton M, Billinton A, et al. Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 2018;22(13):3612–24.29590627 10.1016/j.celrep.2018.03.021
470. Rauch JN Luna G Guzman E Audouard M Challis C Sibih YE LRP1 is a master regulator of tau uptake and spread Nature 2020 580 7803 381 385 10.1038/s41586-020-2156-5 32296178
Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580(7803):381–5.32296178 10.1038/s41586-020-2156-5
471. Drummond E Wisniewski T Alzheimer's disease: experimental models and reality Acta Neuropathol 2017 133 2 155 175 10.1007/s00401-016-1662-x 28025715
Drummond E, Wisniewski T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155–75.28025715 10.1007/s00401-016-1662-x
472. Chen ZY Zhang Y Animal models of Alzheimer's disease: applications, evaluation, and perspectives Zool Res 2022 43 6 1026 1040 10.24272/j.issn.2095-8137.2022.289 36317468
Chen ZY, Zhang Y. Animal models of Alzheimer’s disease: applications, evaluation, and perspectives. Zool Res. 2022;43(6):1026–40.36317468 10.24272/j.issn.2095-8137.2022.289
473. Wang L Zhang Y Zhao Y Marshall C Wu T Xiao M Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice Brain Pathol 2019 29 2 176 192 10.1111/bpa.12656 30192999
Wang L, Zhang Y, Zhao Y, Marshall C, Wu T, Xiao M. Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice. Brain Pathol. 2019;29(2):176–92.30192999 10.1111/bpa.12656
474. Holcomb L Gordon MN McGowan E Yu X Benkovic S Jantzen P Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes Nat Med 1998 4 1 97 100 10.1038/nm0198-097 9427614
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4(1):97–100.9427614 10.1038/nm0198-097
475. Elder GA Gama Sosa MA De Gasperi R Dickstein DL Hof PR Presenilin transgenic mice as models of Alzheimer's disease Brain Struct Funct 2010 214 2–3 127 143 10.1007/s00429-009-0227-3 19921519
Elder GA, Gama Sosa MA, De Gasperi R, Dickstein DL, Hof PR. Presenilin transgenic mice as models of Alzheimer’s disease. Brain Struct Funct. 2010;214(2–3):127–43.19921519 10.1007/s00429-009-0227-3
476. Esquerda-Canals G Montoliu-Gaya L Güell-Bosch J Villegas S Mouse models of Alzheimer's disease J Alzheimers Dis 2017 57 4 1171 1183 10.3233/JAD-170045 28304309
Esquerda-Canals G, Montoliu-Gaya L, Güell-Bosch J, Villegas S. Mouse models of Alzheimer’s disease. J Alzheimers Dis. 2017;57(4):1171–83.28304309 10.3233/JAD-170045
477. Games D Adams D Alessandrini R Barbour R Berthelette P Blackwell C Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein Nature 1995 373 6514 523 527 10.1038/373523a0 7845465
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373(6514):523–7.7845465 10.1038/373523a0
478. Lanz TA Carter DB Merchant KM Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype Neurobiol Dis 2003 13 3 246 253 10.1016/S0969-9961(03)00079-2 12901839
Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003;13(3):246–53.12901839 10.1016/S0969-9961(03)00079-2
479. Kelly PH Bondolfi L Hunziker D Schlecht HP Carver K Maguire E Progressive age-related impairment of cognitive behavior in APP23 transgenic mice Neurobiol Aging 2003 24 2 365 378 10.1016/S0197-4580(02)00098-2 12498971
Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, et al. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging. 2003;24(2):365–78.12498971 10.1016/S0197-4580(02)00098-2
480. Rockenstein E Mallory M Mante M Sisk A Masliaha E Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42) J Neurosci Res 2001 66 4 573 582 10.1002/jnr.1247 11746377
Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J Neurosci Res. 2001;66(4):573–82.11746377 10.1002/jnr.1247
481. Wright AL Zinn R Hohensinn B Konen LM Beynon SB Tan RP Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease PLoS ONE 2013 8 4 e59586 10.1371/journal.pone.0059586 23560052
Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS ONE. 2013;8(4): e59586.23560052 10.1371/journal.pone.0059586
482. Chishti MA Yang DS Janus C Phinney AL Horne P Pearson J Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695 J Biol Chem 2001 276 24 21562 21570 10.1074/jbc.M100710200 11279122
Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276(24):21562–70.11279122 10.1074/jbc.M100710200
483. Guénette SY Tanzi RE Progress toward valid transgenic mouse models for Alzheimer's disease Neurobiol Aging 1999 20 2 201 211 10.1016/S0197-4580(99)00042-1 10537029
Guénette SY, Tanzi RE. Progress toward valid transgenic mouse models for Alzheimer’s disease. Neurobiol Aging. 1999;20(2):201–11.10537029 10.1016/S0197-4580(99)00042-1
484. Gearing M Tigges J Mori H Mirra SS beta-Amyloid (A beta) deposition in the brains of aged orangutans Neurobiol Aging 1997 18 2 139 146 10.1016/S0197-4580(97)00012-2 9258890
Gearing M, Tigges J, Mori H, Mirra SS. beta-Amyloid (A beta) deposition in the brains of aged orangutans. Neurobiol Aging. 1997;18(2):139–46.9258890 10.1016/S0197-4580(97)00012-2
485. Kimura N Nakamura S Goto N Narushima E Hara I Shichiri S Senile plaques in an aged western lowland gorilla Exp Anim 2001 50 1 77 81 10.1538/expanim.50.77 11326427
Kimura N, Nakamura S, Goto N, Narushima E, Hara I, Shichiri S, et al. Senile plaques in an aged western lowland gorilla. Exp Anim. 2001;50(1):77–81.11326427 10.1538/expanim.50.77
486. Liu L Orozco IJ Planel E Wen Y Bretteville A Krishnamurthy P A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment Neurobiol Dis 2008 31 1 46 57 10.1016/j.nbd.2008.03.005 18504134
Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, et al. A transgenic rat that develops Alzheimer’s disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis. 2008;31(1):46–57.18504134 10.1016/j.nbd.2008.03.005
487. Perez SE Raghanti MA Hof PR Kramer L Ikonomovic MD Lacor PN Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla) J Comp Neurol 2013 521 18 4318 4338 10.1002/cne.23428 23881733
Perez SE, Raghanti MA, Hof PR, Kramer L, Ikonomovic MD, Lacor PN, et al. Alzheimer’s disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J Comp Neurol. 2013;521(18):4318–38.23881733 10.1002/cne.23428
488. Gordon MN Holcomb LA Jantzen PT DiCarlo G Wilcock D Boyett KW Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse Exp Neurol 2002 173 2 183 195 10.1006/exnr.2001.7754 11822882
Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, et al. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol. 2002;173(2):183–95.11822882 10.1006/exnr.2001.7754
489. Holcomb LA Gordon MN Jantzen P Hsiao K Duff K Morgan D Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits Behav Genet 1999 29 3 177 185 10.1023/A:1021691918517 10547924
Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999;29(3):177–85.10547924 10.1023/A:1021691918517
490. Flood DG Reaume AG Dorfman KS Lin YG Lang DM Trusko SP FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction Neurobiol Aging 2002 23 3 335 348 10.1016/S0197-4580(01)00330-X 11959395
Flood DG, Reaume AG, Dorfman KS, Lin YG, Lang DM, Trusko SP, et al. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol Aging. 2002;23(3):335–48.11959395 10.1016/S0197-4580(01)00330-X
491. Jawhar S Trawicka A Jenneckens C Bayer TA Wirths O Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease Neurobiol Aging 2012 33 1 196.e129 140 10.1016/j.neurobiolaging.2010.05.027
Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol Aging. 2012;33(1):196.e129-140.10.1016/j.neurobiolaging.2010.05.027
492. Richard BC Kurdakova A Baches S Bayer TA Weggen S Wirths O Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD mouse model of Alzheimer's Disease J Alzheimers Dis 2015 45 4 1223 1236 10.3233/JAD-143120 25697701
Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O. Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD mouse model of Alzheimer’s Disease. J Alzheimers Dis. 2015;45(4):1223–36.25697701 10.3233/JAD-143120
493. Oakley H Cole SL Logan S Maus E Shao P Craft J Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation J Neurosci 2006 26 40 10129 10140 10.1523/JNEUROSCI.1202-06.2006 17021169
Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129–40.17021169 10.1523/JNEUROSCI.1202-06.2006
494. Oddo S Caccamo A Shepherd JD Murphy MP Golde TE Kayed R Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 2003 39 3 409 421 10.1016/S0896-6273(03)00434-3 12895417
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409–21.12895417 10.1016/S0896-6273(03)00434-3
495. Billings LM Oddo S Green KN McGaugh JL LaFerla FM Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice Neuron 2005 45 5 675 688 10.1016/j.neuron.2005.01.040 15748844
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45(5):675–88.15748844 10.1016/j.neuron.2005.01.040
496. Stover KR Campbell MA Van Winssen CM Brown RE Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer's disease Behav Brain Res 2015 289 29 38 10.1016/j.bbr.2015.04.012 25896362
Stover KR, Campbell MA, Van Winssen CM, Brown RE. Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer’s disease. Behav Brain Res. 2015;289:29–38.25896362 10.1016/j.bbr.2015.04.012
497. Graybeal JJ Bozzelli PL Graybeal LL Groeber CM McKnight PE Cox DN Human ApoE ε4 alters circadian rhythm activity, IL-1β, and GFAP in CRND8 mice J Alzheimers Dis 2015 43 3 823 834 10.3233/JAD-132009 25159669
Graybeal JJ, Bozzelli PL, Graybeal LL, Groeber CM, McKnight PE, Cox DN, et al. Human ApoE ε4 alters circadian rhythm activity, IL-1β, and GFAP in CRND8 mice. J Alzheimers Dis. 2015;43(3):823–34.25159669 10.3233/JAD-132009
498. Kim HY Lee DK Chung BR Kim HV Kim Y Intracerebroventricular injection of amyloid-β peptides in normal mice to acutely induce Alzheimer-like cognitive deficits J Vis Exp 2016 109 e53308
Kim HY, Lee DK, Chung BR, Kim HV, Kim Y. Intracerebroventricular injection of amyloid-β peptides in normal mice to acutely induce Alzheimer-like cognitive deficits. J Vis Exp. 2016;109:e53308.
499. Tucker KL Meyer M Barde YA Neurotrophins are required for nerve growth during development Nat Neurosci 2001 4 1 29 37 10.1038/82868 11135642
Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4(1):29–37.11135642 10.1038/82868
500. Duff K Knight H Refolo LM Sanders S Yu X Picciano M Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes Neurobiol Dis 2000 7 2 87 98 10.1006/nbdi.1999.0279 10783293
Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis. 2000;7(2):87–98.10783293 10.1006/nbdi.1999.0279
501. Andorfer C Kress Y Espinoza M de Silva R Tucker KL Barde YA Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms J Neurochem 2003 86 3 582 590 10.1046/j.1471-4159.2003.01879.x 12859672
Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86(3):582–90.12859672 10.1046/j.1471-4159.2003.01879.x
502. Polydoro M Acker CM Duff K Castillo PE Davies P Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology J Neurosci 2009 29 34 10741 10749 10.1523/JNEUROSCI.1065-09.2009 19710325
Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29(34):10741–9.19710325 10.1523/JNEUROSCI.1065-09.2009
503. Ishihara T Hong M Zhang B Nakagawa Y Lee MK Trojanowski JQ Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform Neuron 1999 24 3 751 762 10.1016/S0896-6273(00)81127-7 10595524
Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24(3):751–62.10595524 10.1016/S0896-6273(00)81127-7
504. Ramsden M Kotilinek L Forster C Paulson J McGowan E SantaCruz K Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci 2005 25 46 10637 10647 10.1523/JNEUROSCI.3279-05.2005 16291936
Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci. 2005;25(46):10637–47.16291936 10.1523/JNEUROSCI.3279-05.2005
505. Santacruz K Lewis J Spires T Paulson J Kotilinek L Ingelsson M Tau suppression in a neurodegenerative mouse model improves memory function Science 2005 309 5733 476 481 10.1126/science.1113694 16020737
Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476–81.16020737 10.1126/science.1113694
506. Gamache J Benzow K Forster C Kemper L Hlynialuk C Furrow E Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice Nat Commun 2019 10 1 2479 10.1038/s41467-019-10428-1 31171783
Gamache J, Benzow K, Forster C, Kemper L, Hlynialuk C, Furrow E, et al. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat Commun. 2019;10(1):2479.31171783 10.1038/s41467-019-10428-1
507. Yoshiyama Y Higuchi M Zhang B Huang SM Iwata N Saido TC Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model Neuron 2007 53 3 337 351 10.1016/j.neuron.2007.01.010 17270732
Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337–51.17270732 10.1016/j.neuron.2007.01.010
508. Gao Y Wang Y Lei H Xu Z Li S Yu H A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau Transl Neurodegen 2023 12 1 51 10.1186/s40035-023-00379-5
Gao Y, Wang Y, Lei H, Xu Z, Li S, Yu H, et al. A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau. Transl Neurodegen. 2023;12(1):51.10.1186/s40035-023-00379-5
509. Leon WC Canneva F Partridge V Allard S Ferretti MT DeWilde A A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment J Alzheimers Dis 2010 20 1 113 126 10.3233/JAD-2010-1349 20164597
Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, et al. A novel transgenic rat model with a full Alzheimer’s-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010;20(1):113–26.20164597 10.3233/JAD-2010-1349
510. Nilsen LH Melø TM Saether O Witter MP Sonnewald U Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study J Neurochem 2012 123 4 532 541 10.1111/jnc.12003 22943908
Nilsen LH, Melø TM, Saether O, Witter MP, Sonnewald U. Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer’s disease: a longitudinal in vivo 1 H MRS study. J Neurochem. 2012;123(4):532–41.22943908 10.1111/jnc.12003
511. Cohen RM Rezai-Zadeh K Weitz TM Rentsendorj A Gate D Spivak I A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss J Neurosci 2013 33 15 6245 6256 10.1523/JNEUROSCI.3672-12.2013 23575824
Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci. 2013;33(15):6245–56.23575824 10.1523/JNEUROSCI.3672-12.2013
512. Teng E Kepe V Frautschy SA Liu J Satyamurthy N Yang F [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment Neurobiol Dis 2011 43 3 565 575 10.1016/j.nbd.2011.05.003 21605674
Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, et al. [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol Dis. 2011;43(3):565–75.21605674 10.1016/j.nbd.2011.05.003
513. Flood DG Lin YG Lang DM Trusko SP Hirsch JD Savage MJ A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition Neurobiol Aging 2009 30 7 1078 1090 10.1016/j.neurobiolaging.2007.10.006 18053619
Flood DG, Lin YG, Lang DM, Trusko SP, Hirsch JD, Savage MJ, et al. A transgenic rat model of Alzheimer’s disease with extracellular Abeta deposition. Neurobiol Aging. 2009;30(7):1078–90.18053619 10.1016/j.neurobiolaging.2007.10.006
514. Muratore CR Rice HC Srikanth P Callahan DG Shin T Benjamin LN The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons Hum Mol Genet 2014 23 13 3523 3536 10.1093/hmg/ddu064 24524897
Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LN, et al. The familial Alzheimer’s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet. 2014;23(13):3523–36.24524897 10.1093/hmg/ddu064
515. Kondo T Asai M Tsukita K Kutoku Y Ohsawa Y Sunada Y Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness Cell Stem Cell 2013 12 4 487 496 10.1016/j.stem.2013.01.009 23434393
Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell. 2013;12(4):487–96.23434393 10.1016/j.stem.2013.01.009
516. Yagi T Ito D Okada Y Akamatsu W Nihei Y Yoshizaki T Modeling familial Alzheimer's disease with induced pluripotent stem cells Hum Mol Genet 2011 20 23 4530 4539 10.1093/hmg/ddr394 21900357
Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet. 2011;20(23):4530–9.21900357 10.1093/hmg/ddr394
517. Israel MA Yuan SH Bardy C Reyna SM Mu Y Herrera C Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells Nature 2012 482 7384 216 220 10.1038/nature10821 22278060
Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 2012;482(7384):216–20.22278060 10.1038/nature10821
518. Choi SH Kim YH Hebisch M Sliwinski C Lee S D'Avanzo C A three-dimensional human neural cell culture model of Alzheimer's disease Nature 2014 515 7526 274 278 10.1038/nature13800 25307057
Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D’Avanzo C, et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature. 2014;515(7526):274–8.25307057 10.1038/nature13800
519. Raja WK Mungenast AE Lin YT Ko T Abdurrob F Seo J Self-organizing 3D human neural Tissue derived from induced pluripotent stem cells recapitulate Alzheimer's disease phenotypes PLoS ONE 2016 11 9 e0161969 10.1371/journal.pone.0161969 27622770
Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, et al. Self-organizing 3D human neural Tissue derived from induced pluripotent stem cells recapitulate Alzheimer’s disease phenotypes. PLoS ONE. 2016;11(9): e0161969.27622770 10.1371/journal.pone.0161969
520. Kim YH Choi SH D'Avanzo C Hebisch M Sliwinski C Bylykbashi E A 3D human neural cell culture system for modeling Alzheimer's disease Nat Protoc 2015 10 7 985 1006 10.1038/nprot.2015.065 26068894
Kim YH, Choi SH, D’Avanzo C, Hebisch M, Sliwinski C, Bylykbashi E, et al. A 3D human neural cell culture system for modeling Alzheimer’s disease. Nat Protoc. 2015;10(7):985–1006.26068894 10.1038/nprot.2015.065
521. Karmirian K Holubiec M Goto-Silva L Fernandez Bessone I Vitória G Mello B Modeling Alzheimer's disease using human brain organoids Methods Mol Biol 2023 2561 135 158 10.1007/978-1-0716-2655-9_7 36399268
Karmirian K, Holubiec M, Goto-Silva L, Fernandez Bessone I, Vitória G, Mello B, et al. Modeling Alzheimer’s disease using human brain organoids. Methods Mol Biol. 2023;2561:135–58.36399268 10.1007/978-1-0716-2655-9_7
522. Machairaki V Human pluripotent stem cells as in vitro models of neurodegenerative diseases Adv Exp Med Biol 2020 1195 93 94 10.1007/978-3-030-32633-3_13 32468463
Machairaki V. Human pluripotent stem cells as in vitro models of neurodegenerative diseases. Adv Exp Med Biol. 2020;1195:93–4.32468463 10.1007/978-3-030-32633-3_13
523. McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 3 263 269 10.1016/j.jalz.2011.03.005 21514250
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.21514250 10.1016/j.jalz.2011.03.005
524. Jack CR Jr Bennett DA Blennow K Carrillo MC Feldman HH Frisoni GB A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers Neurology 2016 87 5 539 547 10.1212/WNL.0000000000002923 27371494
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.27371494 10.1212/WNL.0000000000002923
525. Jack CR Jr Bennett DA Blennow K Carrillo MC Dunn B Haeberlein SB NIA-AA Research Framework: toward a biological definition of Alzheimer's disease Alzheimers Dement 2018 14 4 535 562 10.1016/j.jalz.2018.02.018 29653606
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.29653606 10.1016/j.jalz.2018.02.018
526. Loftus JR Puri S Meyers SP Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging Insights Imaging 2023 14 1 8 10.1186/s13244-022-01358-6 36645560
Loftus JR, Puri S, Meyers SP. Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. Insights Imaging. 2023;14(1):8.36645560 10.1186/s13244-022-01358-6
527. Albert MS DeKosky ST Dickson D Dubois B Feldman HH Fox NC The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 3 270 279 10.1016/j.jalz.2011.03.008 21514249
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.21514249 10.1016/j.jalz.2011.03.008
528. Salmon DP Thomas RG Pay MM Booth A Hofstetter CR Thal LJ Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals Neurology 2002 59 7 1022 1028 10.1212/WNL.59.7.1022 12370456
Salmon DP, Thomas RG, Pay MM, Booth A, Hofstetter CR, Thal LJ, et al. Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals. Neurology. 2002;59(7):1022–8.12370456 10.1212/WNL.59.7.1022
529. Folstein MF Folstein SE McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatric Res 1975 12 3 189 198 10.1016/0022-3956(75)90026-6
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975;12(3):189–98.10.1016/0022-3956(75)90026-6
530. Nasreddine ZS Phillips NA Bédirian V Charbonneau S Whitehead V Collin I The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc 2005 53 4 695 699 10.1111/j.1532-5415.2005.53221.x 15817019
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.15817019 10.1111/j.1532-5415.2005.53221.x
531. Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-Cog J Alzheimers Dis 2008 15 3 461 464 10.3233/JAD-2008-15312 18997299
Connor DJ, Sabbagh MN. Administration and scoring variance on the ADAS-Cog. J Alzheimers Dis. 2008;15(3):461–4.18997299 10.3233/JAD-2008-15312
532. Tsai N Gao ZX Validity of Hasegawa's Dementia Scale for screening dementia among aged Chinese Int Psychogeriat 1989 1 2 145 152 10.1017/S1041610289000153
Tsai N, Gao ZX. Validity of Hasegawa’s Dementia Scale for screening dementia among aged Chinese. Int Psychogeriat. 1989;1(2):145–52.10.1017/S1041610289000153
533. Wang Y Xu H Geng Z Geng G Zhang F Dementia and the history of disease in older adults in community BMC Public Health 2023 23 1 1555 10.1186/s12889-023-16494-x 37582737
Wang Y, Xu H, Geng Z, Geng G, Zhang F. Dementia and the history of disease in older adults in community. BMC Public Health. 2023;23(1):1555.37582737 10.1186/s12889-023-16494-x
534. Foss MP de Carvalho VA Machado TH Dos Reis GC Tumas V Caramelli P Mattis dementia rating scale (DRS) normative data for the brazilian middle-age and elderly populations Dement Neuropsychol 2013 7 4 374 379 10.1590/S1980-57642013DN74000004 29213861
Foss MP, de Carvalho VA, Machado TH, Dos Reis GC, Tumas V, Caramelli P, et al. Mattis dementia rating scale (DRS) normative data for the brazilian middle-age and elderly populations. Dement Neuropsychol. 2013;7(4):374–9.29213861 10.1590/S1980-57642013DN74000004
535. Lukatela KA Cohen RA Kessler HA Jenkins MA Moser DJ Stone WF Dementia rating scale performance: a comparison of vascular and Alzheimer's dementia J Clin Exp Neuropsychol 2000 22 4 445 454 10.1076/1380-3395(200008)22:4;1-0;FT445 10923054
Lukatela KA, Cohen RA, Kessler HA, Jenkins MA, Moser DJ, Stone WF, et al. Dementia rating scale performance: a comparison of vascular and Alzheimer’s dementia. J Clin Exp Neuropsychol. 2000;22(4):445–54.10923054 10.1076/1380-3395(200008)22:4;1-0;FT445
536. Teng EL Hasegawa K Homma A Imai Y Larson E Graves A The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia Int Psychogeriat 1994 6 1 45 58 10.1017/S1041610294001602
Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriat. 1994;6(1):45–58.10.1017/S1041610294001602
537. Hughes CP Berg L Danziger WL Coben LA Martin RL A new clinical scale for the staging of dementia Br J Psychiatry 1982 140 566 572 10.1192/bjp.140.6.566 7104545
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72.7104545 10.1192/bjp.140.6.566
538. Reisberg B Ferris SH de Leon MJ Crook T The Global Deterioration Scale for assessment of primary degenerative dementia Am J Psychiatry 1982 139 9 1136 1139 10.1176/ajp.139.9.1136 7114305
Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.7114305 10.1176/ajp.139.9.1136
539. Hamilton M A rating scale for depression J Neurol Neurosurg Psychiatry 1960 23 1 56 62 10.1136/jnnp.23.1.56 14399272
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.14399272 10.1136/jnnp.23.1.56
540. Wang J Jin C Zhou J Zhou R Tian M Lee HJ PET molecular imaging for pathophysiological visualization in Alzheimer's disease Eur J Nucl Med Mol Imaging 2023 50 3 765 783 10.1007/s00259-022-05999-z 36372804
Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2023;50(3):765–83.36372804 10.1007/s00259-022-05999-z
541. Aschenbrenner AJ Gordon BA Benzinger TLS Morris JC Hassenstab JJ Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease Neurology 2018 91 9 e859 e866 10.1212/WNL.0000000000006075 30068637
Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91(9):e859–66.30068637 10.1212/WNL.0000000000006075
542. Jack CR Jr Petersen RC O'Brien PC Tangalos EG MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease Neurology 1992 42 1 183 188 10.1212/WNL.42.1.183 1734300
Jack CR Jr, Petersen RC, O’Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology. 1992;42(1):183–8.1734300 10.1212/WNL.42.1.183
543. Benzinger TL Blazey T Jack CR Jr Koeppe RA Su Y Xiong C Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease Proc Natl Acad Sci USA 2013 110 47 E4502 4509 10.1073/pnas.1317918110 24194552
Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA. 2013;110(47):E4502-4509.24194552 10.1073/pnas.1317918110
544. Klunk WE Wang Y Huang GF Debnath ML Holt DP Mathis CA Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain Life Sci 2001 69 13 1471 1484 10.1016/S0024-3205(01)01232-2 11554609
Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69(13):1471–84.11554609 10.1016/S0024-3205(01)01232-2
545. Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 2004 55 3 306 319 10.1002/ana.20009 14991808
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.14991808 10.1002/ana.20009
546. Jack CR Jr Lowe VJ Senjem ML Weigand SD Kemp BJ Shiung MM 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 2008 131 Pt 3 665 680 10.1093/brain/awm336 18263627
Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665–80.18263627 10.1093/brain/awm336
547. Whitwell JL Graff-Radford J Tosakulwong N Weigand SD Machulda MM Senjem ML Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease Alzheimers Dement 2018 14 8 1005 1014 10.1016/j.jalz.2018.02.020 29605222
Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer’s disease. Alzheimers Dement. 2018;14(8):1005–14.29605222 10.1016/j.jalz.2018.02.020
548. La Joie R Ayakta N Seeley WW Borys E Boxer AL DeCarli C Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology Alzheimers Dement 2019 15 2 205 216 10.1016/j.jalz.2018.09.001 30347188
La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15(2):205–16.30347188 10.1016/j.jalz.2018.09.001
549. Ossenkoppele R Smith R Ohlsson T Strandberg O Mattsson N Insel PS Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease Neurology 2019 92 6 e601 e612 10.1212/WNL.0000000000006875 30626656
Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601–12.30626656 10.1212/WNL.0000000000006875
550. Leuzy A Chiotis K Lemoine L Gillberg PG Almkvist O Rodriguez-Vieitez E Tau PET imaging in neurodegenerative tauopathies-still a challenge Mol Psychiatry 2019 24 8 1112 1134 10.1038/s41380-018-0342-8 30635637
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112–34.30635637 10.1038/s41380-018-0342-8
551. Cassinelli Petersen G Roytman M Chiang GC Li Y Gordon ML Franceschi AM Overview of tau PET molecular imaging Curr Opin Neurol 2022 35 2 230 239 10.1097/WCO.0000000000001035 35191407
Cassinelli Petersen G, Roytman M, Chiang GC, Li Y, Gordon ML, Franceschi AM. Overview of tau PET molecular imaging. Curr Opin Neurol. 2022;35(2):230–9.35191407 10.1097/WCO.0000000000001035
552. Tanner JA Iaccarino L Edwards L Asken BM Gorno-Tempini ML Kramer JH Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease Brain 2022 145 12 4489 4505 10.1093/brain/awac229 35762829
Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease. Brain. 2022;145(12):4489–505.35762829 10.1093/brain/awac229
553. Jagust W Imaging the evolution and pathophysiology of Alzheimer disease Nat Rev Neurosci 2018 19 11 687 700 10.1038/s41583-018-0067-3 30266970
Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018;19(11):687–700.30266970 10.1038/s41583-018-0067-3
554. Huang S Wang YJ Guo J Biofluid biomarkers of Alzheimer's Disease: progress, problems, and perspectives Neurosci Bull 2022 38 6 677 691 10.1007/s12264-022-00836-7 35306613
Huang S, Wang YJ, Guo J. Biofluid biomarkers of Alzheimer’s Disease: progress, problems, and perspectives. Neurosci Bull. 2022;38(6):677–91.35306613 10.1007/s12264-022-00836-7
555. Cousins KAQ Phillips JS Das SR O'Brien K Tropea TF Chen-Plotkin A Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease Alzheimers Dement 2024 10.1002/alz.13777 38644682
Cousins KAQ, Phillips JS, Das SR, O’Brien K, Tropea TF, Chen-Plotkin A, et al. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease. Alzheimers Dement. 2024. 10.1002/alz.13777.38644682 10.1002/alz.13777
556. Ashton NJ Janelidze S Mattsson-Carlgren N Binette AP Strandberg O Brum WS Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring Nat Med 2022 28 12 2555 2562 10.1038/s41591-022-02074-w 36456833
Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat Med. 2022;28(12):2555–62.36456833 10.1038/s41591-022-02074-w
557. An J Kim K Lim HJ Kim HY Shin J Park I Early onset diagnosis in Alzheimer's disease patients via amyloid-beta oligomers-sensing probe in cerebrospinal fluid Nat Commun 2024 15 1 1004 10.1038/s41467-024-44818-x 38307843
An J, Kim K, Lim HJ, Kim HY, Shin J, Park I, et al. Early onset diagnosis in Alzheimer’s disease patients via amyloid-beta oligomers-sensing probe in cerebrospinal fluid. Nat Commun. 2024;15(1):1004.38307843 10.1038/s41467-024-44818-x
558. Mahaman YAR Embaye KS Huang F Li L Zhu F Wang JZ Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention Ageing Res Rev 2022 74 101544 10.1016/j.arr.2021.101544 34933129
Mahaman YAR, Embaye KS, Huang F, Li L, Zhu F, Wang JZ, et al. Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention. Ageing Res Rev. 2022;74: 101544.34933129 10.1016/j.arr.2021.101544
559. Liu Z, Liu L, Weng S, Xu H, Xing Z, Ren Y, et al. BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors. bioRxiv. 2022:2022.2010.2021.513300.
560. Gonzalez-Ortiz F Kac PR Brum WS Zetterberg H Blennow K Karikari TK Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications Mol Neurodegener 2023 18 1 18 10.1186/s13024-023-00605-8 36927491
Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener. 2023;18(1):18.36927491 10.1186/s13024-023-00605-8
561. Karikari TK Ashton NJ Brinkmalm G Brum WS Benedet AL Montoliu-Gaya L Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility Nat Rev Neurol 2022 18 7 400 418 10.1038/s41582-022-00665-2 35585226
Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18(7):400–18.35585226 10.1038/s41582-022-00665-2
562. Ashton NJ Pascoal TA Karikari TK Benedet AL Lantero-Rodriguez J Brinkmalm G Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology Acta Neuropathol 2021 141 5 709 724 10.1007/s00401-021-02275-6 33585983
Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 2021;141(5):709–24.33585983 10.1007/s00401-021-02275-6
563. Schindler SE Bollinger JG Ovod V Mawuenyega KG Li Y Gordon BA High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis Neurology 2019 93 17 e1647 e1659 10.1212/WNL.0000000000008081 31371569
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647–59.31371569 10.1212/WNL.0000000000008081
564. Kac PR Gonzalez-Ortiz F Emersic A Dulewicz M Koutarapu S Turton M Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology Nat Commun 2024 15 1 2615 10.1038/s41467-024-46876-7 38521766
Kac PR, Gonzalez-Ortiz F, Emersic A, Dulewicz M, Koutarapu S, Turton M, et al. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology. Nat Commun. 2024;15(1):2615.38521766 10.1038/s41467-024-46876-7
565. Lantero-Rodriguez J Salvado G Snellman A Montoliu-Gaya L Brum WS Benedet AL Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease Mol Neurodegener 2024 19 1 19 10.1186/s13024-024-00707-x 38365825
Lantero-Rodriguez J, Salvado G, Snellman A, Montoliu-Gaya L, Brum WS, Benedet AL, et al. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease. Mol Neurodegener. 2024;19(1):19.38365825 10.1186/s13024-024-00707-x
566. Gonzalez-Ortiz F Kirsebom BE Contador J Tanley JE Selnes P Gisladottir B Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease Nat Commun 2024 15 1 2908 10.1038/s41467-024-47286-5 38575616
Gonzalez-Ortiz F, Kirsebom BE, Contador J, Tanley JE, Selnes P, Gisladottir B, et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Nat Commun. 2024;15(1):2908.38575616 10.1038/s41467-024-47286-5
567. Goldman JS Hahn SE Catania JW LaRusse-Eckert S Butson MB Rumbaugh M Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors Genet Med 2011 13 6 597 605 10.1097/GIM.0b013e31821d69b8 21577118
Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6):597–605.21577118 10.1097/GIM.0b013e31821d69b8
568. Goate A Chartier-Harlin MC Mullan M Brown J Crawford F Fidani L Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 1991 349 6311 704 706 10.1038/349704a0 1671712
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349(6311):704–6.1671712 10.1038/349704a0
569. Levy-Lahad E Wasco W Poorkaj P Romano DM Oshima J Pettingell WH Candidate gene for the chromosome 1 familial Alzheimer's disease locus Science 1995 269 5226 973 977 10.1126/science.7638622 7638622
Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science. 1995;269(5226):973–7.7638622 10.1126/science.7638622
570. Sherrington R Rogaev EI Liang Y Rogaeva EA Levesque G Ikeda M Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 1995 375 6534 754 760 10.1038/375754a0 7596406
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375(6534):754–60.7596406 10.1038/375754a0
571. Huang G Li R Bai Q Alty J Multimodal learning of clinically accessible tests to aid diagnosis of neurodegenerative disorders: a scoping review Health Inf Sci Syst 2023 11 1 32 10.1007/s13755-023-00231-0 37489153
Huang G, Li R, Bai Q, Alty J. Multimodal learning of clinically accessible tests to aid diagnosis of neurodegenerative disorders: a scoping review. Health Inf Sci Syst. 2023;11(1):32.37489153 10.1007/s13755-023-00231-0
572. Li R St George RJ Wang X Lawler K Hill E Garg S Moving towards intelligent telemedicine: computer vision measurement of human movement Comput Biol Med 2022 147 105776 10.1016/j.compbiomed.2022.105776 35780600
Li R, St George RJ, Wang X, Lawler K, Hill E, Garg S, et al. Moving towards intelligent telemedicine: computer vision measurement of human movement. Comput Biol Med. 2022;147: 105776.35780600 10.1016/j.compbiomed.2022.105776
573. D'Andrea C Cazzaniga FA Bistaffa E Barucci A de Angelis M Banchelli M Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer's disease Transl Neurodegen 2023 12 1 35 10.1186/s40035-023-00367-9
D’Andrea C, Cazzaniga FA, Bistaffa E, Barucci A, de Angelis M, Banchelli M, et al. Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease. Transl Neurodegen. 2023;12(1):35.10.1186/s40035-023-00367-9
574. Bonvicini G Syvänen S Andersson KG Haaparanta-Solin M López-Picón F Sehlin D ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein Transl Neurodegen 2022 11 1 55 10.1186/s40035-022-00324-y
Bonvicini G, Syvänen S, Andersson KG, Haaparanta-Solin M, López-Picón F, Sehlin D. ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein. Transl Neurodegen. 2022;11(1):55.10.1186/s40035-022-00324-y
575. Lu J Ma X Zhang H Xiao Z Li M Wu J Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints Transl Neurodegen 2023 12 1 34 10.1186/s40035-023-00365-x
Lu J, Ma X, Zhang H, Xiao Z, Li M, Wu J, et al. Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints. Transl Neurodegen. 2023;12(1):34.10.1186/s40035-023-00365-x
576. Ossenkoppele R van der Kant R Hansson O Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials Lancet Neurol 2022 21 8 726 734 10.1016/S1474-4422(22)00168-5 35643092
Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21(8):726–34.35643092 10.1016/S1474-4422(22)00168-5
577. Behl T Kaur I Sehgal A Singh S Sharma N Gupta S AChE as a spark in the Alzheimer's blaze - Antagonizing effect of a cyclized variant Ageing Res Rev 2023 83 101787 10.1016/j.arr.2022.101787 36368649
Behl T, Kaur I, Sehgal A, Singh S, Sharma N, Gupta S, et al. AChE as a spark in the Alzheimer’s blaze - Antagonizing effect of a cyclized variant. Ageing Res Rev. 2023;83: 101787.36368649 10.1016/j.arr.2022.101787
578. Howard R McShane R Lindesay J Ritchie C Baldwin A Barber R Donepezil and memantine for moderate-to-severe Alzheimer's disease N Engl J Med 2012 366 10 893 903 10.1056/NEJMoa1106668 22397651
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.22397651 10.1056/NEJMoa1106668
579. Ballard C Margallo-Lana M Juszczak E Douglas S Swann A Thomas A Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial BMJ 2005 330 7496 874 10.1136/bmj.38369.459988.8F 15722369
Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.15722369 10.1136/bmj.38369.459988.8F
580. Erkinjuntti T Kurz A Gauthier S Bullock R Lilienfeld S Damaraju CV Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial Lancet 2002 359 9314 1283 1290 10.1016/S0140-6736(02)08267-3 11965273
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283–90.11965273 10.1016/S0140-6736(02)08267-3
581. Reisberg B Doody R Stöffler A Schmitt F Ferris S Möbius HJ Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 2003 348 14 1333 1341 10.1056/NEJMoa013128 12672860
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.12672860 10.1056/NEJMoa013128
582. Robinson DM Keating GM Memantine: a review of its use in Alzheimer's disease Drugs 2006 66 11 1515 1534 10.2165/00003495-200666110-00015 16906789
Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer’s disease. Drugs. 2006;66(11):1515–34.16906789 10.2165/00003495-200666110-00015
583. Rabinovici GD Controversy and progress in Alzheimer's disease - FDA approval of aducanumab N Engl J Med 2021 385 9 771 774 10.1056/NEJMp2111320 34320284
Rabinovici GD. Controversy and progress in Alzheimer’s disease - FDA approval of aducanumab. N Engl J Med. 2021;385(9):771–4.34320284 10.1056/NEJMp2111320
584. Salloway S Chalkias S Barkhof F Burkett P Barakos J Purcell D Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease JAMA Neurol 2022 79 1 13 21 10.1001/jamaneurol.2021.4161 34807243
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13–21.34807243 10.1001/jamaneurol.2021.4161
585. van Dyck CH Swanson CJ Aisen P Bateman RJ Chen C Gee M Lecanemab in early Alzheimer's disease N Engl J Med 2023 388 1 9 21 10.1056/NEJMoa2212948 36449413
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.36449413 10.1056/NEJMoa2212948
586. Singh PK Simoes-Pires EN Chen ZL Torrente D Calvano M Sharma A Lecanemab blocks the effects of the Abeta/fibrinogen complex on blood clots and synapse toxicity in organotypic culture Proc Natl Acad Sci USA 2024 121 17 e2314450121 10.1073/pnas.2314450121 38621133
Singh PK, Simoes-Pires EN, Chen ZL, Torrente D, Calvano M, Sharma A, et al. Lecanemab blocks the effects of the Abeta/fibrinogen complex on blood clots and synapse toxicity in organotypic culture. Proc Natl Acad Sci USA. 2024;121(17): e2314450121.38621133 10.1073/pnas.2314450121
587. Manly JJ Deters KD Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed? JAMA 2023 330 6 510 511 10.1001/jama.2023.11704 37459138
Manly JJ, Deters KD. Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed? JAMA. 2023;330(6):510–1.37459138 10.1001/jama.2023.11704
588. Mintun MA Lo AC Duggan Evans C Wessels AM Ardayfio PA Andersen SW Donanemab in early Alzheimer's Disease N Engl J Med 2021 384 18 1691 1704 10.1056/NEJMoa2100708 33720637
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s Disease. N Engl J Med. 2021;384(18):1691–704.33720637 10.1056/NEJMoa2100708
589. Sims JR Zimmer JA Evans CD Lu M Ardayfio P Sparks J Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized clinical trial JAMA 2023 330 6 512 527 10.1001/jama.2023.13239 37459141
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized clinical trial. JAMA. 2023;330(6):512–27.37459141 10.1001/jama.2023.13239
590. Pontecorvo MJ Lu M Burnham SC Schade AE Dage JL Shcherbinin S Association of Donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial JAMA Neurol 2022 79 12 1250 1259 10.1001/jamaneurol.2022.3392 36251300
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of Donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250–9.36251300 10.1001/jamaneurol.2022.3392
591. Teng E Manser PT Pickthorn K Brunstein F Blendstrup M Sanabria Bohorquez S Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial JAMA Neurol 2022 79 8 758 767 10.1001/jamaneurol.2022.1375 35696185
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79(8):758–67.35696185 10.1001/jamaneurol.2022.1375
592. Ayalon G Lee SH Adolfsson O Foo-Atkins C Atwal JK Blendstrup M Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease Sci Transl Med 2021 13 593 eabb2639 10.1126/scitranslmed.abb2639 33980574
Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease. Sci Transl Med. 2021;13(593):eabb2639.33980574 10.1126/scitranslmed.abb2639
593. Lozupone M Dibello V Sardone R Castellana F Zupo R Lampignano L The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies Expert Opin Drug Discov 2023 18 5 515 526 10.1080/17460441.2023.2200245 37042028
Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, et al. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. Expert Opin Drug Discov. 2023;18(5):515–26.37042028 10.1080/17460441.2023.2200245
594. Baddeley TC McCaffrey J Storey JM Cheung JK Melis V Horsley D Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease J Pharmacol Exp Ther 2015 352 1 110 118 10.1124/jpet.114.219352 25320049
Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J Pharmacol Exp Ther. 2015;352(1):110–8.25320049 10.1124/jpet.114.219352
595. Gauthier S Feldman HH Schneider LS Wilcock GK Frisoni GB Hardlund JH Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial Lancet 2016 388 10062 2873 2884 10.1016/S0140-6736(16)31275-2 27863809
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873–84.27863809 10.1016/S0140-6736(16)31275-2
596. Wang W Zhou Q Jiang T Li S Ye J Zheng J A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models Theranostics 2021 11 11 5279 5295 10.7150/thno.55680 33859747
Wang W, Zhou Q, Jiang T, Li S, Ye J, Zheng J, et al. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics. 2021;11(11):5279–95.33859747 10.7150/thno.55680
597. Bekes M Langley DR Crews CM PROTAC targeted protein degraders: the past is prologue Nat Rev Drug Discov 2022 21 3 181 200 10.1038/s41573-021-00371-6 35042991
Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200.35042991 10.1038/s41573-021-00371-6
598. Henning NJ Boike L Spradlin JN Ward CC Liu G Zhang E Deubiquitinase-targeting chimeras for targeted protein stabilization Nat Chem Biol 2022 18 4 412 421 10.1038/s41589-022-00971-2 35210618
Henning NJ, Boike L, Spradlin JN, Ward CC, Liu G, Zhang E, et al. Deubiquitinase-targeting chimeras for targeted protein stabilization. Nat Chem Biol. 2022;18(4):412–21.35210618 10.1038/s41589-022-00971-2
599. Wang X Sun G Feng T Zhang J Huang X Wang T Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression Cell Res 2019 29 10 787 803 10.1038/s41422-019-0216-x 31488882
Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019;29(10):787–803.31488882 10.1038/s41422-019-0216-x
600. Xiao S Chan P Wang T Hong Z Wang S Kuang W A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia Alzheimers Res Thery 2021 13 1 62 10.1186/s13195-021-00795-7
Xiao S, Chan P, Wang T, Hong Z, Wang S, Kuang W, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res Thery. 2021;13(1):62.10.1186/s13195-021-00795-7
601. Mdawar B Ghossoub E Khoury R Selective serotonin reuptake inhibitors and Alzheimer's disease Neural Regen Res 2020 15 1 41 46 10.4103/1673-5374.264445 31535641
Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and Alzheimer’s disease. Neural Regen Res. 2020;15(1):41–6.31535641 10.4103/1673-5374.264445
602. Mühlbauer V Möhler R Dichter MN Zuidema SU Köpke S Luijendijk HJ Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia Cochrane Database Syst Rev 2021 12 12 cd013304 34918337
Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):cd013304.34918337
603. Liu L Volpe SL Ross JA Grimm JA Van Bockstaele EJ Eisen HJ Dietary sugar intake and risk of Alzheimer's disease in older women Nutr Neurosci 2022 25 11 2302 2313 10.1080/1028415X.2021.1959099 34328409
Liu L, Volpe SL, Ross JA, Grimm JA, Van Bockstaele EJ, Eisen HJ. Dietary sugar intake and risk of Alzheimer’s disease in older women. Nutr Neurosci. 2022;25(11):2302–13.34328409 10.1080/1028415X.2021.1959099
604. Hoscheidt S Sanderlin AH Baker LD Jung Y Lockhart S Kellar D Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: a randomized trial Alzheimers Dement 2022 18 3 457 468 10.1002/alz.12421 34310044
Hoscheidt S, Sanderlin AH, Baker LD, Jung Y, Lockhart S, Kellar D, et al. Mediterranean and Western diet effects on Alzheimer’s disease biomarkers, cerebral perfusion, and cognition in mid-life: a randomized trial. Alzheimers Dement. 2022;18(3):457–68.34310044 10.1002/alz.12421
605. Whittaker DS Akhmetova L Carlin D Romero H Welsh DK Colwell CS Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer's disease Cell metab 2023 35 10 1704 1721.e1706 10.1016/j.cmet.2023.07.014 37607543
Whittaker DS, Akhmetova L, Carlin D, Romero H, Welsh DK, Colwell CS, et al. Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer’s disease. Cell metab. 2023;35(10):1704-1721.e1706.37607543 10.1016/j.cmet.2023.07.014
606. Sabbagh M Sadowsky C Tousi B Agronin ME Alva G Armon C Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease Alzheimers Dement 2020 16 4 641 650 10.1016/j.jalz.2019.08.197 31879235
Sabbagh M, Sadowsky C, Tousi B, Agronin ME, Alva G, Armon C, et al. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer’s disease. Alzheimers Dement. 2020;16(4):641–50.31879235 10.1016/j.jalz.2019.08.197
607. Fonte C Smania N Pedrinolla A Munari D Gandolfi M Picelli A Comparison between physical and cognitive treatment in patients with MCI and Alzheimer's disease Aging 2019 11 10 3138 3155 10.18632/aging.101970 31127076
Fonte C, Smania N, Pedrinolla A, Munari D, Gandolfi M, Picelli A, et al. Comparison between physical and cognitive treatment in patients with MCI and Alzheimer’s disease. Aging. 2019;11(10):3138–55.31127076 10.18632/aging.101970
608. Xu L Liu R Qin Y Wang T Brain metabolism in Alzheimer's disease: biological mechanisms of exercise Transl Neurodegen 2023 12 1 33 10.1186/s40035-023-00364-y
Xu L, Liu R, Qin Y, Wang T. Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise. Transl Neurodegen. 2023;12(1):33.10.1186/s40035-023-00364-y
609. Lyu J Zhang J Mu H Li W Champ M Xiong Q The effects of music therapy on cognition, psychiatric symptoms, and activities of daily living in patients with Alzheimer's disease J Alzheimers Dis 2018 64 4 1347 1358 10.3233/JAD-180183 29991131
Lyu J, Zhang J, Mu H, Li W, Champ M, Xiong Q, et al. The effects of music therapy on cognition, psychiatric symptoms, and activities of daily living in patients with Alzheimer’s disease. J Alzheimers Dis. 2018;64(4):1347–58.29991131 10.3233/JAD-180183
610. Yu JT Xu W Tan CC Andrieu S Suckling J Evangelou E Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials J Neurol Neurosurg Psychiatry 2020 91 11 1201 1209 10.1136/jnnp-2019-321913 32690803
Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, et al. Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(11):1201–9.32690803 10.1136/jnnp-2019-321913
